PERSISTENCE WITH ANTIHYPERTENSIVE DRUG CLASSES; INFLUENCE OF METHOD ASSUMPTIONS : AC1
SUCCESS FACTORS IMPROVING PATIENT COMPLIANCE BEHAVIOUR— EMPIRICAL FINDINGS FROM EUROPE : AC2
NON-ADHERENCE IN OUTPATIENT THROMBOSIS PROPHYLAXIS AFTER MAJOR ORTHOPAEDIC SURGERY : AC3
A RETROSPECTIVE COHORT STUDY OF MEDICATION ADHERENCE TO TREATMENT OF OSTEOPOROSIS IN A SWEDISH POPULATION : AC4
HOW MUCH DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE MATTER IN COST-EFFECTIVENESS ANALYSIS? A COMPARISON OF COST/LIFE YEAR AND COST/QALY ESTIMATES FOR CANCER INTERVENTIONS : CN1
ECONOMIC EVALUATION OF THE CHEK2 GENOTYPING AND PERSONALIZED BREAST CANCER SCREENING IN THE POLISH HEALTH CARE SYSTEM : CN2
COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY : CN3
COST-EFFECTIVENESS OF PEMETREXED IN FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PORTUGAL : CN4
MARKET CONCENTRATION AND ITS CROSS-LINKAGE WITH THE CONSUMPTION OF ACE INHIBITORS AND ARBS : DE1
INFLUENCE OF GENERIC DRUGS ON PROTON PUMP INHIBITOR PRESCRIPTION IN PRIMARY CARE : DE2
HAVE RECENT PHARMACEUTICAL REFORMS DAMAGED R&D? : DE3
PRESCRIPTION DRUG FORMULARIES AND COVERAGE: DOES A DRUG BY ANY OTHER NAME SMELL AS SWEET? : DE4
A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER—COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE : MH1
THE COST-EFFECTIVENESS OF OPPORTUNISTIC SCREENING AND MINIMAL CONTACT PSYCHOTHERAPY TO PREVENT DEPRESSION IN PRIMARY CARE PATIENTS : MH2
ANTIPSYCHOTIC USE AND DIABETES: A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF NEW ANTIPSYCHOTIC USERS : MH3
COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM): EFFECTS ON QUALITY OF LIFE AND RESOURCE USE : MH4
VALUING EQ-5D USING TIME TRADE-OFF IN FRANCE : UT1
PARADIGM LOST: A CONCEPTUAL AND EMPIRICAL OBITUARY CHRONICLING THE DEMISE OF CARDINAL UTILITY MEASUREMENTNT : UT2
HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE ROTAVIRUS INFECTIONS : UT3
DEVELOPING AND PRELIMINARY TESTING OF AN OFFICIAL FIVE-LEVEL VERSION OF EQ-5D : UT4
COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU) IN GERMANY : CN5
TREATMENT-RELATED TOXICITIES IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) : CN6
TREATMENT VARIATION COMPLICATES REAL-WORLD PHARMACOECONOMICS: DAILY CLINICAL PRACTICE OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA : CN7
METHODOLOGICAL ISSUES OF CONTROL ARM ADJUSTMENTS FOR COMPARATIVE EFFECTIVENESS ASSESSMENTS: AN EXAMPLE BASED ON THE COMPARISON OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN RENAL CELL CARCINOMA : CN8
USING IQWIG'S EFFICIENCY FRONTIER APPROACH FOR THE ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT—A PILOT AND FEASIBILITY STUDY COMMISSIONED BY IQWIG : EE1
DEAR POLICYMAKER: HAVE YOU MADE UP YOUR MIND? : EE2
IS NICE TOO NASTY? A COMPARISON OF ANTICANCER DRUG COVERAGE DECISIONS IN THE UNITED STATES AND UK : EE3
MARKET ACCESS IN GERMANY: WHERE NEXT? : EE4
COHORT MODELLING—IS THE APPROACH TOO OLD FOR THE ELDERLY? : MO1
IMPROVING COST-EFFECTIVENESS ANALYSES OF BEHAVIOURAL INTERVENTIONS BY USING COGNITIVE INTERMEDIATE OUTCOMES: A PILOT STUDY : MO2
R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R : MO3
BAYESIAN GENERALIZED LINEAR MODELLING OF THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX AND HEALTH UTILITIES INDEX MARK III IN EARLY AND LATE RHEUMATOID ARTHRITIS: DATA FROM THE PREMIER AND ARMADA TRIALS : MO4
A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN HEALTH CARE DECISION MAKING : PP1
PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE : PP2
WHAT DIMENSIONS ARE IMPORTANT TO PATIENTS IN THEIR EXPERIENCE OF CONTINUITY OF CARE? A STUDY OF PATIENTS' PREFERENCES USING A DISCRETE CHOICE EXPERIMENT : PP3
LIVES WORTH LIVING: OLDER SMOKERS' STATED PREFERENCES FOR LONGEVITY : PP4
SEVEN, TEN OR THIRTEEN? THE COST-UTILITY OF INFANT VACCINATION WITH A 7-, 10- OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE NETHERLANDS : VA1
A HEALTH ECONOMIC EVALUATION OF A NEW HERPES ZOSTER (HZ) VACCINE FOR THE PREVENTION OF HZ AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM : VA2
GLOBAL MEASLES ERADICATION: COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020-2049 : VA3
HEALTH ECONOMIC EVALUATION OF A NOVEL INTRADERMAL INFLUENZA VACCINE IN TWO EUROPEAN COUNTRIES : VA4
DESIGNING AND IMPLEMENTING OUTCOME-BASED REIMBURSEMENT SCHEMES: EXPERIENCE FROM HUNGARY : CASE1
REVIEW OF THE EARLY EXPERIENCE OF THE NEW NICE SCIENTIFIC ADVICE PROGRAMME : CASE2
THE SLOVAK EXPERIENCE IN THE INTERNATIONAL PRICE BENCHMARKING FOR PRESCRIPTION DRUGS : CASE3
ASSESSMENT AND APPRAISAL IN THE NETHERLANDS : CASE4
THE SEESAW OF COST-EFFECTIVENESS THRESHOLDS: HOW RELAXED REQUIREMENTS FOR LATER LINES OF TREATMENT WILL INCREASE HURDLES FOR NEW THERAPIES : EE5
INCORPORATING EQUITY IN COST-EFFECTIVENESS ANALYSIS: A SYSTEMATIC REVIEW : EE6
A DISCRETE CHOICE EXPERIMENT COMPARING PUBLIC AND DECISION-MAKER STATED PREFERENCES FOR PHARMACEUTICAL SUBSIDY DECISIONS : EE7
BRIDGING HEALTH TECHNOLOGY ASSESSMENT WITH MULTICRITERIA DECISION ANALYSIS (MCDA) AND AN ETHICAL FRAMEWORK FOR COMPLEX DECISIONS: CASE STUDY OF GROWTH HORMONE FOR TURNER SYNDROME : EE8
THE USE OF SURVIVAL ANALYSES FOR COST-EFFECTIVENESS MODELS: AN EVALUATION OF METHODS USED IN NICE APPRAISALS : MO5
MODELLING COST EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS: A NOVEL APPROACH : MO6
EVALUATION OF A BAYESIAN COMPREHENSIVE DECISION-ANALYTICAL MODELLING FRAMEWORK IN CHRONIC HEPATITIS C : MO7
MARGINAL STRUCTURAL MODELS FOR COMPARING THE EFFECTIVENESS OF MULTIPLE TREATMENTS IN OBSERVATIONAL STUDIES : MO8
A LATENT GENERAL GROWTH MIXTURE MODEL FOR HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON DISEASE ACROSS 36 MONTH : PR1
DEVELOPMENT AND PSYCHOMETRIC PROPERTIES OF A PEDIATRIC PERCEIVED COGNITIVE FUNCTION ITEM BANK (PEDSPCF) : PR2
FIBROMYALGIA FATIGUE—DEVELOPMENT OF A CONCEPTUAL MODEL BASED ON QUALITATIVE PATIENT INTERVIEWS : PR3
LINEAR SCORING RULES FOR PATIENT REPORTED OUTCOMES AND PATIENT PREFERENCES : PR4
INDIVIDUALLY-BASED DYNAMIC MODELING OF INFECTIOUS DISEASES: COST-EFFECTIVENESS OF ADOLESCENT PERTUSSIS BOOSTER VACCINATION FOR THE NETHERLANDS : VA5
INTEGRATED DYNAMIC TRANSMISSION/COST-EFFECTIVENESS MODEL FOR INFLUENZA A AND B PART I: DEVELOPMENT OF AN INTEGRATED MODEL : VA6
COMPARISON OF DIFFERENT STATIC AND DYNAMIC SIMULATION TECHNIQUES FOR THE INFLUENCE OF CHILDREN PNEUMOCOCCAL VACCINATION : VA7
HOW SHOULD HEALTH GAINS OF VACCINATION STRATEGIES BE DISCOUNTED? : VA8
ESTIMATE AVERAGE MEDICAL COSTS IN THE PRESENCE OF RIGHT-CENSORING : CO1
ACCOUNTING FOR THE DRUG LIFE CYCLE AND FUTURE DRUG PRICES IN COST EFFECTIVENESS ANALYSIS : CO2
INDIRECT SOCIAL COST OF MULTIPLE SCLEROSIS: RESULTS FROM A REAL-WORLD OBSERVATIONAL STUDY : CO3
MICRO-COSTING VS GROSS-COSTING IN THE ESTIMATION OF COSTS FOR THE PHARMACOECONOMIC EVALUATION OF GLAUCOMA IN KOREA : CO4
USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES : DB1
PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY— COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN : DB2
USING ELECTRONIC MEDICAL RECORDS TO IDENTIFY UNDIAGNOSED DIABETES MELLITUS IN PRIMARY CARE PRACTICES : DB3
RISK OF STROKE OR MYOCARDIAL INFARCTION OF T2DM PATIENTS TREATED WITH PIOGLITAZONE OR NON-THIAZOLIDINEDIONE IN A MANAGED CARE SETTING IN THE UNITED STATES : DB4
HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS : MO9
EARLY MODELLING: METHODS IN THE ECONOMIC ANALYSIS OF PRE-PHASE II PRODUCTS : MO10
WHEN DOES VALUE OF INFORMATION ANALYSIS ADD VALUE? : MO11
COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS : MO12
TRANSLATION AND LINGUISTIC VALIDATION: EVIDENCE TO SUGGEST THAT AN IN-COUNTRY REVIEW IS NECESSARY : PR5
PRESENTATION OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION SPECIAL INTEREST GROUP (TCA-SIG) : PR6
EVALUATION OF ALTERNATIVE METHODS OF TRANSLATING PATIENT-REPORTED OUTCOME MEASURES : PR7
VALIDATION OF THE PROQOL-HIV QUESTIONNAIRE IN LIGHT OF CROSS-CUTURAL DIFFERENCES FROM 5 CONTINENTS : PR8
COMPARISON OF A DIRECT AND AN INDIRECT METHOD TO DERIVE WILLINGNESS TO PAY FOR COMPLEX HEALTH STATES IN OBSTETRICS : WP1
VALUE OF POSTOPERATIVE ACUTE PAIN CARE FOR PATIENTS OPERATED BY LAPAROTOMY IN A DEPARTMENT OF DIGESTIVE SURGERY IN A FRENCH UNIVERSITY HOSPITAL: A WILLINGNESS TO PAY STUDY : WP2
ASSESSING THE WILLINGNESS-TO-PAY (WTP) FOR INTRADERMAL INFLUENZA VACCINATION IN AUSTRALIA USING DISCRETE CHOICE METHODOLOGY : WP3
DISCRETE CHOICE EXPERIMENT TO DETERMINE WILLINGNESS-TO-PAY FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) TREATMENT : WP4
THE COMMERCIALIZATION OF HEALTH CARE ALLOCATION: CONSUMERS' TOTAL AND DISTRIBUTIONAL HEALTH OUTCOME PERCEPTIONS AND ATTITUDE TOWARDS FLEXIBLE CARE ACCESS PRICING STRATEGIES BY HOSPITALS : PHP1
PREDICTING PERSISTENT FREQUENT USE OF THE PRIMARY HEALTH CARE SERVICES IN A FINNISH SETTING: A BAYESIAN APPROACH : PHP2
EFFECTS OF THE IMPLEMENTATION OF AN ANNUAL CO-PAYMENT LIMIT FOR PRESCRIPTION DRUGS IN AUSTRIA : PHP3
USE OF FREE MEDICINE SAMPLES, DOCTOR PATIENT COMMUNICATION AND COST-RELATED NON-ADHERENCE AMONG OLDER ADULTS : PHP4
RISK OF DEATH AND HOSPITAL LENGTH OF STAY ASSOCIATED WITH CLINICAL EVENTS POTENTIALLY CAUSED BY NEUROMUSCULAR BLOCKADE REVERSAL AGENTS : PHP5
ACUT CARE HOSPITAL BED OCCUPANCY RATE IN HUNGARY BETWEEN 2000 AND 2008 : PHP6
BED OCCUPANCY RATE OF HUNGARIAN INTENSIVE CARE UNITS : PHP7
SURVEY ON THE MANAGEMENT OF ORAL ANTICOAGULATION THERAPY (OAT) IN ITALY : PHP8
HELSPOR'S ASSESSMENT OF THE PHARMACEUTICAL POLICY REFORMS IN GREECE: COST-CONTAINMENT AND ECONOMIC EVALUATION CRITERIA : PHP9
QUALITY ASSURANCE OF FOURTH HURDLE IN HUNGARY— A METHODOLOGICAL APPROACH : PHP10
DOES PHARMACEUTICAL CONSUMPTION IMPROVE HEALTH CARE STATUS? : PHP11
SHORTAGES IN THE AMERICAN MEDICAL DRUG MARKET : PHP12
CALCULATION OF DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN SIMPLIFIED PROCEDURE IN HUNGARY : PHP13
A POLICY ANALYSIS OF THE PORTUGUESE GENERIC MEDICINES MARKET : PHP14
BIOSIMILARS: HGH TO TNFS, HOW WILL PAYERS RESPOND? : PHP15
PARALLEL TRADE OF PHARMACEUTICALS IN POLAND : PHP16
CAN ELECTRONIC NOTIFICATIONS ABOUT SUBSTITUTES CHANGE PHYSICIANS' DRUG PRESCRIPTION HABITS? DEFINITELY YES! : PHP17
COMPARATIVE ANALYSIS OF THE IMPACT OF POSITIVE DRUG LIST SYSTEM BETWEEN NEW DRUGS VS INCREMENTALLY MODIFIED DRUGS IN SOUTH KOREA : PHP18
APPLYING “VALUE BASED” PRICING TO REGENERATIVE MEDICINE BASED PHARMACEUTICALS : PHP19
COST-EFFECTIVE PHARMACEUTICAL CARE IN THE NETHERLANDS? A REVIEW OF THE PHARMACOECONOMICS AND ITS ROLE IN THE ASSESSMENT AND REIMBURSEMENT OF NEW DRUGS : PHP20
THE ROLE OF MONETARY AND NON-MONETARY INCENTIVES ON THE CHOICE OF PRACTICE ESTABLISHMENT: A STATED PREFERENCE STUDY OF YOUNG PHYSICIANS IN GERMANY : PHP21
TOO MANY AGENCIES FOR DRUG EVALUATION IN SPAIN? : PHP22
GENERAL PRACTITIONERS' PRESCRIPTIONS INDICATORS TRENDS, A TIME-SERIES REVIEW DURING 1998-2003 IN IRAN : PHP23
ANTIPSYCHOTICS CONSUMPTION IN THE REPUBLIC OF CROATIA IN 2005, 2006 AND 2007 : PHP24
IMPACT OF REDUCED COPAYMENTS ON MEDICATION ADHERENCE: DX-RX PAIRINGTM PROGRAM OUTCOMES : PHP25
IMPOVERISHING MEDICINES: A CROSS-COUNTRY COMPARISON OF THE AFFORDABILITY OF MEDICINES : PHP26
ASSESSMENT OF THE INTERNATIONAL NONPROPRIETARY NAMES (INN) PRESCRIBING PILOT PROJECT IN SOUTH KOREA : PHP27
PHARMACEUTICAL CARE IN THE EYES OF THE PATIENT : PHP28
UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES : PHP29
PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK : PHP30
A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES : PHP31
THE USEFULNESS AND CHALLENGES OF PATIENT ACCESS (RISK SHARING) SCHEMES IN THE UK : PHP32
PERCEPTIONS OF THE SAUDI STUDENTS ATTENDING AMERICAN UNIVERSITIES TOWARDS THE NEW SAUDI MANDATORY COOPERATIVE HEALTH INSURANCE PROGRAM (MCHIP) IMPLEMENTED IN SAUDI ARABIA : PHP33
USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH SYSTEM CHARACTERISTICS IN THE UNITED KINGDOWM AND AUSTRALIA : PHP34
COMPARATIVE ASSESSMENT OF POSITIVE REIMBURSEMENT LISTS AND HTA EFFECTIVENESS IN ADRIATIC REGION : PHP35
HEALTH ECONOMICS DATA: USE AND PERCEIVED VALUE IN U.S. PAYERS' FORMULARY DECISIONS : PHP36
SOCIAL HEALTH INSURANCE, PREVENTIVE CARE AND HEALTH CARE EXPENDITURE : PHP37
HOSPITALIZATION COST OF PATIENTS ADMITTED TO THE TEACHING UNIVERSITY HOSPITAL OF LARISSA (TUHL) IN THE REGION OF THESSALY : PHP38
COST MEASURE IN PRIMARY CARE: RETROSPECTIVE BEHAVIOUR OF ACG CASE-MIX SYSTEM AT A SPANISH INTERREGIONAL LEVEL : PHP39
THE CONCENTRATION OF PHARMACEUTICAL MARKET IN SOME MEDICINE GROUPS IN FINLAND : PHP40
LUMP SUM REIMBURSEMENT OF PHARMACEUTICALS IN HOSPITALS IN BELGIUM: ASSESSING THE ADVERSE EFFECTS : PHP41
PHARMACEUTICAL EXPENDITURE AND POTENTIAL AVENUES FOR COST CONTAINMENT IN IRELAND : PHP42
INTERNATIONAL PAYER RESARCH: COMPARING AND CONTRASTING PAYER ROLES AND RESEARCH METHODS IN CANADA, SPAIN, AND THE UK : PHP43
THE RAPID ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN MIDDLE INCOME COUNTRIES—WHAT INFLULENCE DOES IT HAVE ON PHARMACEUTICAL REIMBURSEMENT. RESULTS FROM A SURVEY OF HEALTH CARE DECISION-MAKERS IN 11 COUNTRIES : PHP45
WTP FOR A QALY: THE INDIVIDUAL PERSPECTIVE : PHP46
EARLY ASSESSMENT OF HIGHLY INNOVATIVE MEDICAL TECHNOLOGY: CLINICAL AND ECONOMICAL GAINS OF POINT-OFCARE APPLICATIONS FOR MEASURING POTASSIUM CONCENTRATIONS : PHP47
A NEW TEST OF THE CARERQOL INSTRUMENT: MEASURING ‘CARERELATED QUALITY OF LIFE’ OF INFORMAL CAREGIVERS FOR USE IN ECONOMIC EVALUATIONS : PHP48
PALLIATIVE CARE AND ITS REIMBURSEMENT FOR OUTPATIENT SERVICES IN GERMANY—A SURVEY AMONG OFFICE-BASED PHYSICIANS : PHP49
ASSESSMENT OF PRESCRIPTION DRUG KNOWLEDGE AND THE IMPACT OF COUNSELING ON IT IN PATIENTS VISITING A PUBLIC TEACHING HOSPITAL IN NORTH INDIA : PHP51
AN EVALUATION OF THE POLICY AND THE PROCEDURES OF SUCCESSFUL PHARMACEUTICAL EXPORTERS AND THE COMPARISON IRANIAN COUNTERPART POLICY : PHP52
APPROPRIATE CLASSIFICATION OF HOSPITAL INFUSION SERVICES: MEDICARE REIMBURSEMENT CONSIDERATIONS : PHP53
RECOMMENDATIONS FOR ORPHAN DRUGS IN TWO EU MEMBER STATES—A FOCUS ON THE UNDERLYING PHARMACOECONOMIC EVALUATIONS : PHP55
THE ROLE OF PHARMACOECONOMICS IN DRUG REIMBURSEMENT DECISION-MAKING IN THE NETHERLANDS : PHP56
GLOBAL PRICING AND REIMBURSEMENT (P & R) TRENDS: FURTHER DEVELOPMENTS IN SUPPLY AND DEMAND SIDE CONTROLS FOR MEDICINES : PHP57
MEDICARE DRUG PAYMENT AND PHARMACY HANDLING COSTS: HOW FAR HAVE WE COME? : PHP58
TRENDS IN COMPARATIVE EFFECTIVENESS OF TOP 20 HIGHEST SELLING DRUGS : PHP59
PRICING AND REIMBURSEMENT (P&R) IN BRIC COUNTRIES : PHP60
POSITIVE DRUG LIST IN BULGARIA—5 YEARS LATER : PHP61
FREE BUT VALUABLE: THE ECONOMIC SIGNIFICANCE OF SERVICES PROVIDED BY PORTUGUESE PHARMACIES : PHP62
CONSENSUS OF KEY DECISION MAKERS AND EXPERTS ON THE PRESENT AND FUTURE ON THE ASSESSMENT OF HEALTH TECHNOLOGIES IN SPAIN : PHP63
QUALITY ADJUSTED LIFE YEARS (QALYS) IN ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES IN SPAIN: A REVIEW OF THE 2003-2009 LITERATURE : PHP64
PUBLICATION OF COST-EFFECTIVENESS ANALYSES AND SUBSEQUENT CITATIONS IN THE MEDICAL AND HEALTH ECONOMICS LITERATURE : PHP65
COST-EFFECTIVENESS RESEARCH ON PREVENTIVE MEASURES: A SURVEY OF THE PUBLICATIONS IN 2008 : PHP66
THE PROBLEM-BASED LEARNING AS A NEW PRACTICAL METHOD OF SKILL DEVELOPMENT IN THE HEALTH SCIENCES HIGHER EDUCATION : PHP67
FIRST IMPRESSIONS FROM A SHORT TRAINING COURSE IN RATIONAL USE OF DRUGS FOR THE PHARMACOLOGISTS IN THE PHARMACY SCHOOLS IN TURKEY : PHP68
DOES THE PROCEDURE MATTER? DIFFERENCES IN THE FUNDING OF DRUGS AND MEDICAL SERVICES IN AUSTRALIA : PHP69
HTA INSITE: ANALYSIS OF AN ON-LINE DATABASE OF ALL NICE SUBMISSIONS AND DECISIONS : PHP70
A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) IN POLAND AND THE SCOTTISH MEDICINES CONSORTIUM (SMC) : PHP71
A REVIEW OF PHARMACOECONOMIC EVALUATIONS OF NEW AND EXISTING TECHNOLOGIES BY THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND : PHP72
APPLYING KEY PRINCIPLES FOR IMPROVED HEALTH TECHNOLOGY ASSESSMENT: AN ANALYSIS OF 14 HTA ORGANIZATIONS : PHP73
ELECTROMAGNETIC INTERFERENCES BETWEEN WIRELESS COMMUNICATION TECHNOLOGY AND CRITICAL CARE MEDICAL EQUIPMENT: A HEALTH TECHNOLOGY ASSESSMENT : PHP74
SCANNING THE HORIZON FOR NEW AND EMERGING OMIC TECHNOLOGIES : PHP75
DESIGN AND TESTING OF AN INDICATOR (FINANCIAL BIAS INDICATOR (FBI)) THAT ESTIMATES THE INFLUENCE OF FUNDING IN THE RESULTS (FINANCING BIAS (FB)) OF ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES (EEHT) : PHP76
NEW DRUGS EVALUATION IN SPAIN: THE JOINT COMMITTEE OF NEW DRUGS EVALUATION EXPERIENCE : PHP77
THE ROLE OF HTA AGENCY IN DRUG REIMBURSEMENT DECISIONMAKING PROCESS IN POLAND (HTA IMPACT) : PHP78
A REVIEW OF THE USE OF PROS IN SUBMISSIONS TO NICE : PHP79
CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW : PHP80
USE OF SELF-REPORTED HEALTH STATUS TO PREDICT EMPLOYEE MEDICAL EXPENDITURES : PHP81
ASSESSMENT OF LIFESPAN AND HEALTH STATUS EXPECTATIONS IN HUNGARY; RESULTS OF A WEB-SURVEY : PHP82
EVALUATING PHARMACEUTICAL MARKETING TOOLS IMPLEMENTED BY THE COMPANIES, OBSERVED AND EXPERIENCED BY PHYSICIANS IN PAKISTAN : PHP83
REGIONAL DIFFERENCES IN ACUTE CARE HOSPITAL BED CAPACITIES FOLLOWING THE 2006-2008 HEALTH CARE REFORM IN HUNGARY : PHP84
RECOMMENDATIONS FOR THE USE OF PATIENT REPORTED OUTCOMES TO ASSESS TREATMENT EFFICACY IN CLINICAL GUIDANCE DOCUMENTS RELEASED BY THE FDA AND EMEA : PHP85
ADHERENCE OF PHARMACOECONOMIC STUDIES SUBMITTED FOR THE REIMBURSEMENT AND PRICING SYSTEM IN 2008 TO THE CZECH PHARMACOECONOMIC GUIDELINES : PHP86
COST-EFFECTIVENESS OF HEALTH PROMOTING INTERVENTIONS : PHP87
HOW DOES THE HEALTH IMPROVEMENT NETWORK (THIN) DATA ON PREVALENCE OF CHRONIC DISEASES COMPARE WITH NATIONAL FIGURES? : PHP88
ARE INCREMENTAL BENEFITS FROM MEDICAL CARE DECREASING? AN ANALYSIS OF QALY GAINS OVER TIME : PHP89
PATIENT-HEALTH CARE PROVIDER COMMUNICATION: IMPACT ON PATIENT SATISFACTION ON THE QUALITY OF HEALTH SERVICE : PHP90
IMPLANTABLE LOOP RECORDERS IN UNEXPLAINED TRANSIENT LOSS OF CONSCIOUSNESS (T-LOC) DIAGNOSTICS: A COST-SAVING OPPORTUNITY FOR THE UK NATIONAL HEALTH SERVICE (NHS) : PHP91
COMPARISON OF THE TIME TO PREPARE CONTRAST MEDIA INJECTION IN CT SCAN EXAM WITH PREFILLED SYRINGES AND BOTTLES IN 7 EUROPEAN COUNTRIES : PHP92
POTENTIAL COST-SAVINGS USING IMPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS: THE CASE FOR THE NETHERLANDS : PHP93
ASSESSMENT OF SHORT AND LONG TERM INGUINAL HERNIA RECURRENCE CASES AFTER HEAVY WEIGHT MESH DEVICE UTILIZATION UNDER PUBLIC HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL. WILL THE NEW TECHNOLOGIES IMPROVE THE SURGICAL OUTCOMES? : PHP94
MEDICAL FOODS AND FOODS FOR SPECIAL MEDICAL PURPOSES : PHP95
ALANYL-GLUTAMINE DIPEPTIDE (DIPEPTIVEN®) IN TOTAL PARENTERAL NUTRITION (TPN) THERAPY IN CRITICALLY ILL ITALIAN PATIENTS: A PHARMACOECONOMIC SIMULATION MODEL : PHP96
THE PHARMACOECONOMIC ANALYSIS OF EXTEMPORAL MEDICINES USED FOR TREATMENT OF DISEASES AT CHILDREN IN UKRAINE : PHP97
COSTS OF BLEEDING RELATED COMPLICATIONS AND BLOOD PRODUCT TRANSFUSIONS AMONG SURGICAL PATIENTS : PHP98
A SYSTEMATIC REVIEW EVALUATING COST-EFFECTIVENESS OF ACUPUNCTURE : PHP99
PHARMACY STUDY OF NATURAL HEALTH PRODUCT ADVERSE REACTIONS (SONAR): ACTIVE SURVEILLANCE INCREASES AR REPORTING AND REVEALS TWO NEW INTERACTIONS : PHP100
BURDEN OF THROMBOCYTOPENIA IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY, 2000-2007 : PCN1
DOSE DELAY AMONGST CANCER PATIENTS UNDERGOING CHEMOTHERAPY : PCN2
HEAD AND NECK CANCER PATIENTS AT INCREASED RISK OF COMORBIDITY COMPARED TO CANCER-FREE CONTROLS : PCN3
BISPHOSPHONATES AND TIME TO OSTEONECROSIS DEVELOPMENT. A SYSTEMATIC REVIEW : PCN4
RENAL CELL CARCINOMA PATIENTS ARE TWICE AS LIKELY TO DEVELOP THROMBOEMBOLIC EVENTS COMPARED TO CANCER-FREE CONTROLS : PCN5
A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF LENOGRASTIM AND FILGRASTIM IN THE STEM CELL MOBILIZATION : PCN6
A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AFTER MOBILIZATION WITH LENOGRASTIM AND FILGRASTIM : PCN7
COMORBIDITIES IN PATIENTS WITH METASTATIC COLORECTAL CANCER : PCN8
DEVELOPMENT OF SERUM TESTS FOR COLORECTAL CANCER SCREENING : PCN9
MALIGNANT GASTROINTESTINAL STROMAL TUMORS TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE : PCN10
INDIRECT COMPARISON TO ESTIMATE THE EFFICACY OF INTERVENTIONS IN TREATMENT OF METASTATIC RENAL CELL CARCINOMA: A MIXED TREATMENT COMPARISON : PCN11
EXPLORING THE ROLE OF OUTCOMES RESEARCH IN DUTCH REIMBURSEMENT POLICY: REAL-WORLD PHARMACOECONOMICS OF OXALIPLATIN IN STAGE III COLON CANCER : PCN12
A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN METASTATIC RENAL CELL CARCINOMA : PCN13
AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) : PCN14
CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE : PCN15
EVALUATION OF THE EFFICACY OF THE POPULATION-BASED CERVICAL CANCER SCREENING IN HUNGARY : PCN16
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA : PCN17
OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES: THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE : PCN18
A LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC OUTCOMES ATTRIBUTABLE TO FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML) WITH IMATINIB MESYLATE AND BONE MARROW TRANSPLANTATION (BMT) : PCN19
REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS—A COMPARATIVE ANALYSIS : PCN20
NUMBER NEEDED TO TREAT (NNT) ANALYSIS COMPARING BENEFITS OF LETROZOLE WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NODE-POSITIVE BREAST CANCER : PCN21
COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE: A NUMBER NEEDED TO TREAT ANALYSIS : PCN22
PHARMACOEPIDEMIOLOGY OF PATIENTS TREATED WITH TEMOZOLOMIDE : PCN23
CLINICAL OUTCOMES AND HEALTH CARE RESOURCE UTILISATION OF PATIENTS RECEIVING LAPATINIB FOR BREAST CANCER IN FRANCE: THE LAPS STUDY (LAPATINIB ATU PARCOURS DE SOINS) : PCN24
HALF OF BREAST CANCER PATIENTS STARTING ON TAMOXIFEN COMPLETE FIVE YEARS OF ENDOCRINE TREATMENT : PCN25
RELATIVE IMPACT OF SCREENING AND THERAPEUTIC PROGRESS ON THE REDUCTION OF BREAST CANCER SPECIFIC MORTALITY IN FRANCE: A SIMULATION MODEL OVER THE PERIOD 1994-2005 : PCN26
TRENDS IN COLORECTAL CANCER SCREENING (CRC) PATTERNS AMONG COMMUNITY DWELLING MEDICARE BENEFICIARIES : PCN27
INCIDENCE AND PREVALENCE OF CUTANEOUS MELANOMA IN FRANCE: A POPULATION BASED STUDY FROM EIGHT CANCER REGISTRIES : PCN28
PATTERNS OF COLORECTAL CANCER SCREENING AND OBESITY AMONG MEDICARE BENEFICIARIES : PCN29
THE BURDEN OF MULTIPLE MYELOMA: ASSESSMENT ON OCCURRENCE, OUTCOMES AND COST USING A RETROSPECTIVE LONGITUDINAL STUDY BASED ON ADMINISTRATIVE CLAIMS DATABASE : PCN30
A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POSTMENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY : PCN31
IMPLEMENTATION OF CLINICAL INTERVENTION REPORTING SYSTEM FOR PHARMACISTS : PCN32
BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL : PCN34
BUDGETARY IMPACT OF ORAL CHEMOTHERAPY: REAL-WORLD DATA ANALYSIS FROM PAYERS' PERSPECTIVES IN BRAZIL : PCN35
EVIDENCE-BASED MEDICINE (EBM) AND THE PROFILE OF APPEALS FOLLOWING AUDITING IN CHEMOTHERAPY TREATMENTS : PCN36
EXPECTED ECONOMIC BURDEN OF TREATING ADVANCED SOFT TISSUE SARCOMAS WITH TRABECTEDIN IN RUSSIA : PCN37
NUMBER NEEDED TO TREAT (NNT) TO AVOID ONE GASTROINTESTINAL STROMAL TUMOUR (GIST) RECURRENCE IN BRAZIL. COST COMPARISON AND BUDGET IMPACT ANALYSIS OF ADJUVANT TREATMENT WITH IMATINIB : PCN38
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING TEMSIROLIMUS COMPARED TO INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA : PCN39
COST OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF FIRST LINE METASTASIC RENAL CELL CARCINOMA: BEVACIZUMAB + INTERFERON ALPHA-2A COMPARED WITH SUNITINIB IN SPAIN : PCN40
COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY : PCN41
ECONOMIC EVALUATION OF THE USE OF HAEMOSTATIC SEALANT PATCH FOR PULMONARY LOBECTOMY PROCEDURE : PCN42
THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE : PCN43
TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN : PCN44
COST COMPARISON BETWEEN 90Y IBRITUMOMAB TIUXETAN CONSOLIDATION AND RITUXIMAB MAINTENANCE POSTCHEMOTHERAPY IN NAÏVE PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA IN SPAIN : PCN45
COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A SENSITIVITY ANALYSIS ON THE ECOG STATUS : PCN46
COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY : PCN47
COST OF CARE FOR COLORECTAL CANCER IN IRELAND: A HEALTH CARE PAYER PERSPECTIVE : PCN48
COSTS AND QUALITY OF LIFE OF MULTIPLE MYELOMA (MM) IN ITALY: THE CO.MI.M. STUDY : PCN49
HOSPITALISATIONS FOR HEAD AND NECK CANCERS IN FRANCE : PCN50
THE COSTS OF BREAST CANCER PRIOR TO AND FOLLOWING DIAGNOSIS : PCN51
COSTS OF ADVANCED GASTRIC CANCER (AGC) IN BRAZIL FROM THE PUBLIC PAYER PERSPECTIVE : PCN52
COST PER DISEASE STAGE OF ADVANCED GASTRIC CANCER IN BRAZIL FROM THE PRIVATE PAYER PERSPECTIVE : PCN53
A DESCRIPTIVE ANALYSIS OF SUBJECTS WITH METASTATIC GASTRIC CANCER (MGC) : PCN54
THE ECONOMIC EVALUATION OF SUNITINIB AND SORAFENIB IN MRCC PATIENTS IN THE CZECH REPUBLIC : PCN55
COST OF RENAL CELL CARCINOMA TREATMENT IN PATIENTS TREATED WITH INTERFERON-ALPHA : PCN56
EVALUATION OF THE COMPLICATION RATE AND COST OF TREATMENT ACCORDING TO THE MASCC INDEX IN PATIENTS WITH FEBRILE NEUTROPENIA : PCN57
RESOURCES USED IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY REQUIRING BLOOD TRANSFUSIONS. EPICOST STUDY, PRELIMINARY RESULTS (ONVIDA GROUP) : PCN58
REAL-WORLD COSTS OF ADJUVANT TREATMENT FOR STAGE III COLON CANCER PATIENTS IN THE NETHERLANDS : PCN59
TREATMENT COSTS ASSOCIATED WITH METASTATIC BREAST CANCER : PCN60
HOSPITAL BURDEN RELATED TO UPPER AERODIGESTIVE TRACT CANCERS IN FRANCE : PCN61
COST ANALYSIS OF HORMONE RECEPTOR POSITIVE, ADVANCED BREAST CANCER TREATMENT WITH ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (BPHS) : PCN62
REVIEW OF THE ECONOMIC IMPACT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY : PCN63
CHARACTERIZING RESOURCE USE AND TREATMENT COSTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE UK (UK) : PCN64
INPATIENT COST AND REIMBURSEMENT FOR PATIENTS WITH PROGRESSIVE MALIGNANT THORACIC NEOPLASM IN GERMANY : PCN65
COST EVALUATION OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND QUADRIVALENT HPV VACCINE AGAINST CERVICAL CANCER WITHIN EUROPEAN COUNTRIES : PCN66
LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS : PCN67
US AND CANADIAN COST-EFFECTIVENESS ANALYSES OF US ONCOLOGY TRIAL 9735 PROVIDE ADDITIONAL RATIONALE FOR AVOIDING ANTHRACYCLINES IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER : PCN68
COST-EFFECTIVENESS OF ADDING CAPECITABINE TO TRASTUZUMAB AND DOCETAXEL AS FIRST LINE THERAPY FOR PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (HER2+MBC)—RESULTS FROM SPAIN, FRANCE AND ITALY : PCN69
COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN : PCN70
COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE : PCN71
EPIDEMIOLOGICAL AND COST-EFFECTIVENESS ANALYSIS OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND THE QUADRIVALENT HPV VACCINES IN FRANCE : PCN72
COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY : PCN73
COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID THERAPY FOR RENAL CELL CARCINOMA (RCC) PATIENTS WITH BONE METASTASES IN FRENCH, GERMAN, AND THE UK POPULATIONS : PCN74
COST-EFFECTIVENESS OF THALIDOMIDE COMBINED WITH MELPHALAN AND PREDNISONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA IN WALES : PCN75
COST-EFFECTIVENESS OF CHEMOPREVENTION WITH DUTASTERIDE BASED ON RESULTS FROM THE REDUCE CLINICAL TRIAL : PCN76
COST-EFFECTIVENESS ANALYSIS OF TEMSIROLIMUS VS. SUNITINIB MALATE IN POOR PROGNOSIS METASTATIC RENAL CELL CARCINOMA (MRCC) IN PORTUGAL : PCN77
COST-EFFECTIVENESS ASSESSMENT OF ZOLEDRONIC ACID (ZOL) RELATIVE TO PLACEBO (PBO) IN THE TREATMENT OF LUNG CANCER PATIENTS WITH SKELETAL METASTASES IN FIVE EUROPEAN COUNTRIES : PCN78
COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE+DOCETAXEL VS GEMCITABINE+DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE : PCN79
THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS : PCN80
COST EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS IN CANADA : PCN81
COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION IN SLOVENIA : PCN82
COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE + LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION: A UK PERSPECTIVE : PCN83
COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS PACLITAXEL ONCE WEEKLY IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSED AFTER ANTHRACYCLINE CHEMOTHERAPY IN SPAIN : PCN84
COST-EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN RELAPSED MANTLE CELL LYMPHOMA PATIENTS IN CANADA : PCN85
THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/ REFRACTORY MULTIPLE MYELOMA—A NORDIC COMPARISON : PCN86
A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY : PCN87
AN ECONOMIC EVALUATION OF RITUXIMAB VERSUS OTHER FIRSTLINE TREATMENTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND : PCN88
A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN : PCN89
MASS SCREENING FOR COLORECTAL CANCER: ARE ALTERNATIVES TO THE GUAIAC FECAL OCCULT BLOOD TEST COST-EFFECTIVE? : PCN90
LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER : PCN91
COST-EFECTIVENESS ANALYSIS OF DOCETAXEL VS DOCETAXEL+TRASTUZUMAB AS FIRST LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METATSTASTIC BREAST CANCER HER2/NEU+ : PCN92
HEALTH ECONOMICS OF HPV VACCINATION IN AUSTRIA—COST-EFFECTIVENESS OF VACCINATING 12 YEAR OLD GIRLS : PCN93
ECONOMIC EVALUATION OF DOCETAXEL IN THE CONTEXT OF BREAST CANCER IN PORTUGAL : PCN94
COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN METASTATIC COLORECTAL CANCER: RESULTS OF MARKOV COHORT SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA : PCN95
COLORECTAL CANCER SCREENING: COST-EFFECTIVENESS OF CT COLONOGRAPHY : PCN96
COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC) : PCN97
COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY : PCN98
COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN PATIENTS WITH SUPERFICIAL BASAL CELL CARCINOMA AND CONTRAINDICATION TO SURGICAL INTERVENTION/CRYOTHERAPY : PCN99
COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN : PCN100
COST-EFFECTIVENESS OF SHORT-ACTING OPIOIDS FOR BREAKTHROUGH PAIN IN CANCER PATIENTS—A SCOTTISH-BASED DECISION-ANALYSIS MODEL : PCN101
COST EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2+VE BREAST CANCER IN ITALY UTILIZING FOLLOW UP DATA : PCN102
PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FLUDARABINE-CYCLOPHOSPHAMIDE REGIMEN IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS IN SPAIN : PCN103
COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA : PCN104
ECONOMIC EVALUATION OF TRABECTEDIN IN THE TREATMENT OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) IN THE FINNISH SETTING : PCN105
EXPLORING THE COST-EFFECTIVENESS OF A SMOKING-CESSATION PROGRAM ENHANCED WITH INDIVIDUAL GENETIC FEEDBACK ON LUNG CANCER RISK : PCN106
COST-EFFECTIVENESS OF HPV VACCINATION—AN OVERVIEW ON INTERNATIONAL STUDY RESULTS : PCN107
PHARMAECONOMIC EVALUATION OF THE USE OF PROLONGED LIBERATION HIDROMORFONE IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN FOR CANCER AT AN INSTITUTIONAL LEVEL IN MEXICO : PCN108
COST-EFFECTIVENESS OF RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE DUTCH SETTING : PCN109
COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX ± BEVACIZUMAB FOR TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN SAUDI ARABIAN HOSPITAL SETTING : PCN110
COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE : PCN111
COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER BRAZILIAN PRIVATE PAYER PERSPECTIVE : PCN112
PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN : PCN113
COST-EFFECTIVENESS ANALYSIS OF PEMETREXED/CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY: RESULTS FOR THE ADENOCARCINOMA HISTOLOGY SUB-POPULATION : PCN114
COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN : PCN115
A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE : PCN116
COST-UTILITY MODEL TO EVALUATE ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER IN THE USA : PCN117
COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: DESCRIPTION OF A NICE SUBMISSION : PCN118
COST EFFECTIVENESS ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT THERAPY FOR EARLY STAGE BREAST CANCER BASED ON THE 100-MONTH ANALYSIS OF THE ATAC TRIAL FROM A GERMAN PERSPECTIVE : PCN119
COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND : PCN120
COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND : PCN121
COST-EFFECTIVENESS ANALYSIS OF HORMONAL THERAPIES IN PATIENTS WITH ADVANCED PROSTATE CANCER IN ITALY : PCN122
LONG-TERM COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN—AN UPDATED ANALYSIS BASED UPON THE 100 MONTH FOLLOW UP OF THE ANASTROZOLE OR TAMOXIFEN ALONE OR IN COMBINATION (ATAC) TRIAL : PCN123
COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL : PCN124
AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANçAIS DE PNEUMO-CANCéROLOGIE) 05-06 STUDY : PCN125
LOSS OF WORK ACTIVITY AND PRODUCTIVITY IN CAREGIVERS ATTENDING TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH TEMSIROLIMUS OR INTERFERON-ALFA: EVALUATIONS FROM A PHASE 3 RANDOMIZED TRAIL : PCN126
DYNAMIC CONTRAST-ENHANCED ULTRASOUND WITH QUANTIFICATION TO ASSESS TARGETED TREATMENT EFFICACY: RESULTS OF A MULTI-CENTRIC PROSPECTIVE COST STUDY : PCN127
BREAST CANCER DIAGNOSTIC PROCESS: MANAGEMENT AND COST EVALUATION IN ITALY : PCN128
FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC : PCN129
HEALTH UTILITIES OF CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN DFCI 95-01 RANDOMIZED CLINICAL TRIAL : PCN130
UTILITY LIBRARY TO CAPTURE UTILITIES IN THE AREA OF ONCOLOGY : PCN132
POPULATION PREFERENCES FOR TREATMENT OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA : PCN133
VALIDATION OF A KOREAN TRANSLATION OF CANCER THERAPY SATISFACTION QUESTIONNAIRE (CTSQ): A PILOT STUDY : PCN134
USING THE FACT-LEUKEMIA SUBSCALE TO EVALUATE QUALITY OF LIFE IN LEUKEMIA PATIENTS WORLDWIDE : PCN135
COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG LOCAL STAGE PROSTATE CANCER PATIENTS: TYPES, FACTORS ASSOCIATED WITH USE AND PERCEIVED BENEFITS : PCN136
ONCOLOGY PATIENT-REPORTED CLAIMS: MAXIMISING THE CHANCE FOR SUCCESS : PCN137
INFORMATION NEEDS: A STUDY ABOUT ONCOLOGICAL PATIENTS IN THE ITALIAN CONTEXT : PCN138
FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) : PCN139
IMPACT OF TUMOR RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VELCADE/MELPHALAN/PREDNISONE (V-MP): RESULTS FROM THE VISTA TRIAL : PCN140
QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) FROM THE AVADO STUDY: THE IMPORTANCE OF IMPUTATION METHODS FOR HANDLING MISSING DATA : PCN141
EVALUATION OF THE QUALITY OF LIFE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WHO FAILED TO FIRST LINE CHEMOTHERAPY IN TREATMENT WITH ERLOTINIB VS TAXANES : PCN142
WILLINGNESS TO PAY FOR A LIFE-YEAR GAINED FROM THE PERSPECTIVE OF THE GENERAL POPULATION : PCN143
PATTERNS OF EMPLOYMENT AFTER CANCER: RESULTS OF A LONGITUDINAL STUDY : PCN144
HEALTH ECONOMIC REVIEW OF NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT IN THE UNITED STATES : PCN145
MIND THE GAP: ASSESSING THE DIFFERENT DATA REQUIREMENTS BETWEEN REGULATORY APPROVAL AND HEALTH TECHNOLOGY ASSESSMENT : PCN146
FIELD TESTING OF A MULTICRITERIA DECISION ANALYSES (MCDA) FRAMEWORK FOR COVERAGE OF A DIAGNOSTIC TEST FOR CERVICAL CANCER IN SOUTH AFRICA : PCN147
ADDRESSING DECISIONS ABOUT CLINICAL GUIDANCE AND ITS ACTIVE IMPLEMENTATION: SEQUENTIAL OR INTEGRAL ANALYSIS? AN APPLICATION IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER : PCN148
COST ANALYSIS OF 10-YEARS FOLLOW-UP OF CHEMOTHERAPY REGIMENS WITHIN THE SLOVAK REPUBLIC : PCN149
THE RELATIONSHIP BETWEEN DRUG UTILIZATION AND OUT OF POCKET EXPENSES FOR ORAL ANTINEOPLASTICS COMPARED TO A MARKET BASKET OF COMMONLY USED DRUGS : PCN150
CROSS-REGIONAL FLOWS OF CANCER PATIENTS IN GREECE: URBANIZATION OF CANCER TREATMENT : PCN151
NEW JAPANESE PREFECTURAL GOVERNMENT CANCER CONTROL PROGRAMS: A SYSTEMATIC REVIEW AND AN INTERNATIONAL COMPARISON : PCN152
PERFORMANCE MONITORING OF ORGANIZED CANCER SCREENING PROGRAMMES USING ADMINISTRATIVE DATA : PCN153
ANTICANCER DRUG EXPENDITURE IN CATALONIA 2003-2007 : PCN154
“PATIENT ACCESS SCHEMES”—THE USE OF RISK-SHARING IN THE UK : PCN155
EFFECTS OF PHARMACEUTICAL INNOVATION AND DEMOGRAPHIC CHANGE ON THE GERMAN ONCOLOGY MARKET : PCN156
COST-EFFECTIVENESS OF UGTIAI GENOTYPING IN IRINOTECAN CANCER THERAPY : PCN157
LUXEMBOURG LUNG CANCER PROJECT: POTENTIAL CLINICAL AND ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES IN LUXEMBOURG : PCN158
TREND OF METASTASECTOMY AND CHEMO- AND BIOLOGIC THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER : PCN159
MODELLING NUMBER OF CANCER PATIENTS POTENTIALLY TREATED WITH TARGETED PHARMACOTHERAPY IN THE CZECH REPUBLIC : PCN160
REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY : PCN161
REIMBURSEMENT OF ACTIVE-IMMUNOTHERAPEUTICS (AI): AN ANALYSIS BASED ON A STUDY OF CURENT REIMBURSEMENT APPROACHES : PCN162
RURAL-URBAN DIFFERENCES IN COLORECTAL CANCER HOSPITALIZATIONS IN WEST VIRGINIA, USA : PCN163
TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA) : PCN164
SYSTEMATIC REVIEW OF PUBLISHED META-ANALYSES, SYSTEMATIC REVIEWS, AND HEALTH TECHNOLOGY ASSESSMENTS OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA : PCN165
TRAZTUZUMAB ON ADJUVANT BREAST CANCER TREATMENT: EVIDENCE SYNTHESIS AND A HEALTH TECHNOLOGY EVALUATION : PCN166
REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF COLORECTAL CANCER : PCN167
REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF BREAST CANCER : PCN169
PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN FRENCH HOSPITALS : PCN170
IDENTIFYING STRUCTURAL UNCERTAINTY IN ECONOMIC MODELS OF CANCER TREATMENTS: A CASE STUDY OF IRINOTECAN IN COLORECTAL CANCER (CRC) : PCN171
TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE: A RETROSPECTIVE LONGITUDINAL STUDY : PCN172
PERCEPTION OF PAIN AFTER CAESAREAN SECTION FROM THE POINT OF VIEW OF PUERPERAL MOTHERS : PIH1
ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI'S) ANTIDEPRESSANT MEDICATIONS AMONG CHILDREN: A REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS) : PIH2
DUTASTERIDE PLUS TAMSULOSIN PROVIDES SUPERIOR IMPROVEMENTS IN PATIENT-REPORTED QUALITY OF LIFE: 4-YEAR RESULTS FROM THE COMBINATION OF AVODART® AND TAMSULOSIN (COMBAT) STUDY : PIH3
ROLE OF LIFESTYLE-RELATED FACTORS IN PELVIC FLOOR MUSCLE STRENGTH CHANGES DURING PREGNANCY : PIH4
EXAMINATION OF GAIT DURING THE TRIMESTERS OF PREGNANCY : PIH5
CHANGES OF HEART RATE VARIABILITY AFTER SHORT-TERM MEDITATION TRAINING IN COLLEGE STUDENT : PIH6
MORTALITY ACCORDING TO THE DAY OF ADMISSION IN INTENSIVE CARE UNITS AND MATERNITY WARDS IN HUNGARY : PIH7
A BUDGET IMPACT ANALYSIS OF DIENOGEST IN TREATING ENDOMETRIOSIS ASSOCIATED PELVIC PAIN IN GERMANY : PIH8
PREVALENCE AND BURDEN OF ILLNESS OF MENOPAUSE: A CANADIAN OBSERVATIONAL STUDY : PIH9
ESTIMATING THE BURDEN OF WOMEN SUFFERING FROM PMS/PMDD: ANALYSIS OF A CROSS-SECTIONAL DATASET : PIH10
SOCIO-ECONOMIC ASPECTS OF THE PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS (CMV) INFECTION IN GERMANY: A BURDEN OF DISEASE STUDY : PIH11
ECONOMIC BURDEN OF POSTMENOPAUSAL OSTEOPOROSIS IN GERMANY: A SYSTEMATIC REVIEW : PIH12
COST-EFFECTIVENESS OF REDUCING MULTIPLE BIRTHS: IN-VITRO FERTILIZATION STRATEGIES IN CANADA : PIH13
THE COST-EFFECTIVENESS OF ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING IN SCOTLAND : PIH14
AN ECONOMIC EVALUATION OF DROSPIRENONE 2 MG / ESTRADIOL 1.033 MG VERSUS TIBOLONE 2.5MG IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH GRADE 1 OR 2 HYPERTENSION IN KOREA : PIH15
ECONOMIC EVALUATION OF TWO ALTERNATIVE TREATMENTS FOR OVARIAN STIMULATION IN ASSISTED REPRODUCTION : PIH16
ECONOMIC EVALUATION OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO: THE POPULAR HEALTH CARE SYSTEM PERSPECTIVE : PIH17
PHARMACOECONOMIC STUDY OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO: INSURANCE COMPANIES PERSPECTIVE : PIH18
COST-EFFECTIVENESS ANALYSIS OF THE NEW FERTILITY TREATMENT (RFSH+RLH) : PIH19
COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS) : PIH21
HEALTH ECONOMIC EVALUATION OF A NEW VACCINE FOR THE PREVENTION OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN ADULTS A GERMAN ANALYSIS : PIH22
ECONOMIC EVALUATION OF ATOSIBAN COMPARED TO BETAMIMETICS FOR THE TREATMENT OF PRETERM LABOUR IN AUSTRIA : PIH23
CHANGING THE SURGICAL WOUND CLOSURE MANAGEMENT PATHWAY: TIME AND SUPPLIES WITH PRINEO* VS. STANDARD OF CARE FOR BREAST RECONSTRUCTION SURGERY : PIH24
TIME AND SUPPLIES FOR WOUND MANAGEMENT DURING AND AFTER BREAST REDUCTION SURGERY IN GERMANY AND THE NETHERLANDS: PRINEO* VS STANDARD OF CARE : PIH25
TREATMENT DURATION AND PRESCRIPTION REFILL RATE FOR VAGINAL ESTROGEN THERAPY IN MEDICAID ENROLLED WOMEN WITH ATROPHIC VAGINITIS : PIH26
HEALTH RELATED QUALITY OF LIFE AND UTILITY SCORES IN MENOPAUSAL WOMEN : PIH27
VALIDATION OF THE SF-36 IN PATIENTS WITH ENDOMETRIOSIS : PIH28
VALIDATION AND CROSS-NATIONAL EQUIVALENCE OF THE EYELASH SATISFACTION QUESTIONNAIRE : PIH29
SYMPTOMS AND IMPACT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD): CONCEPTS AND MEASUREMENT : PIH30
WOMEN'S PREFERENCES FOR OVARIAN STIMULATING HORMONES IN THE TREATMENT OF INFERTILITY : PIH32
DRUG USE BEFORE AND DURING PREGNANCY IN REPUBLIC OF SERBIA : PIH33
THE APPLICATIONS OF GEOGRAPHIC INFORMATION SYSTEM TO QUALITY OF LIFE STUDIES: USING TAIWAN AS AN EXAMPLE : PIH35
DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN POSTMENOPAUSAL WOMEN ENROLLED IN POSSIBLE EU® : PIH36
ASSESSMENT OF THE QUALITY OF LIFE IN WOMEN WITH VENOUS DISEASE : PIH37
RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND MULTIMORBIDITY AMONG OLDER PERSONS IN GERMANY—RESULTS OF THE PRISCUS-COHORT : PIH38
VALIDITY AND RELIABILITY OF QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE FOR TURKISH WOMEN : PIH39
WILLINGNESS TO PAY PER QUALITY-ADJUSTED LIFE YEAR OF CHRONIC PROSTATITIS PATIENTS IN CHINA : PIH40
PRESCRIPTION PATTERNS AND EXPENDITURE OF LONG-TERM BENZODIAZEPINE TREATMENT IN ELDERLY OUTPATIENTS IN TAIWAN : PIH41
RESULTS OF AN OBSERVATIONAL STUDY IN 574 COMMUNITY PHARMACIES IN SPAIN CHARACTERIZING PATIENT PROFILES OF MEN ASKING FOR ERECTILE DYSFUNCTION MEDICATION : PIH42
EARLY ASSESSMENT OF A NEW TREATMENT FOR ADOLESCENT IDIOPATHIC SCOLIOSIS : PIH43
VARIATIONS IN CHANGES OF PRESCRIBING BEHAVIORS AMONG PHYSICIANS AFTER THE RELEASE OF WHI REPORT : PIH44
A COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1:2 DOSE RATIO IN THE TREATEMENT OF BRONCHIAL ASTHMA : PRS1
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VARENICLINE FOR SMOKING CESSATION COMPARED WITH PLACEBO, NICOTINE REPLACEMENT THERAPY OR SUSTAINED-RELEASE BUPROPION : PRS2
A COMPARISON OF EFFICACY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1:1 DOSE RATIO IN THE TREATMENT OF BRONCHIAL ASTHMA : PRS3
INDIRECT COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE AND BUDESONIDE IN THE TREATEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE : PRS4
PRIMARY CARE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS FROM GENERAL PRACTICE DATABASE : PRS5
LESS THAN 20% OF COPD PATIENTS PERSIST WITH LONG-ACTING INHALED DRUGS FOR AT LEAST THREE YEARS : PRS6
IMPACT OF COUGH AND/OR SPUTUM SYMPTOMS ON THE BURDEN OF COPD IN EUROPE AND THE USA: A CROSS-SECTIONAL, OBSERVATIONAL STUDY : PRS7
OPTIMA MODEL-BASED COST-UTILITY ANALYSIS OF FIXED COMBINATIONS SALMETEROL/FLUTICASONE VS. BUDESONIDE/ FORMOTEROL IN TREATMENT OF ASTHMA IN RUSSIA : PRS8
THE IMPACT AND COSTS OF REIMBURSED SMOKING CESSATION USING VARENICLINE IN DENMARK : PRS9
THE ECONOMIC IMPLICATION OF EARLY DETECTION OF COPD IN GENERAL PRACTICE IN DENMARK : PRS10
ANALYSIS OF ASTHMA-RELATED OUTCOMES AND COSTS FOR PERSISTENT ASTHMA PATIENTS TREATED WITH BECLOMETHASONE DIPROPIONATE HFA OR BUDESONIDE INHALATION POWDER : PRS11
THE CZECH BURDEN STUDY: BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION : PRS12
THE CZECH BURDEN STUDY: SUBGROUP ANALYSIS (BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION) : PRS13
MEDICAL AND PRODUCTIVITY COSTS ATTRIBUTABLE TO OBESITY IN WORKING ADULTS WITH ASTHMA IN THE U.S. : PRS14
NEW PHARMACOECONOMIC MODEL OF ASTHMA MAINTENANCE TREATMENT (OPTIMA) IN RUSSIA. TO TREAT OR NOT TO TREAT: MAINTENANCE TREATMENT VS. NO MAINTENANCE TREATMENT : PRS15
COST EFFECTIVENESS OF VARENICLINE COMPARED WITH EXISTING SMOKING CESSATION STRATEGIES IN HONG KONG : PRS16
COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY : PRS17
COST-EFFECTIVENESS ANALYSIS OF FORMOTEROL ASSOCIATED TO BUDESONIDE FOR MAINTENANCE AND RELIEVER THERAPY (SYMBICORT SMART) VERSUS SALMETEROL ASSOCIATED TO FLUTICASONE IN THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA UNDER THE BRAZILIAN SOCIETAL PERSPECTIVE : PRS18
IS IT TIME FOR SMOKING CESSATION PRODUCTS TO BE REIMBURSABLE IN THAILAND? : PRS19
ECONOMIC EVALUATION OF THE IMPACT OF THE MEXICO CITY'S NON-SMOKERS HEALTH PROTECTION ACT : PRS20
COST-EFFECTIVENESS ANALYSIS OF XOLAIR UNDER REAL LIFE CONDITIONS IN BELGIAN PATIENTS WITH SEVERE ALLERGIC ASTHMA : PRS21
COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN SPAIN. : PRS22
FRENCH GATEKEEPING COST-EFFECTIVENESS IMPACT ON CHRONIC PATIENTS TREATED WITH INHALED CORTICOSTEROIDS, IN REAL LIFE : PRS23
THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING CESSATION IN POLAND : PRS24
CAN THE FRENCH GATEKEEPING SYSTEM BE COST-EFFECTIVE FOR PATIENTS WITH CHRONIC RESPIRATORY DISORDER? : PRS25
COST-EFFECTIVENESS OF GRAZAX IN THE PAEDIATRIC POPULATION FOR THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS IN GERMANY : PRS26
MARKOV MODEL FOR HEALTH-ECONOMIC EVALUATIONS OF COPD IN GERMANY : PRS27
ADD-ON OMALIZUMAB IN PERSISTENT DIFFICULT-TO-TREAT ASTHMA: A 12-MONTH STUDY ON CLINICAL, ECONOMIC OUTCOMES AND RELATED COST/UTILITY : PRS28
QUALITY OF LIFE AND WORK PRODUCTIVITY IN ALLERGIC RHINITIS PATIENTS SUFFERING FROM BOTH NASAL AND OCULAR SYMPTOMS—AN OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES IN EUROPE : PRS29
IMPACT OF OCULAR SYMPTOMS ON RESOURCE UTILISATION AND WORK PRODUCTIVITY IN MANAGEMENT OF AR—AN OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES IN EUROPE : PRS30
PRESCRIPTION PATTERNS OF AND TREATMENT ADHERENCE TO INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS AMONG ASTHMATIC CHILDREN : PRS31
ADJUSTING THE NICOTINE DOSE: THE KEY TO A SUCCESSFUL, “TAILORED” METHOD OF QUITTING SMOKING : PRS32
DEVELOPMENT OF A PREFERENCE-BASED ALGORITHM TO REPORT UTILITIES FOR EXACERBATIONS OF COPD FROM THE EXACT : PRS33
ITEM SELECTION AND SCORING DEFINITION OF A DISEASE-SPECIFIC INSTRUMENT TO ASSESS THE HANDICAP IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS, FOR USE IN CLINICAL ROUTINE PRACTICE : PRS34
OPINION OF ASTHMA PATIENTS TREATED ACCORDING TO GINA 2006 GUIDELINES—THE EPAGGELIA STUDY : PRS35
XOLAIR QUALITY OF LIFE RESULTS AS MEASURED IN A BELGIAN OBSERVATIONAL STUDY IN PATIENTS WITH SEVERE ALLERGIC ASTHMA : PRS36
IMPROVEMENTS IN QUALITY OF LIFE FOR PATIENTS UNDERGOING COPD REHABILITATION AT MUNICIPALITY HEALTH CARE CENTRES IN DENMARK : PRS37
ASSOCIATION BETWEEN SMOKING AND HEALTH-RELATED QUALITY OF LIFE : PRS38
VALIDATION OF THE SPANISH VERSION OF THE “COPD AND ASTHMA SLEEP IMPACT SCALE (CASIS)” QUESTIONNAIRE : PRS39
IMPACT OF COUGH AND/OR SPUTUM SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE IN COPD PATIENTS: AN OBSERVATIONAL, CROSS-SECTIONAL STUDY IN EUROPE AND THE USA : PRS40
VALIDATION OF THE SPANISH VERSION OF THE “LIVING WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (LCOPD)” QUESTIONNAIRE : PRS41
VALIDATION OF THE SPANISH VERSION OF THE “COPD AND ASTHMA FATIGUE SCALE (CAFS)” QUESTIONNAIRE : PRS42
RELIABILITY AND VALIDITY OF THE SMOKER COMPLAINT SCALE : PRS43
CLINICO-PHARMACOLOGICAL PRESENTATION AND THE OUTCOME OF QUALITY OF LIFE OF PATIENTS WITH EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) : PRS44
CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 475: A POPULATION-BASED STUDY : PRS45
OFF-LABEL PRESCRIBING OF INHALED CORTICOSTEROID/ LONG ACTING BETA-AGONIST COMBINATION PRODUCTS IN COPD PATIENTS : PRS46
SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULES— THE EXAMPLE OF RSV : PRS47
A SURVEY OF TOBACCO CESSATION INTERVENTIONS IN THE DENTAL SETTING IN JAPAN: NICOTINE REPLACEMENT THERAPY, ATTITUDES TOWARDS TOBACCO CESSATION EDUCATION, AND BARRIERS TO CESSATION COUNSELING : PRS48
FACTORS RELATED TO STOP SMOKING'S ATTEMPTS AMONG A FRENCH COHORT OF SMOKERS: (FOCUS STUDY) : PRS49
USE OF A BAYESIAN MIXED TREATMENT META ANALYSIS TO SUPPORT REIMBURSEMENT DECISION MAKING OF PHOSPHATE BINDER THERAPY IN END-STAGE RENAL DISEASE : PUK1
EFFECTIVENESS AND COST-EFFICACY OF PHOSPHATBINDERS IN HEMODIALYSIS : PUK2
FORECASTING SPANISH RENAL REPLACEMENT THERAPY TRENDS FROM REGISTRY DATA: A QUANTILE REGRESSION APPROACH : PUK3
THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PUBLIC HEALTH CARE SYSTEM IN BRAZIL : PUK4
THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL : PUK5
ANALYSIS OF THE PHARMACOTHERAPY COST OF PATIENTS WITH KIDNEY TRANSPLANTATION IN BULGARIA : PUK7
THE COST-EFFECTIVENESS OF PHOSPHATE BINDERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE (CKD) : PUK8
OPEN COLPOSUSPENSION, TENSION-FREE VAGINAL TAPE AND TENSION-FREE OBTURATOR TAPES IN THE MANAGEMENT OF STRESS URINARY INCONTINENCE IN WOMEN: A COLOMBIAN COST-EFFECTIVENESS MODEL : PUK9
COST-EFFECTIVENESS OF COMBINATION THERAPY FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA : PUK10
COST-MINIMIZATION ANALYSIS: MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA) VS. ARANESP (DARBEPOETIN ALFA) IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) WHO ARE NOT RECEIVING HAEMODIALYSIS, IN POLISH SETTING : PUK11
COST-EFFECTIVENESS OF ACE INHIBITOR THERAPY TO PREVENT DIALYSIS IN NON-DIABETIC NEPHROPATHY—INFLUENCE OF THE ACE INSERTION / DELETION POLYMORPHISM : PUK12
DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE (SIGIT-QOL) TO EVALUATE THE EFFECTS OF GASTROINTESTINAL SYMPTOMS ON HEALTH RELATED-QUALITY OF LIFE IN SOLID-ORGAN TRANSPLANT RECIPIENTS WITH A FUNCTIONING GRAFT : PUK13
HOW DO PATIENTS DESCRIBE THEIR SYMPTOMS OF INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS)? QUALITATIVE INTERVIEWS WITH PATIENTS TO SUPPORT THE DEVELOPMENT OF A PATIENT-REPORTED SYMPTOM-BASED SCREENER FOR IC/PBS : PUK14
STRESS URINARY INCONTINENCE: ASSESSMENT OF WOMEN'S PREFERENCES : PUK15
QUALITY OF LIFE OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT RECIPIENTS WITH GASTROINTESTINAL TRACT COMPLAINTS TO MYCOPHENOLATE MOFETIL (MMF). MYVIDA STUDY : PUK16
CHRONIC OPIOID THERAPY IN ELDERLY PATIENTS WITH IMPAIRED RENAL FUNCTION OR WITH A HIGH RISK OF KIDNEY FAILURE IN GERMANY : PUK17
MISDIAGNOSIS AND MISTREATMENT OF A COMMON SIDE-EFFECT— ACE INHIBITOR INDUCED COUGH : PCV1
INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM : PCV2
USE OF SPIRONOLACTONE IN THE TREATMENT OF CONGESTIVE HEARTH FAILURE : PCV3
SIGNAL DETECTION OF BRADYCARDIA ASSOCIATED WITH ATENOLOL HYDROCHLORIDE : PCV4
PERIODONTAL DISEASE, STATIN USE, AND CARDIOVASCULAR EVENTS : PCV5
DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENT RISK AMONG PRIMARY AND SECONDARY RISK DYSLIPIDEMIA MANAGED CARE PATIENTS IN THE UNITED STATES : PCV6
ASSOCIATION BETWEEN DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENTS AND ASSOCIATED COST IN DYSLIPIDEMIA MANAGEMENT AMONG MANAGED CARE PATIENTS IN THE UNITED STATES : PCV7
PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS WITH A MODERATE CVD RISK, WITH NO OVERT VASCULAR DISEASES NOR DIABETES MELLITUS. THE PANDORA SURVEY—BELGIUM RESULTS : PCV8
CARDIOVASCULAR EVENT REDUCTION AFTER TREATMENT WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS GENERIC SIMVASTATIN THERAPY FROM A MANAGED CARE ORGANIZATION'S PERSPECTIVE IN THE UNITED STATES : PCV9
A MARGINAL STRUCTURAL MODEL TO COMPARE THE EFFECTIVENESS OF INDIVIDUAL ANGIOTENSIN RECEPTOR BLOCKERS IN VETERANS WITH CHRONIC HEART FAILURE : PCV10
UNDERSTANDING THE IMPACT OF STATIN TITRATION; A MODELLING APPROACH : PCV11
WHAT IS THE IMPACT OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES ON CV-EVENTS IN HYPERTENSIVE PATIENTS? : PCV12
EFFECTIVENESS OF ATORVASTATIN, PRAVASTATIN AND SIMVASTATIN IN THE REDUCTION OF CARDIOVASCULAR EVENTS: AN INDIRECT COMPARISON META-ANALYSIS : PCV13
A COMPARISON OF BLOOD PRESSURE OUTCOMES ASSOCIATED WITH THE USE OF ANGIOTENSIN-RECEPTOR BLOCKERS (ARBS) IN PATIENTS SEEN PREDOMINANTLY IN PRIMARY CARE PRACTICES : PCV14
COMBINED OPTIMAL LIPID VALUE GOAL ATTAINMENT AFTER TREATMENT INITIATION WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS EZETIMIBE PLUS SIMVASTATIN COMBINATION THERAPY IN A MANAGED CARE PATIENT POPULATION WITH PRIOR CARDIOVASCULAR DISEASE IN THE UNITED STATES : PCV15
COMPARATIVE EFFICACY OF LOSARTAN AND IRBESARTAN IN HYPERTENSIVE PATIENTS AT SARABURI HOSPITAL, THAILAND 2007 : PCV16
HOW DOES THE DUAL COMBINATION OF ARBS+HCTZ COMPARE TO OTHER DUAL COMBINATIONS IN THE TREATMENT OF HYPERTENSION? : PCV17
COST OF ACHIEVING LDL REDUCTION AMONG PATIENTS TREATED WITH EZETIMIBE CO-ADMINISTRATION COMPARED TO STATIN MONOTHERAPY IN THE UK : PCV18
EFFECT OF CALCIUM CHANNEL BLOCKERS ON CARDIOVASCULAR DISEASE PREVENTION : PCV19
THE EFFICACY OF CLOPIDOGREL VERSUS THE COMBINATION OF LOW DOSE ASPIRIN PLUS EXTENDED-RELEASE DIPYRIDAMOLE IN PREVENTING SERIOUS VASCULAR EVENTS: A NETWORK META-ANALYSIS : PCV20
AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF COMBINATION THERAPIES CONTAINING ARBS VERSUS ACE INHIBITORS : PCV21
CLINICAL EFFICACY OF IMPLANTABLE LOOP RECORDER IN ESTABLISHING THE CAUSES OF UNEXPLAINED OR RECURRENT SYNCOPES : PCV22
WHAT IS THE EFFECTIVENESS OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES WHEN USED AS MONOTHERAPY IN THE REAL-WORLD? : PCV23
A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CLINICAL TRIALS REVIEWING ANTI-ARRHYTHMIC DRUGS FOR THE TREATMENT OF ATRIAL FIBRILLATION : PCV24
THE EFFECT OF ANTI-ARRHYTHMIC DRUG THERAPY ON ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN ATRIAL FIBRILLATION PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS : PCV25
PRACTICE PATTERNS AND QUALITY OF LIFE IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE NORDIC COUNTRIES: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II) : PCV26
COUNTRY-SPECIFIC DIFFERENCES IN 12-MONTH PATTERNS OF ANTIPLATELET USE IN ACS PATIENTS UNDERGOING PCI IN 2007-08: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR) : PCV27
BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POPULATION ANALYSIS OF NET CLINICAL BENEFIT : PCV28
OUTCOMES ASSESSMENT IN LOW & HIGH RISK P.T.C.A. PATIENTS : PCV29
PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008: CZECH REPUBLIC BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II) : PCV30
LONGITUDINAL ASSESSMENT OF LIPID ABNORMALITIES IN A SAMPLE OF ITALIAN PATIENTS: PREVALENCE AND ATTAINMENT OF GOAL/NORMAL LEVELS : PCV31
A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG FRENCH PATIENTS IN PRIMARY CARE : PCV32
ADHERENCE AND PERSISTENCE WITH STATIN THERAPY: PHARMACOUTILIZATION ANALYSIS FROM ADMINISTRATIVE DATABASES OF 5 ITALIAN LOCAL HEALTH UNITS (LHU) : PCV33
QUANTIFICATION METHODS OF ITALIAN PREVALENT POPULATION SUFFERING FROM ATRIAL FIBRILLATION USING PUBLISHED EPIDEMIOLOGICAL DATA : PCV34
PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES : PCV35
CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS UNDER THE EFFECTS OF CERTAIN HARMFUL HABITS AND OPERATIVE DATA : PCV36
PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS AT MODERATE CARDIOVASCULAR RISK—GREEK RESULTS OF THE PANDORA STUDY : PCV37
HOSPITALIZATION AND MORTALITY IN ADVANCED-AGE PATIENTS WITH ATRIAL FIBRILLATION/ATRIAL FLUTTER BUT WITHOUT HEART FAILURE IN THE UNITED STATES : PCV38
RETROSPECTIVE CLAIM DATABASE ANALYSIS OF THE IMPACT OF THE ASCOT-TYPE PROFILE ON ALL-CAUSES MORTALITY AND CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS WITHOUT KNOWN CORONARY HEART DISEASE IN A MEDITERRANEAN POPULATION IN SPAIN : PCV39
ACUTE MYOCARDIAL AND CEREBRAL INFARCTION REGARDING TO SEASONAL, WEEKLY AND DAILY VARIATION IN CASE OF HUNGARY : PCV40
ESTIMATION OF PERSONS ELIGIBLE FOR ICD/CRT THERAPY IN WESTERN EUROPE UNDER THE CURRENT ESC GUIDELINES: A SYSTEMATIC REVIEW OF THE LITERATURE : PCV41
CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS ACCORDING TO METEOROLOGICAL AND ASTRONOMICAL FACTORS : PCV42
USING ELECTRONIC MEDICAL RECORDS (EMRS) TO ASSESS ANTICOAGULATION STATUS ACCORDING TO STROKE RISK IN PATIENTS WITH ATRIAL FIBRILLATION IN AMBULATORY CARE SETTINGS : PCV43
HEART FAILURE IN OLDER PEOPLE: A STUDY OF FACTORS THAT LEAD TO HOSPITALISATION : PCV44
DETERMINING A MODEL-DERIVED RELATIVE STROKE RISK THRESHOLD TO JUSTIFY CAROTID STENTING IN SURGICAL HIGH-RISK PATIENTS : PCV45
PERFLUTREN PROTEIN-TYPE A MICROSPHERES INJECTABLE SUSPENSION, USP DOES NOT INCREASE MORTALITY IN CRITICALLY ILL PATIENTS: RESULTS FROM A RETROSPECTIVE PROPENSITYMATCHED CASE-CONTROL STUDY : PCV46
THE QUANTIFICATION OF THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND ALL-CAUSE MORTALITY : PCV47
A GERMAN HOSPITAL BUDGET IMPACT MODEL COMPARING ANTICOAGULATION STRATEGIES IN PERCUTANEOUS CORONARY INTERVENTION : PCV48
FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE : PCV49
BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN UK HOSPITALS : PCV50
THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE IN ITALY : PCV51
RECONFIGURING TIA CARE PATHWAYS IN HUNGARY: AVOIDING RECURRENT STROKE : PCV52
FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A UK HEALTH CARE PAYER PERSPECTIVE : PCV53
EXAMINING THE COST IMPACTS OF RECONFIGURING TIA CARE IN SPAIN : PCV54
BUDGET IMPACT ANALYSIS OF DIAGNOSTIC OF UNEXPLAINED AND/ OR RECURRENT SYNCOPE WITH APPLICATION OF IMPLANTABLE LOOP RECORDER : PCV55
IMPACT OF INCLUDING PRASUGREL ON THE FORMULARY FOR PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME : PCV56
COSTS OF ATRIAL FIBRILLATION IN SLOVAKIA FROM A PAYER PERSPECTIVE : PCV57
THE DIAGNOSTIC BENEFIT OF STRESS TEST PRIOR TO CARDIAC MULTI-SLICE COMPUTED TOMOGRAPHY IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: CLINIC AND ECONOMIC OUTCOMES FROM THE EMILIA-ROMAGNA MSCT REGISTRY : PCV58
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BETA BLOCKERS FOR CHRONIC HEART FAILURE PATIENTS IN SPAIN : PCV59
BUDGET IMPACT MODEL FOR DETERMINING THE HOSPITAL COSTS OF INTRODUCING PRASUGREL FOR THE LONG TERM TREATMENT OF ACUTE CORONARY SYNDROME TREATED BY PERCUTANEOUS CORONARY INTERVENTION IN FRANCE : PCV60
COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL RESOURCE USE AND COSTS: RESULTS OF HF-ACTION TRIAL : PCV61
PULMONARY ARTERIAL HYPERTENSION (PAH) COST OF ILLNESS IN THE U.S. PRIVATELY-INSURED POPULATION : PCV62
COST OF CARDIOVASCULAR DISEASE IN KOREA: INCIDENCE-BASED APPROACH : PCV63
SHORT AND LONG-TERM ECONOMIC BURDEN OF ISCHEMIC STROKE/TIA PATIENTS : PCV64
TWO-YEAR CLINICAL AND ECONOMIC IMPACT OF PERIPHERAL ARTERIAL DISEASE ON PATIENTS FROM SPAIN WITH ESTABLISHED CORONARY ARTERY OR CEREBROVASCULAR DISEASE: RESULTS FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY : PCV65
COST BURDEN OF ATHENA ENDPOINTS IN ATHENA-LIKE PATIENTS WITH ATRIAL FIBRILLATION/ATRIAL FLUTTER BUT WITHOUT HEART FAILURE IN THE UNITED STATES : PCV66
A COST-OF-ILLNESS ANALYSIS OF ATRIAL FIBRILLATION IN SWEDEN : PCV67
CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) COST OF ILLNESS IN THE PRIVATELY-INSURED POPULATION IN THE UNITED STATES : PCV68
THE COST-OF-ILLNESS OF ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW : PCV69
MANAGEMENT OF ACUTE ISCHEMIC STROKE (IS) AND ASSOCIATED COSTS OVER A 12-MONTH PERIOD IN FRANCE : PCV70
PREVALENCE AND ECONOMIC BURDEN OF HYPERTENSION IN PATIENTS WITH METABOLIC SYNDROME IN SPAIN: AN EPIDEMIOLOGICAL COST-OF-ILLNESS MODEL : PCV71
ESTIMATING LIFETIME ECONOMIC BURDEN OF STROKE IN KOREA ACCORDING TO THE AGE OF ONSET: USING NATIONAL HEALTH INSURANCE CLAIMS DATABASE : PCV72
COST-ANALYSIS OF STROKE PATIENTS WITH THE INTEGRATED WESTERN AND ORIENTAL MEDICAL TREATMENT IN SOUTH KOREA : PCV73
INCREMENTAL COSTS OF HYPERTENSION, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND THEIR COMBINATIONS : PCV74
PATIENTS WITH PULMONARY EMBOLISM AFTER ORTHOPAEDIC SURGERY HAVE SIGNIFICANTLY INCREASED COSTS FOR INPATIENT STAY : PCV75
DIRECT COSTS OF DIAGNOSTIC AND TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN GERMANY : PCV76
HEALTH CARE COSTS AND RESOURCE UTILIZATION FOR ACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS : PCV77
ONE-YEAR HEALTH CARE COSTS FOR ACUTE CORONARY SYNDROME PATIENTS WITH DIFFERENT TREATMENT STRATEGIES DURING THE INITIAL HOSPITALIZATION : PCV78
BURDEN OF ILLNESS STUDY IN PATIENTS WITH RESISTANT HYPERTENSION IN UK : PCV79
LONGITUDINAL COST IMPACT OF ATRIAL FIBRILLATION IN PATIENTS SUFFERING FROM CARDIOVASCULAR DISEASES : PCV80
ECONOMIC IMPLICATIONS OF OBESITY AMONG PEOPLE WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIA : PCV81
THE IMPACT OF LOST THERAPEUTIC BENEFIT (LTB) IN HIGH RISK PATIENTS MANAGED FOR HYPERTENSION IN AUSTRALIAN GENERAL PRACTICE : PCV82
RELATIONSHIP BETWEEN THE COST AND HOSPITAL QUALITY : PCV83
AN ASSESSMENT OF THE COST OF PERCUTANEOUS PULMONARY VALVE IMPLANTATION USING MELODY VERSUS SURGICAL VALVE REPLACEMENT IN PATIENTS WITH RIGHT VENTRICULAR OUTFLOW TRACT DYSFUNCTION : PCV84
COST CONSEQUENCES OF REDUCED CVD RISK THROUGH IMPROVED SBP CONTROL: A COMPARATIVE ANALYSIS OF VALSARTAN VERSUS LOSARTAN : PCV85
COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN HIGH-RISK PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN FRANCE : PCV86
COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND PLANNED PCI: RESULTS FROM THE TRITON-TIMI 38 TRIAL FROM THE GERMAN PERSPECTIVE : PCV87
THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN IRELAND : PCV88
PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE? A MODEL-BASED ANALYSIS : PCV89
PATIENTS ADMITTED TO THE ICU AFTER CARDIOPULMONARY RESUSCITATION: AN ANALYSIS OF OUTCOME, QUALITY OF LIFE AND COST-EFFECTIVENESS : PCV90
COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN AS ADJUNCTIVE THERAPY WITH FIBRINOLYSIS IN SPANISH PATIENTS WITH STELEVATION MYOCARDIAL INFARCTION (STEMI): RESULTS FROM EXTRACT-TIMI 25 : PCV91
COST-EFFECTIVENESS OF AN EXERCISE TRAINING PROGRAM IN HEART FAILURE : PCV92
COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED WITH DOUBLING THE STATIN DOSE: ANALYSIS OF THE INFORCE STUDY IN THE UK : PCV93
THE COST-EFFECTIVENESS OF TITRATION TO GOAL WITH BRAND ROSUVASTATIN COMPARED TO GENERIC SIMVASTATIN IN PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL: PRIMARY AND SECONDARY PREVENTION IN THE BELGIAN HEALTH CARE SETTING : PCV94
COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES IN SOUTH KOREA : PCV95
COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN A FINNISH SETTING : PCV96
COST-EFFECTIVENESS OF IVABRADINE IN PATIENTS WITH CHRONIC STABLE ANGINA IN A DUTCH SETTING : PCV97
COST-EFFECTIVENESS OF ORGANISED INPATIENT CARE FOR STROKE : PCV98
PHARMACOECONOMICS OF DIRECT RENIN INGIBITOR ALISKIREN IN HYPERTENSION TREATMENT OF PATIENTS WITH TYPE-2 DIABETES AND NEPHROPATHY : PCV99
THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), NICOTINIC ACID AND ALL-CAUSE MORTALITY : PCV100
IS PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE GERMAN HEALTH CARE SYSTEM? A MODEL-BASED ANALYSIS : PCV101
COST-EFFECTIVENESS OF VARIOUS ‘SCREEN-AND-TREAT’ SCENARIOS DIRECTED AT ELEVATED ALBUMINURIA TO PREVENT CARDIOVASCULAR AND RENAL DISEASE IN THE GENERAL POPULATION : PCV102
COST-EFFECTIVENESS OF EXTENDED VERSUS NON-EXTENDED PROPHYLAXIS WITH ENOXAPARIN IN HIGH-RISK SURGICAL PATIENTS IN AUSTRALIA : PCV103
THE COST-EFFECTIVENESS ANALYSIS IN SCREENING OF DEEP VEIN THROMBOSIS IN A CLINICAL LABORATORY : PCV104
COST-EFFECTIVENESS OF GENEOTYPE-GUIDED DOSING OF SHORTTERM USE OF WARFARIN AMONG DVT/PE PATIENTS : PCV105
PREDICTED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE OPTIMAL LIPID VALUES WHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH A STATIN IN SPECIAL PATIENT POPULATIONS WITH MIXED DYSLIPIDEMIA : PCV106
ECONOMIC EVALUATION OF EZETIMIBE COMBINED WITH SIMVASTATIN FOR TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA : PCV107
COST EFFECTIVENESS OF MPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS IN FRANCE : PCV108
COST EFFECTIVENESS OF STATIN THERAPY IN SOUTH KOREA : PCV109
COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY : PCV110
A PATIENT'S VIEW OF THE COST-EFFECTIVENESS OF USING LOWDOSE ASPIRIN FOR CVD (CARDIOVASCULAR DISEASE) PRIMARY PREVENTION IN MIDDLE-AGED MEN IN THE UK : PCV111
COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP REPLACEMENT IN IRELAND : PCV112
COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN IN EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN MAJOR ORTHOPEDIC SURGERY IN POLAND : PCV113
DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS : PCV114
TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE MYOCARDIAL INFARCTION : PCV115
COST-EFFECTIVENESS OF BIVALIRUDIN VERSUS HEPARIN PLUS GLYCOPROTEIN IIB/IIIA INHIBITOR IN THE TREATMENT OF ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION—A HORIZONS TRIAL ANALYSIS USING UK VALUATIONS : PCV116
COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND—A DISCRETE EVENT SIMULATION MODELLING : PCV117
ECONOMIC EVALUATION OF INHALED ILOPROST IN PRIMARY PULMONARY HYPERTENSION IN THE UK : PCV118
COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS : PCV119
DRONEDARONE IN ATRIAL FIBRILLATION: MODELING HEALTH OUTCOMES : PCV120
ENDOVASCULAR TREATMENT FOR ACUTE ISCHEMIC STROKE IN THE NETHERLANDS. A COST-UTILITY ANALYSIS : PCV121
ANGIOGRAPHY FOR DIAGNOSING PAOD: COST COMPARISON OF THE DIAGNOSTIC PROCEDURES MRA AND DSA : PCV122
COST OF ARTERIAL HYPERTENSION ACCORDING TO LEVELS OF MORBIDITY IN PRIMARY CARE SETTING : PCV123
COST OF CORONARY ARTERY BYPASS GRAFT (CABG) IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC : PCV124
EVALUATION OF THE ASSOCIATION BETWEEN SERUM SODIUM AND LENGTH OF STAY (LOS) IN PATIENTS HOSPITALIZED FOR HEART FAILURE : PCV125
REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA : PCV126
EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART FAILURE : PCV127
LOADING WITH WARFARIN PROLONGS LENGTH OF HOSPITAL STAY IN PATIENTS WITH ATRIAL FIBRILLATION : PCV128
METHODOLOGY TO ASSESS THE IMPACT OF POOR COMPLIANCE WITH COMMON TREATMENTS : PCV129
COMPLIANCE (ADHERENCE) TO ANTIHYPERTENSIVE THERAPY IN AUSTRALIA : PCV130
NONADHERENCE AND DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID IN PATIENTS WITH CARDIOVASCULAR RISK: THE IMPACT OF GASTROINTESTINAL SYMPTOMS : PCV131
DIFFERENCES IN PERSISTENCE BETWEEN CCBS WHEN COMBINED WITH AN A2RA OR AN ACE ANTIHYPERTENSIVE IN AUSTRALIA : PCV132
INFLUENCING FACTORS TO A GOOD ADHERENCE IN PATIENTS WITH CHRONIC HEART DISEASES : PCV133
PREDICTORS OF NON-PERSISTENCE ON STATIN TREATMENTS IN ITALY: A RETROSPECTIVE : PCV134
HEALTH STATUS IN AN ARGENTINIAN POPULATION SURVEY : RESULTS FROM THE NATIONAL RISK FACTOR SURVEY : PCV135
HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS : PCV136
PREFERENCES OF PATIENTS, PHYSICIANS AND CAREGIVERS IN THE CHOICE OF ABDOMINAL AORTIC ANEURYSMS TREATMENT OPTIONS: THE PREFER STUDY : PCV137
COMPARATIVE RESEARCH BETWEEN ORAL AND SUBCUTANEOUS THROMBOPROPHYLAXIS: THE STOPWATCH PROJECT : PCV138
PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: A UK PILOT STUDY OF ATRIAL FIBRILLATION PATIENTS RECEIVING WARFARIN : PCV139
PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: A UK PILOT STUDY OF WARFARIN-NAÏVE ATRIAL FIBRILLATION PATIENTS : PCV140
UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TAKING LOW-DOSE ACETYLSALICYLIC ACID: AN OBSERVATIONAL STUDY : PCV141
ASSESSING THE QUALITY OF QUALITY OF LIFE MEASURES IN HEART FAILURE: A COMPARISON OF AVAILABLE INSTRUMENTS : PCV142
EXPLORING PATIENTS' SATISFACTION WITH ANTICOAGULANT TREATMENT BY APPLYING STRUCTURAL EQUATION MODELS TO THE PERCEPTION OF ANTICOAGULANT TREATMENT QUESTIONNAIRE (PACT-Q) : PCV143
HEALTH-RELATED QUALITY OF LIFE AND RESOURCE USE IN PATIENTS WITH METABOLIC SYNDROME: A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN : PCV144
IMPACT OF HOSPITALIZATION ON HEALTH-RELATED QUALITY OF LIFE IN ATRIAL FIBRILLATION PATIENTS : PCV145
HAS THE TYPE OF ATRIAL FIBRILLATION DIFFERENT IMPACT ON HRQOL? : PCV146
EXPERIENCE WITH UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TREATED WITH LOW-DOSE ACETYLSALICYLIC ACID : PCV147
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERCHOLESTEROLEMIA : PCV148
ASSESSMENT OF QUALITY OF LIFE AMONG PATIENTS WITH HYPERTENSION AND DIABETES TYPE 2 : PCV149
WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH METABOLIC SYNDROME: A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN : PCV150
REVIEW OF STUDIES EVALUATING THE IMPACT OF POLICY-DRIVEN STATIN SWITCH PROGRAMS ON PATIENTS : PCV151
ASSESSING THE IMPACT OF A COMMUNITY PHARMACY BASED MTM PROGRAM ON OUTCOMES FOR EMPLOYEES WITH HYPERTENSION : PCV152
MARYLAND MEN'S CARDIOVASCULAR PROMOTION—MVP : PCV153
THE INFLUENCE OF INSURANCE COMPANIES' REGULATIONS ON DRUG UTILIZATION; THE EXAMPLE OF SIMVASTATIN AND PREFERENCE POLICY : PCV154
IMPACT OF EXPANDING PHARMACY BENEFITS ON TREATMENT OF CONGESTIVE HEART FAILURE: THE CASE OF MEDICARE PART D : PCV155
MEDICATION ADHERENCE AND PERSISTENCE OF CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS WITH AND WITHOUT DIABETES MELLITUS : PCV157
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM: USAGE IN CROATIA DURING A SEVEN-YEAR PERIOD : PCV158
REAL-WORLD PRACTICE PATTERNS OF ACUTE CORONARY SYNDROME (ACS) PATIENTS WITH AND WITHOUT DIABETES MELLITUS (DM) : PCV160
HEALTH CARE RESOURCES UTILIZATION IN ACUTE CORONARY SYNDROME PATIENTS ONE YEAR AFTER PCI : FRENCH RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR) : PCV161
PUBLIC TENDERING FOR OFF PATENT PHARMACEUTICALS IN BELGIUM—THE SIMVASTATIN CASE : PCV162
GENDER-BASED DIFFERENCES IN HEALTH CARE COSTS AMONG ACS PATIENTS: AN APPLICATION OF THE BLINDER-OAXACA DECOMPOSITION : PCV163
PRESSURES FACED BY PEOPLE WHO CARE FOR SOMEBODY DIAGNOSED WITH A CARDIOVASCULAR CONDITION : PCV164
CHANGES IN THE COST-EFFICACY OF STATINS IN SPAIN AFTER THE INTRODUCTION OF GENERICS AND REFERENCE PRICES : PCV165
ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE IMAGING IN SUSPECTED CORONARY ARTERY DISEASE: A NET COST ANALYSIS & REIMBURSEMENT IMPLICATIONS : PCV166
A CLUSTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE AN AMBULATORY PRIMARY CARE MANAGEMENT PROGRAM FOR PATIENTS WITH DYSLIPIDEMIA: TEAM STUDY : PCV167
COMMUNITY PHARMACY DISPENSING OF PRESCRIPTION MEDICINE SAMPLE PACKS—CHANGING THE BUSINESS OF MEDICINE INITIATION? : PCV168
ACETYLSALICYLIC ACID(ASA) MONOTHERAPY FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: AN ASSESSMENT OF THE MEDICAL BENEFIT USING THE IQWIG METHODOLOGICAL APPROACH : PCV169
A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG HUNGARIAN PATIENTS IN PRIMARY CARE : PCV170
CRITICAL APPRAISAL OF THE JAPANESE GUIDELINE FOR THE MANAGEMENT OF STROKE : PCV171
TREATMENT PATTERNS AMONG PATIENTS WITH HYPERTENSION: RESULTS OF A US SURVEY : PCV172
A RECORD-LINKAGE STUDY OF ADVERSE UPPER GASTRO-INTESTINAL EVENTS WITH NSAIDS IN A UK POPULATION UTILISING DIFFERENT EPIDEMIOLOGICAL DESIGNS TO MINIMISE CONFOUNDING : PGI1
WORK PRODUCTIVITY IN PRIMARY CARE PATIENTS CONSULTING WITH COMPLAINTS OF UPPER GASTROINTESTINAL SYMPTOMS: ESTIMATES FROM THE DANISH RESPONSE STUDY : PGI2
INTRAVENOUS (IV) PROTON PUMP INHIBITORS (PPIS) FOR THE TREATMENT OF PEPTIC ULCER BLEEDING (PUB) : PGI3
SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE : PGI4
PREDICTORS FOR RESPONSE TO PRUCALOPRIDE IN PATIENTS WITH CHRONIC CONSTIPATION : PGI5
EVALUATION OF RESOURCE UTILIZATION AND ECONOMIC IMPACT OF RECURRENCE FOR INGUINAL HERNIA REPAIR PERFORMED WITH PHS DEVICE VERSUS POLYPROPYLENE MESH UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE : PGI6
MANAGEMENT OF OPIOID INDUCED CONSTIPATION (OIC) IN PAIN PATIENTS: A COST OF ILLNESS STUDY IN BELGIUM AND THE NETHERLANDS : PGI7
COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITORS (IV PPI) FOR THE PREVENTION OF GASTRIC OR DUODENAL ULCER REBLEEDING AFTER THERAPEUTIC ENDOSCOPY : PGI8
COST-EFFECTIVENESS OF INTRAVENOUS IRON IN INFLAMMATORY BOWEL DISEASE PATIENTS INTOLERANT TO ORAL IRON : PGI9
ECONOMIC EVALUATION OF A MULTIDISCIPLINARY SUPPORT PROGRAM IN HEPATITIS C TREATMENT: PRELIMINARY RESULTS : PGI10
THE COST EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF ACUTE ULCERATIVE COLITIS PATIENTS IN SCOTLAND : PGI11
RESOURCE UTILIZATION AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C (CHC) IN THAILAND: A HEAVY BUT MANAGEABLE ECONOMIC BURDEN : PGI12
TREATMENT OF MODERATE TO SEVERE PAIN WITH OXYCODONE/NALOXONE TO REDUCE OPIOID-INDUCED CONSTIPATION: A COST-UTILITY ANALYSIS IN BELGIUM AND THE NETHERLANDS : PGI15
RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH OPIOIDINDUCED CONSTIPATION (OIC) IN CANCER PATIENTS IN SWEDEN : PGI16
CONSUMPTION OF HEALTH CARE RESOURCES ASSOCIATED WITH CURRENT MANAGEMENT STRATEGIES FOR NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: AN OBSERVATIONAL EUROPEAN STUDY : PGI17
EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON GENERIC HEALTH RELATED QUALITY OF LIFE USING THE EQ-5D INDEX SCORES IN PATIENTS WITH CHRONIC NON-MALIGNANT PAIN AND OPIOID-INDUCED CONSTIPATION : PGI18
PATIENT RELEVANT ASPECTS OF DIAGNOSTIC QUESTIONNAIRES AND THEIR SUBSCALES IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD) : PGI19
EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON PATIENT REPORTED CONSTIPATION SPECIFIC QUALITY OF LIFE IN A RANDOMIZED DOUBLE—BLIND CLINICAL TRIAL : PGI20
TREATMENT OF CHRONIC HEPATITIS C WHICH DO NOT FOLLOW CLINICAL GUIDELINES IS INCREASING DIRECT MEDICAL COSTS : PGI21
CIRCULAR STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE: HTA REPORT—LOMBARDIA REGION, ITALY : PGI22
STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE—COMPARISON OF HTA REPORTS, FOR TWO ITALIAN REGIONS : PGI23
COMPLIANCE WITH ANTIPSYCHOTIC DRUGS AND HOSPITALIZATION: A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF PEOPLE WITH SCHIZOPHRENIA : PMH1
EVIDENCE FOR SSRI IN THE TREATMENT OF DEPRESSION: EARLY KNOWLEDGE GAIN—LATE CONSEQUENCES IN ROUTINE CARE? : PMH2
OVERCOMING THE CHALLENGES OF MODELLING SCHIZOPHRENIA: A UK CASE STUDY OF THE COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION VS. RISPERIDONE LONG-ACTING INJECTION : PMH3
A SYSTEMATIC REVIEW OF THE REAL-WORLD STUDY EVIDENCE COMPARING THE SAFETY AND TOLERABILITY OF DONEPEZIL, RIVASTIGMINE AND GALANTAMINE FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE : PMH4
USING TREEMAPS TO ASSESS PHYSICAL COMORBIDITY RISK IN PATIENTS WITH BIPOLAR DISORDER : PMH5
IMPACT OF COMORBIDITIES ON ANTIDEPRESSANT INITIATION: DULOXETINE, VENLAFAXINE, AND ESCITALOPRAM VERSUS OTHER SSRIS : PMH6
EFFICACY OF ANTIPSYCHOTICS IN THE PREVENTION OF SCHIZOPHRENIA RELAPSE: A SYSTEMATIC REVIEW OF DOUBLE BLIND RANDOMISED CONTROLLED TRIALS : PMH7
CLINICAL EFFICACY AND SAFETY OF DULOXETINE IN COMPARISON WITH PLACEBO IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN POLAND : PMH8
A SYSTEMATIC REVIEW OF PHARMACOLOGICAL TREATMENTS FOR BIPOLAR I MANIA : PMH9
EFFECTIVENESS AND COST-EFFECTIVENESS OF LIFESTYLE INTERVENTIONS IN PERSONS WITH SEVERE MENTAL DISORDERS. A SYSTEMATIC REVIEW : PMH10
DIFFERENCES BETWEEN CHILDREN AND ADOLESCENTS IN TREATMENT RESPONSE TO ATOMOXETINE AND THE CORRELATION BETWEEN QOL AND ADHD CORE SYMPTOMS : PMH11
COMPARISON OF POLYPHARMACY VS MONOTHERAPY ON OCCURRENCE OF RELAPSE IN SCHIZOPHRENIC PATIENTS - ADVANTAGE OF PROPENSITY SCORING ADJUSTMENT : PMH12
TIME TO OPTIMIZATION OF DOSE IN PATIENTS WITH ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD): DATA FROM THE NETHERLANDS : PMH13
ALZHEIMER'S DISEASE: A PHARMACOEPIDEMIOLOGICAL STUDY : PMH14
INITIAL HIGH-DOSE PRESCRIPTION OF DULOXETINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: DEMOGRAPHIC AND CLINICAL PREDICTORS : PMH15
PREDICTIVE FACTORS FOR HOSPITALIZATION IN FRENCH SCHIZOPHRENIC PATIENTS : PMH16
PREVALENCE, INCIDENCE AND PERSISTENCE OF ANTIDEPRESSANT DRUG PRESCRIBING IN THE ITALIAN GENERAL POPULATION: RETROSPECTIVE DATABASE ANALYSIS : PMH17
SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE : PMH18
MEASUREMENT OF CHRONIC STRESS BETWEEN PEOPLE WORKING IN PROFIT-ORIENTED ENVIRONMENT : PMH19
IMPACT OF DISEASE SEVERITY ON DURATION OF HOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH OLANZAPINE OR HALOPERIDOL IN GERMANY: POST-HOC ANALYSIS OF DATA COLLECTED IN THE GEO STUDY : PMH20
BUDGET IMPACT ANALYSIS OF DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER : PMH21
BUDGET IMPACT OF THE USE OF RISPERIDONE LONG ACTING INJECTABLE IN THE GERMAN HEALTH CARE SYSTEM : PMH22
LABELLED DRUG-RELATED HEALTH PUBLIC EXPENDITURE IN RELATION TO GROSS DOMESTIC PRODUCT IN EUROPE : PMH23
ECONOMIC BENEFITS OF ESCITALOPRAM VERSUS DULOXETINE IN SPAIN : PMH24
CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NONADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/ MIXED EPISODE OF BIPOLAR DISORDER: RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUDY : PMH25
A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE : PMH26
COMPARISON OF COST FOR DIFFERENT TESTS OF DEMENTIA SCREENING : PMH27
INITIAL PRESCRIPTION DOSE OF DULOXETINE AND HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER : PMH28
DIFFERENCES IN HEALTH CARE USES AFTER TREATMENT OF DULOXETINE VERSUS OTHER ANTIDEPRESSANTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK : PMH29
A DYNAMIC MARKOV APPROACH ASSESSING THE BURDEN OF ILLNESS OF GENERALIZED ANXIETY (GAD) DISORDER IN CANADA : PMH30
MEASURING THE ECONOMIC BURDEN OF DEPRESSION USING PATIENT RECORDS : PMH31
COST OF SCHIZOPHRENIA IN FRANCE : PMH32
BURDEN OF BIPOLAR DISORDER: WHAT ARE WE REALLY MEASURING? : PMH33
COSTS OF SCHIZOPHRENIA WITHIN A LARGE GERMAN STATUTORY HEALTH INSURANCE FUND : PMH34
BURDEN OF ILLNESS AND COMORBIDITIES IN ADULT PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) : PMH35
MENTAL HEALTH COSTS INCURRED BY PATIENTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER WHO DO NOT RESPOND TO SUCCESSIVE LINES OF TREATMENT : PMH36
COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN DULOXETINE-REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER: AN ECONOMIC EVALUATION UNDER MEDICAL USUAL PRACTICE IN MENTAL HEALTH CENTERS : PMH37
COST-EFFECTIVENESS OF PREGABALIN VERSUS ISRS/ISRN IN BENZODIAZEPINE-REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER: AN ECONOMIC EVALUATION UNDER MEDICAL USUAL PRACTICE IN MENTAL HEALTH CENTERS : PMH38
COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER: A NESTED-CASE-CONTROL ECONOMIC EVALUATION UNDER USUAL MEDICAL PRACTICE IN MENTAL HEALTH CENTERS : PMH39
COST-EFFECTIVENESS ANALYSIS OF THE INCREDIBLE YEARS PARENT PROGRAM AS A PREVENTIVE INTERVENTION : PMH40
COST-EFFECTIVENESS ANALYSIS OF ANTI-PSYCHOTICS BY ROUTE IN SCHIZOPHRENIA : PMH41
COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY : PMH42
THE COST-EFFECTIVENESS OF QUETIAPINE XR IN THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN SCHIZOPHRENIA : PMH43
COST AND EFFECTIVENESS OF FLUPENTIXOL COMPARED TO OTHER FIRST AND SECOND GENERATION ANTIPSYCHOTIC AGENTS FOR THE TREATMENT OF SCHIZOPHRENIA IN ROUTINE CARE : PMH44
COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND—ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA : PMH45
ESTIMATING THE COSTS OF PSYCHIATRIC HOSPITAL SERVICES IN NIGERIA; A CASE STUDY OF FEDERAL NEUROPSYCHIATRIC HOSPITAL ENUGU, SOUTH EAST NIGERIA : PMH46
ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND CLINICAL AND ECONOMIC OUTCOMES IN SCHIZOPHRENIA AND BIPOLAR DISORDER : PMH47
COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS PAROXETINE AND LITHIUM IN ACUTE BIPOLAR DEPRESSION : PMH48
COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS OTHER ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR DEPRESSION : PMH49
CLINICAL VALIDITY OF REMISSION IN PATIENTS WITH MAJOR DEPRESSION IN POPULATION DATABASES : PMH50
TRENDS IN RATES OF PEDIATRIC BIPOLAR DISORDER-RELATED HOSPITALIZATIONS AND RELATED RESOURCE USE IN THE UNITED STATES : PMH51
PATIENT-REPORTED OUTCOMES IN A VULNERABLE POPULATION: A PILOT STUDY CONDUCTED WITH A NOVEL PATIENT COMMUNITY : PMH52
PATTERNS OF HEALTH CARE RESOURCE UTILIZATION IN JAPANESE PSYCHIATRIC OUTPATIENTS: RESULTS FROM THE ONE-DAY SURVEY CONDUCTED BY THE JAPANESE ASSOCIATION OF NEUROPSYCHIATRIC CLINICS : PMH53
COMPLEX ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: PATIENT CHARACTERISTICS, HEALTH CARE UTILIZATION AND COSTS IN A RETROSPECTIVE OBSERVATIONAL CLAIMS STUDY : PMH54
DEPRESSION TREATMENT ADHERENCE AMONG DEPRESSION PATIENTS WITH COMORBIDITY : PMH55
A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC THERAPY: THE TOOL INSTRUMENT : PMH56
NON-ADHERENCE TO ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA: RELAPSE AND UTILIZATION OF HEALTH CARE RESOURCES IN A 6-MONTH FOLLOW-UP PERIOD : PMH57
TOOL: MULTI-ATTRIBUTE UTILITY FUNCTION REFLECTING PATIENT EXPERIENCE OF SIDE EFFECTS TO ANTIPSYCHOTIC THERAPY : PMH58
FURTHER VALIDITY EVIDENCES OF THE GENERALIZED ANXIETY DISORDER—7 SCALE (GAD-7) : PMH59
A CONCEPTUAL MODEL OF ‘CLEAR THINKING’ RELEVANT TO PATIENTS DIAGNOSED WITH SCHIZOPHRENIA : PMH60
PATIENTS PREFERENCES IN ADULTS WITH ADHD—A DISCRETE CHOICE EXPERIMENT : PMH61
THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: VALIDATION OF A SPECIFIC MEASURE TO EVALUATE HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER : PMH62
ESTIMATION OF A MULTI-ATTRIBUTE UTILITY FUNCTION FOR THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE : PMH63
THE POSTTRAUMATIC STRESS AMONG AMBULANCE PERSONNEL IN HUNGARY : PMH64
ASSOCIATION BETWEEN EARLY ANTIDEPRESSANT RESPONSE AND QUALITY OF LIFE AMONG PATIENT WITH DEPRESSION: RESULTS FROM A 1-YEAR FOLLOW-UP LARGE EPIDEMIOLOGICAL STUDY : PMH65
QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES: COMPARISONS OF INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ORAL AND LONG-ACTING INJECTABLE FORMULATIONS OF OLANZAPINE : PMH66
QUALITY OF LIFE OF OUTPATIENT DEMENTED PATIENTS IN HUNGARY : PMH67
IMPACT OF DEMENTIA UPON CAREGIVER EMPLOYMENT & QUALITY OF LIFE : PMH68
DAILY AVERAGE CONSUMPTION AND AVERAGE DAILY COSTS OF DULOXETINE, VENLAFAXINE-XR, AND PREGABALIN AMONG US COMMERCIALLY INSURED PATIENTS : PMH70
SOCIODEMOGRAPHIC FACTORS AND TOXIC HABITS RELATED TO STUDENT DRUG USE: THE CASE OF THE TECHNOLOGICAL EDUCATIONAL INSTITUTE OF ATHENS : PMH71
BENZODIAZEPINE USE AMONG FREQUENT ATTENDERS TO EMERGENCY DEPARTMENTS: A NATIONWIDE STUDY IN TAIWAN : PMH72
POTENTIAL ABUSE OF COMBINATION ANALGESICS: A DATABASE ANALYSIS : PMH73
REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA— PHARMACOECONOMICS OF AGOMELATIN IN DEPRESSION : PMH74
PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE : PMH75
PREDICTORS FOR DULOXETINE TREATMENT FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK : PMH76
RELATIONSHIP BETWEEN ADHERENCE TO INTERFERONS TO TREAT MULTIPLE SCLEROSIS AND THE NUMBER AND SEVERITY OF RELAPSES : PND1
A BAYESIAN META-ANALYSIS COMPARING TREATMENTS FOR ALZHEIMER'S DISEASE : PND2
EFFICACY AND TOLERABILITY OF NATALIZUMAB IN RELAPSING MULTIPLE SCLEROSIS; A META-ANALYSIS : PND3
THE FEATURES OF MULTIPLE SCLEROSIS IN IRAN : PND4
BUDGET IMPACT ANALYSIS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN VARIOUS ITALIAN REGIONS: THE ROLE OF VENLAFAXINE : PND5
ESTIMATION OF PER-MEMBER-PER-YEAR COSTS FOR MANAGING FALLS OR FRACTURES AMONG HYPNOTIC USERS IN A MANAGED CARE PLAN : PND6
BUDGET IMPACT AND COST—EFFECTIVENESS OF SUGAMMADEX IN THE REVERSAL OF PATIENTS WITH NEUROMUSCULAR BLOCK : PND7
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN : PND8
COST-EFFECTIVENESS AND BUDGET IMPACT MODELLING OF LACOSAMIDE IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN FINLAND : PND9
COST ANALYSIS OF ACTIVA RC®: RECHARGABLE NEUROESTIMULATOR FOR DEEP BRAIN ESTIMULATION THERAPY (DBS) : PND10
NEW ACTIVA PC® FAMILY: COST ANALYSIS OF THE NEW FEATURES FOR DEEP BRAIN STIMULATION THERAPY (DBS) : PND11
COST AND RESOURCE USE RELATED TO NEWLY DIAGNOSED MULTIPLE SCLEROSIS: REAL-WORLD DATA FROM A LARGE US CLAIMS DATABASE : PND12
IMPACT OF CHRONIC (CM) AND EPISODIC MIGRAINE (EM) ON WORK PRESENTEEISM IN 9 COUNTRIES : PND13
COSTS OF ILLNESS IN PARKINSON'S DISEASE IN SIX EUROPEAN COUNTRIES : PND14
THE POTENTIAL ECONOMIC IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON HEALTH CARE COSTS IN THE G4 EUROPEAN COUNTRIES : PND15
ECONOMIC IMPACT OF GENERIC ENTRY OF TOPIRAMATE IN GERMANY: CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF GERMANY : PND16
THE COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE PATIENTS : PND17
COST-EFFECTIVENESS OF A NEW ABSORBABLE HYDROGEL FOR THE PREVENTION OF CSF LEAKS IN FRENCH HOSPITALS : PND18
COST—EFFECTIVENESS OF SUGAMMADEX IN THE MANAGEMENT OF PATIENTS WITH UNANTICIPATED DIFFICULT INTUBATION AND PATIENTS NEEDING RAPID SEQUENCE INTUBATION : PND19
REVERSAL OF NEUROMUSCULAR BLOCKADE WITH SUGAMMADEX— COST-EFFECTIVENESS ANALYSIS : PND20
COST-EFFECTIVENESS OF RASAGILINE COMPARED TO OTHER FIRST LINE TREATMENT OPTIONS OF EARLY PARKINSON'S DISEASE IN THE UNITED STATES : PND21
COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN : PND22
HEALTH ECONOMIC EVALUATION OF LAMOTRIGINE VERSUS LEVETIRACETAME IN THE INITIAL MONOTHERAPY OF EPILEPSY (LALIMO-TRIAL) : PND23
TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES: A COST-UTILITY MODEL : PND24
COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY : PND25
COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS IN SPAIN : PND26
A DISCRETE EVENT SIMULATION OF PREGABALIN COMPARED TO USUAL CARE IN REFRACTORY NEUROPATHIC PAIN : PND27
ADHERENCE AS A PREDICTOR OF THE UTILIZATION OF HEALTH CARE RESOURCES IN A MULTIPLE SCLEROSIS POPULATION USING INTERFERONS : PND28
PARKINSON'S DISEASE DRUG THERAPIES: MEDICATION COMPLIANCE AND PERSISTENCE : PND29
MEDICATION ADHERENCE WITH DISEASE MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS: FINDINGS FROM A US NATIONAL DATABASE OF EMPLOYEES : PND30
HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMER'S DISEASE HEALTH STATE: A CANADIAN SURVEY OF THE GENERAL PUBLIC : PND31
NEW QUALITY OF LIFE (QOL) DATA ON UK PATIENTS WITH REFRACTORY NEUROPATHIC PAIN : PND32
LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) FOR USE IN 29 LANGUAGES : PND33
REVIEW OF PATIENT-REPORTED OUTCOME MEASURES FOR DAYTIME FUNCTIONING : PND34
FACTORS DRIVING PATIENT SELECTION OF PRIMARY MEDICATION FOR MULTIPLE SCLEROSIS : PND35
HEALTH-RELATED QUALITY OF LIFE, EDSS AND TIMED 25-FOOT WALK IN A MULTIPLE SCLEROSIS POPULATION OF A REAL-WORLD OBSERVATIONAL OUTCOMES STUDY: BASELINE DATA FROM ROBUST : PND36
RESPONSIVENESS AND CLINICAL IMPORTANT DIFFERENCES OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS: RESULTS OF A LARGE MULTINATIONAL OBSERVATION STUDY : PND37
COSTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GILLES DE LA TOURETTE'S SYNDROME : PND38
IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS ON NATALIZUMAB IN THE UNITED STATES : PND39
PATIENT REPORTED OUTCOMES IN THE EARLY STAGES OF MULTIPLE SCLEROSIS: THE BEGIN STUDY : PND40
IMPROVEMENT IN PATIENT SATISFACTION WITH INCREASING NATALIZUMAB TREATMENT DURATION IN MULTIPLE SCLEROSIS PATIENTS IN THE UNITED STATES : PND41
INTERPRETING SCORES ON THE MULTIPLE SCLEROSIS-SPECIFIC PRIMUS AND U-FIS OUTCOME MEASURES : PND42
ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE AND RELAPSE IN THE PREVIOUS YEAR AMONG MULTIPLE SCLEROSIS PATIENTS: BASELINE DATA FROM ROBUST : PND43
EVALUATION OF THE IMPACT OF PARKINSON'S DISEASE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE. PD-QOL STUDY : PND44
PROLONGED-RELEASE MELATONIN: REAL-LIFE EVIDENCE FROM A GERMAN LONGITUDINAL PRESCRIPTION DATABASE : PND45
A SYSTEMATIC REVIEW AND META-ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF CIDP : PND46
ASSESSING CANADIANS' WILLINGNESS-TO-PAY FOR ALZHEIMER'S DISEASE MEDICATIONS : PND47
SUPPORT FOR PROVIDING UNRESTRICTED ACCESS TO AN ALZHEIMER'S DISEASE MEDICATION IN CANADA: RESULTS FROM A STUDY OF THE GENERAL POPULATION : PND48
MIGRAINE: PRESCRIBING PATTERNS IN A SOUTH AFRICAN PRIMARY CARE PATIENT POPULATION : PND49
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF PHARMACOTHERAPIES USED IN CHRONIC LOW BACK PAIN : PSY1
EVALUATING ADVERSE EVENT RISK WITH PROPOXYPHENE: ARE THERE DIFFERENCES BETWEEN ELDERLY VERSUS YOUNGER PATIENTS? : PSY2
DETERMINING THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES FROM A COMMERCIAL CLAIMS DATABASE : PSY3
CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA : PSY4
A RETROSPECTIVE CHART REVIEW OF THE TREATMENT OF PHENYLKETONURIA IN THE UK AND ASSOCIATED CLINICAL AND HEALTH OUTCOMES : PSY5
EFFECT OF MODERATE-INTENSITY EXERCISE TRAINING AND DIET ON BODY COMPOSITION AND EXERCISE CAPACITY IN OBESE CHILDREN : PSY6
EVALUATION OF MEASURES UNDERTAKEN TO ENHANCE THE ROBUSTNESS OF THE FABRY OUTCOME SURVEY (FOS) : PSY7
TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK PAIN: RESULTS OF EUROQOL-5 DIMENSION (EQ-5D) AND SHORT FORM-36 (SF-36) HEALTH STATUS QUESTIONNAIRES : PSY8
ADHERENCE TO DULOXETINE THERAPY AND HEALTH CARE COSTS AMONG PATIENTS WITH FIBROMYALGIA : PSY9
TREATING FIBROMYALGIA WITH DULOXETINE: WHAT IS THE ASSOCIATION BETWEEN AVERAGE DAILY DOSE, MEDICATION ADHERENCE, AND HEALTH CARE COSTS? : PSY10
DEFI (DETERMINATION OF EPIDEMIOLOGY OF FIBROMYALGIA) A FRENCH PREVALENCE STUDY OF FIBROMYALGIA : PSY11
ECONOMIC AND CLINICAL EFFICACY BENEFITS OF THE USE OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE : PSY12
REIMBURSEMENT OF FOODS FOR SPECIAL MEDICAL PURPOSES PRODUCTS FOR PHENYLKETONURIA IN POLAND: A BUDGET IMPACT ANALYSIS : PSY13
COST-EFFECTIVENESS AND BUDGET IMPACT OF LOW DOSE 7-DAY BUPRENORPHINE PATCH FOR MODERATE TO SEVERE OSTEOARTHRITIS PAIN IN THE CONTEXT OF KOREA NATIONAL HEALTH INSURANCE : PSY14
A COMPARATIVE OUTCOMES ANALYSIS OF DIFFERENT BARIATRIC SURGERIES : PSY15
THE DIRECT AND INDIRECT COSTS OF THE ANKYLOSING SPONDYLITIS IN THE CZECH REPUBLIC—COMPARISON BETWEEN 2005 AND 2008 STUDIES : PSY16
COSTS OF FIBROMYALGIA: RESULTS FROM A CROSS-SECTIONAL STUDY IN GERMANY : PSY17
THE BURDEN OF OBESITY IN ONTARIO : PSY18
DIRECT AND INDIRECT COSTS FOR PATIENTS WITH OPIOID INDUCED CONSTIPATION (OIC) AFTER TREATMENT WITH STRONG OPIOIDS IN SWEDEN : PSY19
COSTS AND COST DRIVERS OF IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA AND INHIBITORS : PSY20
COST STUDY OF HAEMOPHILIA IN MOROCCO : PSY21
COST OF OBESITY TREATMENT IN POLAND : PSY22
COST OF FIRST LINE TREATMENT OF NON-HODGKIN'S LYMPHOMA AT PRIVATE HOSPITAL EN MEXICO : PSY23
A COST CONSEQUENCE EVALUATION OF TWO MODELS OF CARE OF OUTPATIENTS WITH CHRONIC NEUROPATHIC PAIN IN NEUROLOGY SETTINGS IN SPAIN: GENERAL CLINICS VERSUS SPECIALIZED PAIN CLINICS : PSY24
RENAL ANEMIA (RA) TREATMENT IN MEXICAN PUBLIC HEALTH CARE INSTITUTIONS: AN EVALUATION OF THE COSTS AND CONSEQUENCES : PSY25
ECONOMIC EVALUATION OF THE ADDITION OF RITUXIMAB TO CVP FOR ADVANCED FOLLICULAR LYMPHOMA IN ROMANIA : PSY26
COST-EFFECTIVENESS OF ANTIGUNGAL PROPHYLAXIS WITH POSACONAZOLE VERSUS STANDARD AZOLE THERAPY IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG HIGH RISK HAEMATOLOGY PATIENTS IN CZECH REPUBLIC : PSY27
IRON DEFICIENCY IN SWEDEN—TREATMENT OPTIONS, COST-EFFECTIVENESS AND REIMBURSEMENT : PSY28
PHARMACOECONOMIC EVALUATION OF TREATMENT ANEMIA WITH ERYTHROPOIETIC AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS : PSY29
COST-UTILITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) COMPARED WITH CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN CANADA : PSY30
COST-MINIMIZATION ANALYSIS COMPARING 5% AND 10% INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS IN THE TREATMENT OF PRIMARY IMMUNE DEFICIENCY : PSY31
THALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOR AUSTRALIAN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA IS COST-EFFECTIVE WHEN COMPARED WITH MELPHALAN AND PREDNISONE ALONE : PSY32
A COST-UTILITY ANALYSIS OF IDET COMPARED WITH SPINAL FUSION : PSY33
COST-UTILITY OF BARIATRIC SURGERY IN THE TREATMENT FOR MORBID OBESITY IN FINLAND : PSY34
PROCESS MEASUREMENT IN IV-PCA AT UPPSALA UNIVERSITY HOSPITAL SWEDEN : PSY35
CHANGES IN RATES OF SICKLE CELL DISEASE-RELATED INPATIENT STAYS AND ASSOCIATED RESOURCE USE AMONG AFRICAN AMERICANS IN THE UNITED STATES FOLLOWING APPROVAL OF HYDROXYUREA : PSY36
IMPACT OF TOLVAPTAN ON SELF-REPORTED UTILITY SCORES IN HYPONATREMIC PATIENTS : PSY37
ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA: RESULTS OF A GENERAL PUBLIC BASED TIME TRADE-OFF SURVEY : PSY38
UTILITY MEASUREMENT STUDY FOR PATIENTS WITH CONTROLLED AND UNCONTROLLED PHENYLKETONURIA—A CASE STUDY FOR AN ORPHAN DISEASE : PSY39
A COMPARATIVE STUDY ON HEMOPHILIA TREATMENT AND MEDICATION BY THE PRESENCE OF INHIBITORS IN SOUTH KOREA : PSY40
MEASUREMENT OF HEALTH UTILITY VALUES IN THE UK FOR HEALTH STATES RELATED TO IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP) : PSY41
BLEEDING DISORDERS, MENORRHAGIA AND IRON DEFICIENCY: AN EXAMINATION OF QUALITY OF LIFE : PSY42
MAPPING THE ROLAND MORRIS DISABILITY QUESTIONNAIRE FOR BACK PAIN INTO UTILITY INDEX : PSY43
LINGUISTIC VALIDATION OF HAEMOPHILIA-SPECIFIC PATIENT-RATED OUTCOMES (HAEMO-QOL, HAEM-A-QOL, HEMO-SAT) IN UP TO 32 LANGUAGES : PSY44
DEVELOPMENT OF A QUESTIONNAIRE TO EVALUATE TREATMENT SATISFACTION OF PATIENTS WITH SEVERE CROHN'S DISEASE: QUALITATIVE STEPS : PSY45
HEALTH-RELATED QUALITY OF LIFE BURDEN AMONG FIBROMYALGIA PATIENTS: RESULTS FROM A CROSS-SECTIONAL STUDY IN FRANCE : PSY46
VALIDATION OF THE FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT)—FATIGUE SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) : PSY47
INSOMNIA AMONGST PATIENTS WITH CHRONIC PAIN AND INFLUENCE OF ADJUSTMENT OF PAIN MEDICATION IN GERMANY : PSY48
VALIDATION OF THE SF-36 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) : PSY49
THE EFFECT OF OBESITY ON PHYSICAL AND MENTAL HEALTH : PSY50
THE IMPACT OF OBESITY ON QUALITY OF LIFE IN POLISH POPULATION : PSY51
DEFI A FRENCH PREVALENCE STUDY OF FIBROMYALGIA (FM), HEALTH RELATED QUALITY OF LIFE : SF36 : PSY52
PELVIC PAIN IN ENDOMETRIOSIS: EFFECT OF PAINKILLERS OR SPORT TO ALLEVIATE SYMPTOMS : PSY53
COST-EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY FOR GAUCHER'S DISEASE IN THE URAL ADMINISTRATION DISTRICT OF RUSSIA FEDERATION : PSY54
IMPACT OF THE NEW RECOMMENDATIONS IN THE USE OF PROTHROMBIN COMPLEX CONCENTRATES AND VITAMIN K ANTAGONISTS IN FRANCE: ILLUSTRATION OF THE GUIDELINES RESPECT IN HOSPITAL AND ITS ECONOMIC CONSEQUENCES : PSY55
SYSTEMATIC REVIEW OF THE DIRECT COSTS RELATED TO OBESITY AND ASSOCIATED DISEASES IN POLAND : PSY56
REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA— PHARMACOECONOMICS OF USTEKINUMAB IN PSORIASIS : PSY57
RIMONABANT IN CLINICAL PRACTICE (RICP). A SWEDISH MULTICENTER SURVEY IN PRIMARY CARE : PSY58
REVIEW OF RECOMMENDATIONS OF HEALTH TECHNOLOGY ASSESSMENTS ON ORLISTAT AND SIBUTRAMINE : PSY59
CORRECTING AN UNDERESTIMATE OF INCREMENTAL COST EFFECTIVENESS RATIO CONSIDERING STATISTICAL ERRORS AND PROBABILITY OF TRUTH : PMC1
A STANDARDIZED EVIDENCE BASED APPROACH TO ASSESS NON-TRADITIONAL OUTCOME MEASURES FOR USE IN HEALTH CARE DECISION MAKING: THE DIABETES EXAMPLE : PMC2
CRITICAL REVIEW OF PUBLISHED COST EFFECTIVENESS ANALYSES OF ORAL TRIPTANS IN THE MANAGEMENT OF ACUTE MIGRAINE: DIFFERENT MEASURES OF EFFICACY EXTRACTED FROM THE SAME META-ANALYSIS : PMC3
LARGELY IGNORED: THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR : PMC4
MEASURING AND MONITORING THE REAL-WORLD COST-EFFECTIVENESS OF NEW TECHNOLOGIES IN HOSPITALS : PMC5
THE NATURE AND SCALE OF INADEQUATE REPORTING OF CONTINUOUS OUTCOMES FROM FOUR SYSTEMATIC REVIEWS : PMC6
THE NATURE AND SCALE OF INADEQUATE REPORTING OF DICHOTOMOUS OUTCOMES FROM SIX SYSTEMATIC REVIEWS : PMC7
USING ATLAS.TI AS A TOOL TO EXTRACT AND SYNTHESIZE DATA OBTAINED IN LITERATURE REVIEWING : PMC8
REDUCING BIAS IN A RETROSPECTIVE CASE-CONTROL STUDY: AN APPLICATION OF PROPENSITY SCORE MATCHING. : PMC9
HOW TO MAKE USE OF AVAILABLE SURVIVAL EVIDENCE IN AN INDIRECT COMPARISON : PMC10
IMPUTE INCOMPLETE PATIENT-LEVEL MEDICAL COSTS : PMC11
DEVELOPMENT OF COST CATALOGS FOR COST-EFFECTIVENESS ANALYSES IN GERMANY: RESULTS OF A FEASIBILITY STUDY : PMC12
INDIRECT COST OF ILLNESS IN POLISH ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES : PMC13
THE COST OF ABSENTEEISM IN POLAND IN 2007—DIFFERENCES WITHIN THE PROVINCES : PMC14
A STANDARD COST TOOLKIT FOR ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE : PMC15
QUALITY ASSESSMENT OF PUBLISHED HEALTH ECONOMIC ANALYSES FROM CHINA : PMC16
SHOULD INDIRECT COSTS OF ILLNESS BE INCLUDED IN PHARMACOECONOMIC ANALYSIS: SURVEY AMONG POLISH DECISION MAKERS AND EXPERTS : PMC17
ANALYSIS OF TRANSFERABILITY TOOLS FOR COST-EFFECTIVENESS DATA AND COSIDERATION IN KOREA SETTINGS : PMC18
EVALUATING AN ONLINE INCREMENTAL COST-EFFECTIVENESS CALCULATOR STRUCTURED AS A DECISION ANALYTIC TREE THAT IMPLEMENTS MONTE CARLO SIMULATIONS OF KEY VARIABLES : PMC19
IMPLEMENTING A BENCHMARKING MODEL FOR EXPENDITURES OF PRESCRIPTION DRUGS IN AUSTRIA : PMC20
REAL AND THEORETICAL COST OF ABSENTEEISM IN POLAND : PMC21
DEVELOPMENT OF A SENSITIVE RESOURCE USE QUESTIONNAIRE : PMC22
UNDERESTIMATION OF UNCERTAINTY IN COST-EFFECTIVENESS ACCEPTABILITY CURVES AND EXPECTED VALUE OF INFORMATION ANALYSES : PMC23
SAMPSON: A HYBRID SIMULATION AND OPTIMIZATION MODEL FOR MANAGING SURGICAL RESOURCES AND REDUCING WAITING TIMES : PMC24
CLINICAL HISTORY, RESOURCE UTILIZATION, AND OTHER PATIENT-REPORTED OUTCOMES (PROS) IN MIGRAINEURS: AN ADAPTABLE WEB-BASED METHODOLOGY FOR THE DESIGN, IMPLEMENTATION AND CONDUCT OF A MULTI-NATIONAL SURVEY OF PATIENTS : PMC25
LINKING PERSON-LEVEL INPATIENT DATA TO LONGITUDINAL RECORDS : PMC26
IDENTIFYING ECONOMIC EVALUATIONS IN MEDLINE AND EMBASE: HOW WELL DO PUBLISHED SEARCH FILTERS PERFORM? : PMC27
EXPERT SURVEY FOR INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) THRESHOLD RANGE IN KOREA: DISCRETE CHOICE EXPERIMENTS : PMC28
IMPACT OF MISSING DATA ON POTENTIAL CONFOUNDERS IN PERINATAL PHARMACOEPIDEMIOLOGIC STUDIES USING ADMINISTRATIVE DATABASES : PMC29
HOW TO GAIN HIGH DATA QUALITY IN A NON-INTERVENTIONAL TRIAL TAKING THE LIVE-COM STUDY AS EXAMPLE : PMC30
THE MONDRIAAN PROJECT: THE DUTCH HEALTH CARE LANDSCAPE AS A POPULATION LABORATORY : PMC31
MULTI AGENT SIMULATION TECHNIQUES FOR DYNAMIC SIMULATION OF SOCIAL INTERACTION AND SPREAD OF DISEASES WITH DIFFERENT SEROTYPES : PMC32
CRITICAL REVIEW OF ECONOMIC MODELS IN TYPE 2 DIABETES : PMC33
SEROTYPE-SPECIFIC TRANSMISSION DYNAMICS OF INVASIVE PNEUMOCOCCAL DISEASE AFTER VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE : PMC34
SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION : PMC35
CREATING NATIONAL WEIGHTS FOR PRIVATE INSURANCE DATABASE : PMC36
COMPARISON OF RISK ADJUSTMENT MODELS IN OUTCOMES RESEARCH : PMC37
COMPARISON OF TWO METHODS TO DETERMINE COSTS FOR AML PATIENTS IN REMISSION: MODEL VALIDATION FROM A UK PERSPECTIVE : PMC38
USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(±) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA : PMC39
ESTIMATING THE NET HERD EFFECT INDUCED BY PCV-VACCINES: A HYPOTHESIS GENERATING STUDY : PMC40
CONTROLLING FOR UNOBSERVABLE BIAS: IS THE CURE WORSE THAN THE DISEASE? : PMC41
COMPARING MARKOV MODEL AND DES—THE EXAMPLE OF COPD : PMC42
A CONCEPTUAL FRAMEWORK TO APPLY DISCRETE-EVENT SIMULATION TO ESTIMATE THE RESOURCES NEEDED TO PERFORM A POPULATION BASED CANCER SCREENING PROGRAM : PMC43
MODELLING THE UPTAKE AND DIFFUSION OF INNOVATIVE TECHNOLOGY: A CRITICAL AND STRATEGIC FEATURE OF BUDGET IMPACT ANALYSIS AND RISK-SHARING AGREEMENTS : PMC44
REVIEWER'S CHECKLIST FOR ASSESSING THE QUALITY OF DECISION MODELS : PMC45
BAYESIAN CALIBRATION OF A NATURAL HISTORY MODEL FOR COLORECTAL CANCER : PMC46
WILLINGNESS TO INITIATE THERAPY AND PUBLIC HEALTH POLICY: AN APPLICATION TO THE STRATEGIC DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR HEPATITIS C TREATMENT : PMC47
A DYNAMIC MODEL TO MAXIMIZE THE HELATH BENEFITS IN MUTUALLY EXCLUSIVE SUSCEPTIBLE INFECTIOUS POPULATION : PMC48
SENSITIVITY OF 15D, EQ-5D AND SF-6D TO DIABETES COMPLICATIONS: THE CASE OF CORONARY HEART DISEASE : PMC49
MEASUREMENT OF OUTPATIENT REHABILITATION OUTCOMES WITH EQ-5D : PMC50
PATIENT COMPLETION OF EPROS: TO PHONE OR TO WEB? : PMC51
ASSESSING THE (DIS) AGREEMENT OF EQ-5D AND SF-6D ACROSS GROUPS WITH INCREASING SEVERITY OF CHRONIC HEART FAILURE : PMC52
HFS 14: A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS WITH HAND-FOOT SYNDROME : PMC53
ESTIMATING SOCIAL PREFERENCES FOR EQ-5D IN TURKEY : A NOVEL METHOD BASED ON A VALUATION EXCHANGE-RATE MECHANISM : PMC54
AGREEMENT BETWEEN PATIENT AND PROXY ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BEFORE INTENSIVE CARE UNIT ADMISSION : PMC55
PREFERENCES FOR PREFERENCES : PMC56
TO MAP OR NOT TO MAP? THE OXFORD HIP SCORE AND EQ-5D COMPARED : PMC57
EVALUATING THE INFLUENCE OF PHYSICAL ACTIVITY ON THE SOCIAL AND ENVIRONMENTAL DOMAINS OF QUALITY OF LIFE : PMC58
CULTURAL AND LINGUISTIC ISSUES ASSOCIATED WITH THE TRANSLATION AND LINGUISTIC VALIDATION OF QUESTIONNAIRES FOR USE IN CHINA : PMC59
WILLINGNESS TO PAY FOR HEALTH INTERVENTIONS: BASED ON SYSTEMATIC REVIEW OF LITERATURES : PMC60
CATALOGUE OF EQ-5D SCORES FOR THE UK : PMC61
ONLINE ADMINISTRATION OF THE TIME TRADE-OFF: A CASE-STUDY AMONG PEOPLE WITH RESTLESS LEGS SYNDROME : PMC62
IS EXTENDING OF TIME TRADE-OFF EXPERIMENT TO 23 STATES PER RESPONDENT RATIONALIZED? ANALYSIS OF DATA FROM POLISH VALUATION STUDY : PMC63
DIFFICULTIES WITH THE APPLICATION OF PRO MEASURES TO CULTURES OUTSIDE OF WESTERN EUROPE AND NORTH AMERICA IN MULTI-NATIONAL TRIALS : PMC64
QUALITATIVE METHODS IN PRO RESEARCH: DEVELOPMENT OF A METHODS MATRIX : PMC65
THE ADVANTAGES OF A CENTRALIZED DISSEMINATION STRATEGY FOR HEALTH OUTCOMES INSTRUMENTS AND THEIR TRANSLATIONS: A CASE EXAMPLE WITH THE ZARIT BURDEN INTERVIEW (ZBI) : PMC66
LINGUISTIC ADAPTATION OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) INTO ENGLISH : PMC67
CORRELATION BETWEEN ADHERENCE RATES MEASURED BY MEDICATION EVENT MANAGEMENT SYSTEM AND SELF-REPORTED QUESTIONNAIRES: A META-ANALYSIS : PMC68
EXAMINING MASLOW'S HIERARCHICAL THEORY OF NEEDS BY USING THE ITEMS OF THE WHOQOL-BREF : PMC69
CLASSIFYING PATIENT REPORTED OUTCOMES: DEVELOPMENTS IN THE FIELD SUGGEST A NEW TAXONOMY : PMC70
THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND THE ROLE OF THE QALY : PMC71
DEVELOPMENT OF THE ACCEPT© QUESTIONNAIRE TO ASSESS ACCEPTABILITY OF LONG TERM TREATMENTS: QUALITATIVE STEPS : PMC72
DIFFERENT STUDY RESULTS OF UTILITIES IN RELATION TO THE DOCUMENTING METHOD USED AND THE GUARANTEE OF LEGALLY COMPLIANT IQWIG RECOMMENDATIONS WITHIN THE FRAMEWORK OF A COST-BENEFIT ASSESSMENT : PMC73
WHICH HEALTH ECONOMIC APPROACHES FOR WHICH DECISIONMAKING SUPPORT IN METASTATIC CANCER ? A LITERATURE REVIEW AND FRENCH EXPERT OPINIONS : PMC74
ARE ONLINE MANAGED PHYSICIAN PANELS A VIABLE SOURCE FOR SCIENTIFIC RESEARCH INITIATIVES? : PMC75
PATIENT REGISTRIES—A LITERATURE REVIEW OF RECENTLY REPORTED REGISTRY BASED STUDIES : PMC76
A COMPARISON OF CLINICAL EFFICACY OF INSULIN GLARGINE ADDED TO ORAL ANTIDIABETIC DRUGS VS PREMIXED INSULINS ALONE IN THE TREATEMENT OF TYPE-2 DIABETES MELLITUS : PDB1
REAL WORLD CLINICAL EFFECTIVENESS OF SITAGLIPTIN THERAPY FOR MANAGEMENT OF TYPE 2 DIABETES: A RETROSPECTIVE DATABASE ANALYSIS : PDB2
FORECASTING THE NUMBER OF DIABETIC PATIENS IN THE UNITED STATES IN 2050 : PDB3
LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70: AN IMPROVE STUDY SUBGROUP ANALYSIS : PDB4
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF VILDAGLIPTIN FOR TYPE 2 DIABETES MELLITUS : PDB5
ADMINISTRATIVE CLAIMS ANALYSIS OF AN L-METHYLFOLATE COMBINATION PRODUCT IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY : PDB6
THE CLINICAL EFFECTIVENESS OF SOMATROPIN (GENOTROPIN®) IN CHILDREN WITH SHORT STATURE: A SYSTEMATIC REVIEW : PDB7
ANTIDIABETIC DRUG UTILIZATION IN A UNIVERSITY HEALTH CARE SETTING : PDB8
IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES CARE FOR USERS OF ROSIGLITAZONE : PDB9
DIFFERENT PERSISTENCE WITH A BASAL SUPPORTED ORAL THERAPY (BOT) LEADS TO UNEQUAL DISTRIBUTIONS OF INSULIN TREATMENT REGIMENS IN TYPE-2-DIABETICS : PDB10
DATABASE ANALYSIS ON PREVALENCE AND RISK FACTORS OF DIABETIC FOOT SYNDROME (DFS) IN GERMANY : PDB11
GLYCATED HAEMOGLOBIN AS A SURROGATE MARKER FOR THE APPEARANCE AND PROGRESSION OF RETINOPATHY IN TYPE-1 DIABETES MELLITUS: SYSTEMATIC REVIEW AND META-ANALYSIS : PDB12
MEDICATION PATTERN AND RISK OF STROKE AMONG TYPE II DIABETES MELLITUS IN TAIWAN-A POPULATION-BASED STUDY : PDB13
THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 DIABETES IN POLAND : PDB14
COST OF AN EPISODE OF DIABETIC FOOT ULCER IN SPAIN : PDB15
GLYCEMIC CONTROL IN THE INPATIENT SETTING: INSULIN ASPART COMPARED TO HUMAN BOLUS INSULIN : PDB16
TREATMENT COSTS ATTRIBUTABLE TO BEING OVERWEIGHT OR OBESE IN U.S. DIABETIC PATIENTS: QUANTILE REGRESSION APPROACH : PDB17
COST OFFSETS ASSOCIATED WITH USE OF EXENATIDE COMPARED TO GLARGINE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES : PDB18
TIME TO OPIOID USE AND HEALTH CARE COSTS AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS : PDB19
A COST CONSEQUENCE MODEL TO ASSESS THE ECONOMIC IMPACT IN GERMANY OF PATIENTS ACHIEVING KDOQITM TARGETS WITH THE USE OF A COMBINATION OF CINACALCET + TRADITIONAL THERAPY (TT) COMPARED WITH TT ALONE : PDB20
WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS : PDB21
SELF-MONITORING OF BLOOD GLUCOSE (SMBG) FOR TYPE 2 DIABETES PATIENTS ON ORAL ANTI-DIABETES DRUGS (OADS): COSTEFFECTIVENESS IN FRANCE, GERMANY, AND SPAIN : PDB22
PREDICTING COST-EFFECTIVENESS OF A DIABETES HEALTH CARE PROGRAM IN BELGIUM AS A POLICY MANAGEMENT TOOL : PDB23
COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING : PDB24
A PATIENT-LEVEL SIMULATION MODEL FOR ECONOMIC EVALUATION OF CINACALCET IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN ITALY : PDB25
THE PHARMACOECONOMIC STUDY OF INSULIN GLRAGINE USAGE IN ROUTINE CLINICAL PRACTICE IN RUSSIAN FEDERATION : PDB26
COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONGTERM HEALTH ECONOMIC ANALYSIS : PDB27
THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND : PDB28
PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENS UNDERGOING DIABETIC END-STAGE RENAL DISEASE : PDB29
CSII COMPARED TO MDI: A HEALTH ECONOMIC ANALYSIS IN THE GERMAN HEALTH CARE SETTING : PDB30
COST-EFFECTIVENESS ANALYSIS OF VOGLIBOSE FOR PREVENTION OF TYPE-2 DIABETES MELLITUS IN JAPANESE INDIVIDUALS WITH IMPAIRED GLUCOSE TOLERANCE : PDB31
COST-EFFECTIVENESS OF NICOTINE REPLACEMENT THERAPY (NRT) FOR SMOKING CESSATION IN PATIENTS WITH CORONARY HEART DISEASE (CHD), DIABETES MELLITUS TYPE 2 (DMT2) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY : PDB32
A COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE-1 DIABETES PATIENTS IN ITALY : PDB33
LOWER LONG-TERM COSTS IN GERMAN TYPE-2-DIABETICS STARTING A BASAL SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE COMPARED TO NPH-INSULIN : PDB34
LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE-2 DIABETES PATIENTS ON BASAL-BOLUS THERAPY UNDER REAL WORLD CONDITIONS IN GERMANY : PDB35
COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL-BOLUS TREATMENT CONCEPT IN GERMANY : PDB36
COST-MINIMIZATION ANALYSIS COMPARING BASAL ANALOGUE INSULINS IN HUNGARY : PDB37
COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY : PDB38
ECONOMIC ANALYSIS OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN MEXICO : PDB39
COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES MELLITUS IN POLAND : PDB40
COST-UTILITY OF INSULIN GLARGINE IN COMBINATION THERAPY WITH ORAL AGENTS COMPARED WITH PREMIX INSULIN WITH OR WITHOUT OF ORAL AGENTS IN TYPE 2 DIABETES. THE POLISH PERSPECTIVE : PDB41
INSULIN ADMINISTRATION WITH FLEXPEN® IS ASSOCIATED WITH INCREASED ADHERENCE AND NO ADDED COSTS TO PAYERS IN A US MANAGED CARE SETTING : PDB42
MEDICATION ADHERENCE IN LOW INCOME ELDERLY TYPE 2 DIABETES PATIENTS: A RETROSPECTIVE COHORT STUDY : PDB43
EXAMINING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND MEDICATION ADHERENCE IN DIABETIC PATIENTS : PDB44
ASSESSING UTILITIES AND DISUTILITIES FOR TYPE 2 DIABETES TREATMENT-RELATED ATTRIBUTES IN AN ASIAN POPULATION : PDB45
UTILITIES FOR INFUSION THERAPY IN TYPE 1 DIABETES : PDB46
HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES OVER THE 24 MONTHS FOLLOWING INITIATION OF INSULIN : PDB47
ASSESSING THE MINIMUM CLINICALLY IMPORTANT DIFFERENCE OF THE WORRY SCALE OF THE HYPOGLYCAEMIA FEAR SURVEY IN PATIENTS WITH TYPE 2 DIABETES : PDB48
UNDERSTANDING AND ASSESSING THE IMPACT OF GROWTH HORMONE DEFICIENCY IN ADULTS : PDB49
THE COST OF DIABETES RELATED MINOR HYPOGLYCEMIC EVENTS IN WORKING ADULTS : PDB50
USING FACTOR ANALYSIS TO CONFIRM THE VALIDITY OF DIABETES HEALTH PROFILE-1, DIABETES AND LIFE STYLE FOR TURKISH DIABETIC PATIENTS : PDB51
PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN: RESULTS FROM THE LIVE-COM STUDY : PDB52
COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES (T2DM): EFFECTS ON WORK PRODUCTIVITY : PDB53
ASSESSING THE BURDEN OF ACROMEGALY: A REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND ECONOMICS : PDB54
LINGUISTIC VALIDATION, INCLUDING CULTURAL ADAPTATION, OF AN UPDATED ADKNOWL, DIABETES KNOWLEDGE QUESTIONNAIRE, FOR INTERNATIONAL USE : PDB55
THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING DRUGS (OGLDS) : PDB56
COMPARING THE IMPACT OF DEPRESSION, DIABETES, AND ANXIETY ON PATIENT PRODUCTIVITY AND QUALITY OF LIFE: RESULTS FROM A NATIONALLY REPRESENTATIVE PANEL DATA : PDB57
THE “WHO, HOW AND THEN WHAT …” OF INSULIN INITIATION IN UK PRIMARY CARE : PDB58
USING THE ECHO MODEL TO EXAMINE THE EFFECT OF AN EMPLOYER-SPONSORED PHARMACIST PROVIDED DIABETES MTM PROGRAM ON OUTCOMES : PDB59
EVALUATION OF THE PATIENT'S PERSPECTIVE OF MEDICAL CARE IN TYPE 2 DIABETES DISEASE MANAGEMENT PROGRAMS : PDB60
DIABETES REGIMEN UTILIZATION IN A LARGE MANAGED CARE SETTING; A COMPARISON WITH ADA/EASD CONSENSUS STATEMENT GUIDELINES : PDB61
ECONOMIC IMPACT OF COMPLIANCE AND PERSISTENCE TO TREATMENT WITH ANTIDIABETES MEDICATION IN T2DM— A SYSTEMATIC REVIEW : PDB62
THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT? : PDB63
A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN : PDB64
REAL-LIFE PRESCRIPTION PATTERNS SHOW FEWER TREATMENT CHANGES WITH BASAL INSULIN ANALOGS COMPARED TO NPH IN TYPE 2 DIABETES IN THE NETHERLANDS : PDB65
PAYING FOR COSTLY PHARMACEUTICALS—REIMBURSEMENT STATUS OF LONG-ACTING INSULIN ANALOGUES IN SELECTED DEVELOPED COUNTRIES : PDB66
HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC : PDB67
A RETROSPECTIVE ANALYSIS OF MEDICATION USE, RESOURCE UTILIZATION, AND CLINICAL EFFECTIVENESS OF EXENATIDE COMPARED TO GLARGINE IN PATIENTS WITH TYPE 2 DIABETES : PDB68
SIGNIFICANT REDUCTIONS IN POLYPHARMACY AND HEALTH CARE UTILIZATION WITH INSULIN PUMP THERAPY (CSII) IN PATIENTS WITH TYPE 2 DIABETES : PDB69
ORAL MEDICATIONS VS INSULIN FOR DIABETES: EPIDEMIOLOGICAL & HEALTH POLICY IMPLICATIONS IN GREECE : PDB70
GLYCAEMIC AND CHOLESTEROL CONTROL OF TYPE 2 DIABETIC PATIENTS ATTENDING SPECIALIST OUTPATIENT CLINICS IN SINGAPORE : PDB71
QUALITY ADJUSTED LIFE YEARS LOSS DUE TO TYPE 2 DIABETES IN SOUTH KOREA : PDB72
ANALYSIS OF FACTORS INFLUENCING DECISION MAKING ON TYPE 2 DIABETES DRUGS IN 5 HTA-AGENCIES : PDB73
ETHICAL DILEMMAS OF PHARMACOLOGICAL TREATMENT AND SELF MANAGEMENT OF DIABETES—A REVIEW OF THE LITERATURE : PDB74
APPLICATION OF HTA TO ANTIDIABETIC DRUG FORMULARY DECISIONS : PDB75
ETHICAL ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS OF DIABETES TREATMENTS : PDB76
BASELINE CHARACTERISTICS OF PATIENTS BEGINNING BASAL, BASAL PLUS SHORT-ACTING, SHORT-ACTING OR PREMIX INSULIN: DATA FROM THE CREDIT STUDY : PDB77
DIFFERENCES IN THE CHARACTERISTICS OF PEOPLE WITH TYPE 2 DIABETES STARTING INSULIN IN THE NORTH, SOUTH AND EAST OF EUROPE: DATA FROM THE CREDIT STUDY : PDB78
DO PEOPLE BEGINNING BASAL INSULIN HAVE A DISTINCT CLINICAL PROFILE COMPARED WITH THE OVERALL POPULATION IN THE CREDIT STUDY? : PDB79
MEASURING GLYCOSYLATED HAEMOGLOBIN LEVELS IN PATIENTS WITH DIABETES: IMPACT OF LOWER QOF TARGETS ON ACHIEVEMENT OF CLINICAL INDICATORS AND QOF POINTS : PDB80
THE ROAD TO INSULIN—A PATH OF TREATMENT ANALYSIS OF REAL-WORLD PHARMACY DATA FROM THE USA : PDB81
FRENCH OBSERVATIONAL COHORT OF HIV-1 INFECTED PATIENTS TREATED WITH ENFUVIRTIDE: LONG-TERM EFFICACY AND SAFETY (ZOOM) : PIN1
HCV INFECTION IS ASSOCIATED WITH HIGH COMORBIDITY BURDEN IN EUROPE : PIN2
PREDICTORS OF EFFECTIVENESS WITH LOPINAVIR/RITONAVIR (LPV/R) SINGLE AGENT THERAPY (SAT) TO IMPROVE CLINICAL OUTCOMES IN HIGH RISK HIV+ PATIENTS IN AN URBAN CLINIC : PIN3
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF EXTERNAL GENITAL WARTS : PIN4
UNDERESTIMATION OF VARICELLA INCIDENCE IN THE NETHERLANDS : PIN5
OUTCOME AND RESOURCES USE OF SEVERE BURN INJURY PATIENTS WITH NOSOCOMIAL BLOODSTREAM INFECTION: RESULTS OF A MATCHED COHORT STUDY : PIN6
BUDGETARY IMPACT OF ADDING DORIPENEM TO A HOSPITAL FORMULARY IN GERMANY : PIN7
BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA : PIN8
THE COST OF PREVENTING INFLUENZA PANDEMIC: MEXICAN ELDERLY POPULATION SCENARIO : PIN9
A BUDGET IMPACT MODEL TO ESTIMATE THE ECONOMIC IMPACT OF ITRACONAZOLE IN PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN : PIN10
BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA : PIN11
BUDGET IMPACT ANALYSIS OF THREE CANDINS IN THE TREATMENT OF INVASIVE CANDIDIASIS IN ADULT NON- NEUTROPENIC PATIENTS IN SPAIN : PIN12
BUDGET IMPACT MODEL: LEVOFLOXACIN VS STANDARD THERAPIES IN THE TREATMENT OF INPATIENT CAP : PIN13
BUDGET IMPACT OF HIV POST-EXPOSURE PROPHYLAXIS: AN EXAMPLE OF HOSPITAL POINT OF VIEW AFTER NEW RECOMMENDATIONS IN FRANCE : PIN14
THE ECONOMIC IMPLICATION OF A RAPID DIAGNOSE AND EARLY SHIFT IN THERAPY IN PATIENTS WITH INVASIVE CANDIDA INFECTION : PIN15
COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-7) IN MEXICO : PIN16
THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN IN FOUR EUROPEAN COUNTRIES: A STUDY IN PRIMARY CARE : PIN17
THE COST BURDEN OF ACUTE GASTROENTERITIS IN INFANTS AND YOUNG CHILDREN ATTENDING DAYCARE CENTRES IN FRANCE : PIN18
TREATMENT COSTS FOR CHRONIC HEPATITIS B (CHB) IN URBAN CHINA : PIN19
BURDEN OF PEDIATRIC INFLUENZA IN EUROPE: A GAP ANALYSIS : PIN20
BURDEN AND COST OF SNAKEBITE ENVENOMING: ANTIVENOM OUT OF REACH? : PIN21
ANNUAL COSTS OF CHRONIC HEPATITIS B DISEASE STATES IN PORTUGAL : PIN22
POOR ADHERENCE TO TREATMENT WITH PEGYLATED INTERFERON/ RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH GREATER HEALTH CARE COSTS : PIN23
DIFFERENT APPROACHES FOR ESTIMATING INDIRECT COST IN THE ECONOMIC ASSESSMENT OF PNEUMOCOCCAL VACCINES IN GERMANY : PIN24
CLINICAL AND ECONOMIC IMPACTS OF BACTEREMIA CAUSED BY EXTENDED-SPECTRUM BETA-LACTAMASES PRODUCING ESCHERICHIA COLI IN HONG KONG : PIN26
COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN AND TEICOPLANIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS IN CZECH REPUBLIC : PIN27
ECONOMIC ANALYSIS ABOUT VALGANCICLOVIR PROPHYLAXIS AGAINST INFECTION FROM CITOMEGALOVIRUS IN PATIENTS WITH RENAL TRANSPLANTATION : PIN28
COST OF DIABETIC FOOT INFECTIONS DUE TO MRSA: AN ECONOMIC ANALYSIS OF DATA FROM PATIENTS TREATED WITH LINEZOLID IN SPAIN : PIN29
USE OF NET-BENEFIT REGRESSION FRAMEWORK TO INVESTIGATE THE COST-EFFECTIVENESS OF COMBINATION ANTIVIRAL THERAPY AMONG HCV-INFECTED PATIENTS ENROLLED IN A MANAGED CARE ORGANIZATION : PIN30
COST-EFFECTIVENESS ANALYSIS OF TELBIVUDINE VS LAMIVUDINE IN TREATING THE PATIENTS WITH HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B IN CHINA : PIN31
COST EFFECTIVENESS OF UNIVERSAL ROTAVIRUS VACCINATION IN IRELAND: A PRELIMINARY ANALYSIS : PIN32
POTENTIAL HEALTH AND ECONOMIC IMPACT OF NEW PNEUMOCOCCAL VACCINES IN CANADA: A MARKOV MODELLING APPROACH : PIN33
ECONOMIC ASSESSMENT OF MASS VACCINATION WITH PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE (PHID-CV) IN POLAND : PIN34
CLINICAL AND ECONOMIC BENEFITS OF NATIONAL IMMUNIZATION WITH THE 13-VALENT COMPARED TO 7- AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN GREECE : PIN35
SCREENING OF MIGRANTS FOR CHRONIC HEPATITIS B VIRUS INFECTION: A COST-EFFECTIVENESS ANALYSIS : PIN36
COST EFFECTIVENESS OF PEGYLATED-INTERFERON ALPHA 2B + RIBAVIRIN FOR CHRONIC HEPATIITIS C (CHC) IN PATIENTS WHO HAVE PREVIOUSLY FAILED TREATMENT WITH INTERFERON- BASED THERAPY IN AUSTRALIA : PIN37
COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB IN THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN CHILDREN WITH CONGENITAL HEART DISEASE : PIN38
COST-EFFECTIVENESS OF MASS VARICELLA VACCINATION IN FRANCE: ECONOMIC CONSEQUENCES OF AN INTENSIVE VACCINATION PROGRAM : PIN39
COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN MEXICO : PIN40
PREVENTION OF AN INFLUENZA PANDEMIC IN MEXICO: ESTABLISHING A COST-EFFECTIVE ALTERNATIVE FOR ELDERLY POPULATION : PIN41
COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENT TO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE : PIN42
COST-EFFECTIVENESS OF 13-VALENT AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION RELATIVE TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA : PIN43
A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY : PIN44
COST-EFFECTIVENESS OF A COCOONING IMMUNIZATION STRATEGY AGAINST PERTUSSIS FOR THE NETHERLANDS : PIN45
COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS PODOPHYLLOTOXIN IN TREATMENT OF GENITAL/PERIANAL WARTS IN POLAND : PIN46
MODELING THE OUTCOMES OF VACCINATION WITH THE 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN SPAIN : PIN47
COMPARATIVE COST-EFFICACY ANALYSIS OF DARUNAVIR/R AND OTHER RITONAVIR-BOOSTED PROTEASE INHIBITORS FOR FIRST-LINE TREATMENT OF HIV-1 INFECTION IN GERMANY : PIN48
A PHARMACOECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION IN ITALY : PIN49
MICAFUNGIN VS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR GERMANY : PIN50
COST-EFFECTIVENESS STUDY OF THE USE OF DAPTOMYCIN VERSUS VANCOMYCIN IN INFECTIVE ENDOCARDITIS AND BACTEREMIA TREATMENT IN PUBLIC HEALTH INSTITUTIONS IN MEXICO : PIN51
COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES: THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL : PIN52
COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE 1 (G1) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE : PIN53
THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK : PIN54
COST-EFFECTIVENESS OF THE SURVIVING SEPSIS CAMPAIGN PROTOCOL FOR SEVERE SEPSIS IN SPAIN : PIN55
COST-EFFECTIVENESS OF ATAZANAVIR/R VS. LOPINAVIR/R IN TREATMENT NAIVE HIV PATIENTS IN SPAIN : PIN56
A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK : PIN57
COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENTEXPERIENCED HIV-1-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS : PIN58
POTENTIAL ECONOMIC IMPACT OF OUTPATIENT CARBAPENEM TREATMENT FOR BACTERAEMIA CAUSED BY ESBL-PRODUCING BACTERIA IN HONG KONG—A DECISION ANALYSIS : PIN59
COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A VERSUS ENTECAVIR IN THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA : PIN60
COST-UTILITY ANALYSIS OF ROTAVIRUS VACCINE (ROTARIX®) IN JAPAN : PIN61
COST-EFFECTIVENESS OF TARGETED SCREENING FOR HEPATITIS C IN THE NETHERLANDS : PIN62
COST-UTILITY ANALYSIS OF PNEUMOCOCCAL CONJUGATE VACCINES IN GERMANY : PIN63
A PROBABILISTIC COST-EFFECTIVENESS MODEL FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN : PIN64
IMPACT OF ETRAVIRINE (ETR) ON HOSPITALISATIONS AND HOSPITAL-RELATED COSTS CALCULATED BY GERMAN-DRGS: 48-WEEK FINDINGS FROM POOLED DUET TRIALS : PIN65
SPILLOVER ADHERENCE EFFECTS OF FIXED-DOSE COMBINATION HIV THERAPY : PIN66
QUALITY OF LIFE AND HEALTH CARE UTILIZATION BURDEN OF HCVINFECTED PATIENTS IN EUROPE : PIN67
PSYCHOMETRIC EVALUATION OF THE FUNCTIONAL ASSESSMENT OF HIV INFECTION (FAHI) QUESTIONNAIRE IN TWO CLINICAL PROGRAMMES : PIN68
A PATIENT SATISFACTION QUESTIONNAIRE FOR ASSESSING PHARMACEUTICAL CARE SERVICES IN NIGERIAN HIV CLINICS : PIN69
PERCEPTION AND ACCEPTANCE OF INTRADERMAL INFLUENZA VACCINE MEASURED BY THE VACCINEE'S PERCEPTION OF INJECTION (VAPI©) QUESTIONNAIRE : PIN70
QUALITY OF LIFE (QOL) AND OTHER ENDPOINTS COMPARISON IN THE TREATMENT OF FACIAL LIPOATROPHY WITH INJECTION OF POLY-L-LACTIC ACID : PIN71
TRANSLATION OF THE HIV PATIENT SYMPTOMS PROFILE INTO 5 LANGUAGES SPOKEN IN ISRAEL : PIN72
CRITICAL CARE ADMISSIONS FOR PNEUMONIA IN ENGLAND : PIN73
LEAST COSTLY VACCINATION STRATEGY (WITH OR WITHOUT SCREENING FOR ANTOBODIES) FOR HEPATITIS A, HEPATITIS B, VARICELLA, MEASLES AND TETANUS IN CATALONIA, SPAIN : PIN74
ECONOMIC IMPACT OF NEW MALARIA DIAGNOSTIC DEVICES ON THE MALARIA CONTROL PROGRAM IN BRAZIL : PIN75
THE PREVALENCE, MORTALITY, AND COST OF CENTRAL LINE BLOOD STREAM INFECTIONS (CLABSI) IN US COMMUNITY HOSPITALS: 2002 TO 2006 : PIN76
THOUGHTS ON THE LABORATORY CULTURES REIMBURSED BY THE SOCIAL SECURITY IN AUSTRIA (OUTPATIENT SECTOR IN PHYSICIANS' CARE AND INSTITUTES, BUT NOT HOSPITAL OUTPATIENT CARE) : PIN77
DIRECT MONTHLY HAART SUPPLY AT THE AIDS CENTER— A COST-EFFECTIVE MODE TO INCREASE ADHERENCE AND OUTCOME : PIN78
SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB IN HIGH-RISK PATIENTS : PIN79
THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH TECHNOLOGY ASSESSMENT (HTA) OF VACCINES—LESSONS LEARNED FROM FINLAND : PIN80
MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS : PIN81
THE APPLICATION OF HEALTH TECNOLOGY ASSESSMENT ON THE NEW PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE IN ITALY : PIN82
RISK ASSESSMENT OF CARDIOVASCULAR THROMBOTIC EVENTS, OTHER CARDIAC EVENTS, AND MORTALITY AMONG VETERANS AFFAIRS PATIENTS WITH DIFFICULT TO MANAGE GOUT : PMS1
SAFETY OF LEFLUNOMIDE, METHOTREXATE AND SULFASALAZINE: ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING : PMS2
PROPORTION OF PATIENTS WITH OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PERFORMING A BONE MINERAL DENSITY DIAGNOSIS MEASUREMENT: THE PRESAGE STUDY : PMS3
EUROQOL-5 DIMENSION HEALTH STATUS QUESTIONNAIRE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVECONTROLLED PHASE 3 STUDY OF TAPENTADOL EXTENDED RELEASE (ER) FOR THE MANAGEMENT OF CHRONIC OSTEOARTHRITIS KNEE PAIN : PMS4
A SYSTEMATIC REVIEW AND MIXED TREATMENT COMPARISON (MTC) OF THE EFFICACY OF PHARMACOLOGICAL TREATMENTS FOR FIBROMYALGIA : PMS5
HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) SCORES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOCILIZUMAB PLUS CONVENTIONAL ANTI-RHEUMATIC DRUGS : PMS6
DOSING PATTERN COMPARISON BETWEEN DULOXETINE AND PREGABALIN AMONG PATIENTS WITH FIBROMYALGIA : PMS7
PREVALENCE OF FIBROMYALGIA IN RUSSIA : PMS8
SECULAR DECREASES IN OSTEOPOROTIC FRACTURE RATES 1986-2006: A POPULATION-BASED ANALYSIS : PMS9
RECURRENT FRACTURES AFTER FIRST HIP FRACTURES POSHIP(PREVENTION OF SECOND HIP FRACTURES) STUDY : PMS10
LONG-TERM MORTALITY RATES AFTER INCIDENT FRACTURES IN A POPULATION-BASED COHORT OF MEN AND WOMEN : PMS11
PROBABILISTIC ANALYSIS OF BUDGETARY IMPACT: GLUCOSAMINE IN KNEE OSTEOARTHRITIS TREATMENT : PMS12
BUDGETARY IMPACT OF A NEW URATE-LOWERING THERAPY (ULT) FOR THE TREATMENT OF GOUT IN A US HEALTH PLAN FORMULARY : PMS13
MODELING THE PROGRESSION OF RHEUMATOID ARTHRITIS IN ITALY: BUDGET IMPACT ANALYSIS FOR BIOLOGIC AGENTS : PMS14
ECONOMIC IMPACT OF BIOTHERAPIES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN FRANCE : PMS15
BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL : PMS16
BUDGET IMPACT ANALYSIS OF REIMBURSEMENT OF ARAVA® (LEFLUNOMIDE) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND : PMS17
MANAGEMENT AND COST OF SCIATICA IN-HOSPITAL : PMS18
BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL : PMS19
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF INTRAARTICULAR SODIUM HYALURONATE VERSUS TOTAL ARTHROPLASTY IN THE TREATMENT OF KNEE OSTEOARTHRITIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE : PMS20
MIXED TREATMENT COMPARISONS: AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA®) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS : PMS21
A COST-OF-ILLNESS STUDY OF PSORIATIC ARTHRITIS IN SPAIN : PMS22
COST OF ILLNESS IN AMYOTROPHIC LATERAL SCLEROSIS, MYASTHENIA GRAVIS AND FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY : PMS23
THE SOCIAL AND ECONOMIC COSTS OF SPINA BIFIDA IN ITALY: A COST OF ILLNESS STUDY : PMS24
MEDICAL RESOURCE UTILIZATION AND WORKDAYS LOST IN PATIENTS WITH FIBROMYALGIA : PMS25
HEALTH CARE RESOURCES AND COSTS OF FIBROMYALGIA: A REVIEW OF THE EVIDENCE : PMS26
DIRECT AND INDIRECT COSTS OF RHEUMATOID ARTHRITIS MANAGEMENT IN POLAND : PMS27
COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA : PMS28
HEALTH ECONOMIC COMPARISON OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA BEFORE AND AFTER DIAGNOSIS IN FIVE EUROPEAN COUNTRIES : PMS29
COST ANALYSIS OF BALLOON KYPHOPLASTY VERSUS NON SURGICAL MANAGEMENT FOR OSTEOPOROTIC VERTEBRAL FRACTURES IN GERMANY : PMS30
COST OF TREATMENT COMPARISON OF TNF-α INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN SOUTH AFRICA : PMS31
ASSESSMENT OF THE TOTAL DIRECT MEDICAL COST OF PATIENTS IN SECOND-LINE TNF INHIBITOR THERAPY AND OF THE RESPECT OF CLINICAL PRACTICE RECOMMENDATIONS : PMS32
COST-BENEFIT ANALYSIS OF MANAGEMENT STRATEGIES TO REDUCE ROAD TRAFFIC INJURIES : PMS33
COST-EFFECTIVENESS OF BIOLOGIC THERAPEUTIC SEQUENCES FOR RHEUMATOID ARTHRITIS IN THE UK : PMS35
COST-EFFECTIVENESS OF ZOLEDRONIC ACID ONCE-YEARLY INFUSION IN THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROTIC FRACTURES BASED ON COMPLIANCE AND NUMBER NEEDED TO TREAT APPROACH IN THE TURKISH HEALTH CARE SETTING : PMS36
DOES GENERIC ALENDRONATE REALLY SAVE MONEY IN THE TREATMENT OF OSTEOPOROSIS GIVEN SUB-OPTIMAL REAL LIFE COMPLIANCE? AN EXAMPLE FROM THE DANISH SETTING : PMS37
ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN : PMS38
SEQUENTIAL COST-EFFECTIVENESS MODELLING OF DIFFERENT BIOLOGIC STRATEGIES IN RHEUMATOID ARTHRITIS IN TURKEY : PMS39
COST-EFFECTIVENESS SIMULATION MODEL OF BIOLOGIC STRATEGIES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS BASED ON DISEASE ACTIVITY IN GERMANY : PMS40
COST-EFFECTIVENESS OF TNF-ALPHA BLOCKERS IN REAL-WORLD SETTING OF CZECH REGISTRY : PMS41
HEALTH ECONOMIC EVALUATION OF THE TREATMENT OF OSTEOPOROSIS IN FIVE ITALIAN REGIONS : PMS42
ECONOMIC EVALUATION OF GLUCOSAMINE SULPHATE TREATMENT IN KNEE OSTEOARTHRITIS : PMS43
COST-EFFECTIVENESS OF BALLOON KYPHOPLASTY IN PATIENTS WITH SYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES IN A UK SETTING : PMS45
INDIRECT COSTS OF RHEUMATOID ARTHRITIS BEFORE AND AFTER 6 MONTHS OF TREATMENT WITH BIOLOGICS: THE GISEA STUDY : PMS46
POTENTIAL HEALTH ECONOMIC BENEFITS OF IMPROVING THE CARDIOVASCULAR SAFETY PROFILE OF NSAIDS : PMS47
PHARMACOECONOMIC MODEL FOR TREATING OSTEOPOROSIS WITH ALPHACALCIDOL IN GERMANY : PMS48
COST-UTILITY ANALYSIS OF LEFLUNOMIDE (ARAVA) IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND : PMS49
COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NONVERTEBRAL FRACTURES UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL : PMS50
COST-MINIMIZATION ANALYSIS OF IV BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NONVERTEBRAL FRACTURES UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL : PMS51
COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NONVERTEBRAL FRACTURES UNDER THE PATIENT PERSPECTIVE IN BRAZIL : PMS52
ECONOMIC EVALUATION OF TRAMADOL/PARACETAMOL COMBINATION TABLETS VS NSAIDS FOR OSTEOARTHRITIS PAIN IN SPAIN : PMS53
COST-EFFECTIVENESS OF TOCILIZUMAB COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN ITALY : PMS54
COST UTILITY ANALYSIS OF TOPICAL DICLOFENAC FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE : PMS55
COST-UTILITY OF AUTOLOGOUS CHONDROCYTES IMPLANTATION USING CHONDROCELECT® IN SYMPTOMATIC KNEE CARTILAGE DAMAGE IN BELGIUM : PMS56
COST-UTILITY ANALYSIS OF BALLOON KYPHOPLASTY FOR PATIENTS WITH OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN JAPAN : PMS57
COST-UTILITY ANALYSIS OF DIFFERENT TREATMENT STRATEGIES AFTER THE FAILURE OF FIRST BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS (RA) IN THE FINNISH SETTING : PMS58
THE CLINICAL AND ECONOMIC BURDEN OF NONADHERENCE WITH OSTEOPOROSIS MEDICATIONS : PMS59
COST-UTILITY OF EXERCISE THERAPY IN ADOLESCENTS AND YOUNG ADULTS SUFFERING FROM THE PATELLOFEMORAL PAIN SYNDROME : PMS60
SHORT-TERM DISABILITY ASSOCIATED WITH HIP, NON-VERTEBRAL, AND VERTEBRAL FRACTURES IN THE UNITED STATES : PMS61
INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR DETERMINANTS : PMS62
COMPARISON OF STAFF RESOURCES AND PATIENT TIME REQUIRED FOR RITUXIMAB AND INFLIXIMAB ADMINISTRATION IN 3 UK NHS HOSPITALS : PMS63
ANALYSIS OF HOSPITAL EVENTS MEANING IATROGENICITY, ANHEMIA : PMS64
IMPACT OF MINIMAL ACCESS SPINAL TECHNOLOGIES (MASTTM) ON HOSPITALIZATION COST: A FRENCH EXPERIENCE : PMS65
GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NONADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES : PMS66
THE EFFECT OF MEDICATION CHOICE BETWEEN DULOXETINE AND PREGABALIN ON MEDICATION COMPLIANCE AND DIRECT CARE COSTS AMONG PATIENTS WITH FIBROMYALGIA : PMS67
GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NONADHERENCE IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES : PMS68
ITEM REDUCTION AND VALIDATION OF A NEW ADHERENCE QUESTIONNAIRE IN OSTEOPOROTIC POST-MENOPAUSAL WOMEN: THE ADHERENCE EVALUATION OF OSTEOPOROSIS TREATMENT (ADEOS) QUESTIONNAIRE : PMS69
USE OF QUALITATIVE RESEARCH TO ELICIT PATIENT-REPORTED OUTCOME APPROACHES IN OSTEOPOROSIS : PMS70
PREDICTING CHANGES IN EQ-5D UTILITY SCORE VIA PASI OR HAQ IN PSORIATIC ARTHRITIS PATIENTS : PMS71
A CALIBRATION OF THE RELATIONSHIP BETWEEN THE HAQ, THE SF-6D AND THE EQ-5D IN INFLAMMATORY ARTHRITIS : PMS72
CONTENT VALIDITY OF THE FIBROMYALGIA SYNDROME BURDEN ASSESSMENT (FMBA©) : PMS73
DEVELOPMENT OF A TOOL TO HELP IN THE EARLY DETECTION OF FIBROMYALGIA (FM) IN GENERAL PRACTICE IN EUROPE : PMS74
OAKHQOL, A DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR OSTEOARTHRITIS OF THE LOWER LIMB. VALIDITY AND RESPONSIVENESS : PMS75
PATIENT REPORTED QUALITY-OF-LIFE ISSUES IN MYOTONIC DYSTROPHY TYPE-1 (DM1): A FIRST STEP IN THE DEVELOPMENT OF A DISEASE-SPECIFIC INSTRUMENT : PMS76
FURTHER DEVELOPMENTS OF THE RHEUMATOID ARTHRITIS QUALITY OF LIFE SCALE (RAQOL) : PMS77
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS : PMS78
IS BODY-MASS-INDEX A PREDICTIVE FACTOR FOR CLINICAL OUTCOME IN PATIENTS WITH MONOSEGMENTAL LUMBAR FUSION? : PMS79
ASSOCIATION BETWEEN ANXIETY AND HRQOL IN PATIENTS WITH LOWER LIMB OSTEOARTHRITIS : PMS80
HAQ-BASED UTILITIES USING EUROQOL, BRAZIER'S SHORT FORM-6D, AND VAS-QOL HAVE DIFFERENT VALUES AND MAY NOT ALL DISCRIMINATE ACROSS DISEASE SEVERITY AMONG A PORTUGUESE COHORT OF RHEUMATOID ARTHRITIS PATIENTS : PMS81
VALIDITY AND RELIABILITY OF A HEATH RELATED QUALITY OF LIFE QUESTIONNAIRE : SOCIAL FUNCTIONING SCALE FOR TURKISH MSDS PATIENTS : PMS82
COMPARISON OF A GENERIC UTILITY MEASURE (EQ-5D) AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS : PMS83
IMPACT OF CERTOLIZUMAB PEGOL (CZP) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL): RHEUMATOID ARTHRITIS (RA) PATIENTS APPROACH POPULATION US NORMS IN MENTAL HEALTH AND VITALITY DOMAINS : PMS84
EQ-5D VISUAL ANALOGUE SCALE (VAS) AND UTILITY INDEX VALUES IN FRENCH WOMEN WITH A DIAGNOSIS OF POST-MENOPAUSAL OSTEOPOROSIS : PMS85
CERTOLIZUMAB PEGOL DEMONSTRATES SIGNIFICANT IMPROVEMENTS IN THE PRODUCTIVITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PARTICULARLY IN THE HOUSEHOLD : PMS86
IMPACT OF RHEUMATOID ARTHRITIS (RA) ON WORKING CONDITIONS AND INCOME : PMS87
MANAGEMENT AND COST OF LOW BACK PAIN IN-HOSPITAL: HOW A LONGITUDINAL HOSPITAL DATA BASE DESCRIBES THE REAL PRACTICES? : PMS88
MANAGEMENT AND COST OF LUMBAGO-SCIATICA IN-HOSPITAL: HOW A LONGITUDINAL HOSPITAL DATA BASE DESCRIBES THE REAL PRACTICES? : PMS89
FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' DISEASE MANAGEMENT : PMS90
ADHERENCE IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO) TREATED WITH ORAL BISPHOSPHONATES IN GERMANY: A SYSTEMATIC REVIEW : PMS91
EXPOSURE TO OSTEOPOROSIS MEDICATION IN MEN : PMS92
GREEK NHS CAPACITY CONSTRAINTS REGARDING IV TREATMENT FOR RHEUMATOID ARTHRITIS PATIENTS : PMS93
MANAGEMENT AND DIAGNOSIS OF OSTEOPOROTIC VERTEBRAL FRACTURES ACCORDING TO PRIMARY CARE PHYSICIANS : PMS94
REAL WORLD DATABASE ANALYSIS: USAGE AND ECONOMIC IMPACT OF ANTI-TNFS AS SECOND LINE THERAPY FOR RHEUMATOID ARTHRITIS PATIENTS IN THE PUBLIC HEALTH CARE SECTOR IN BRAZIL : PMS95
ARE THE ADMINISTRATIVE DATABASE A STRATEGIC TOOL IN DECISION MAKING? CASE STUDY: RHEUMATOID ARTHRITIS IN PIEMONTE REGION : PMS96
FACTORS INFLUENCING REIMBURSEMENT AND PRESCRIPTION DECISIONS ON THE RHEUMATOID ARTHRITIS MAKET IN GERMANY, SPAIN, ITALY, FRANCE AND UK : PMS97
DEVELOPMENT AND VALIDATION OF A DISEASE MODEL FOR POSTMENOPAUSAL OSTEOPOROSIS : PMS98
MANAGEMENT OF KNEE OSTEOARTHRITIS: IMPACT ON PAIN ON A DAILY BASIS : PMS99
VERTEPORFIN IN NEOVASCULAR AMD: REAL LIFE CONFIRMS CLINICAL TRIALS RESULTS : PSS1
COMPARISON OF OUTCOMES FOR MULTIFOCAL INTRA-OCULAR LENSES (MIOLS): A META-ANALYSIS : PSS2
TREATMENT PERSISTENCY OF XALATAN-XALACOM, LUMIGAN-GANFORT AND TRAVATAN-DUOTRAV: AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE : PSS3
SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF ACTINIC KERATOSES : PSS4
RESTOR® VERSUS ACRILISA®: ND-YAG LASER INCIDENCE RATE COMPARISON 18 MONTHS AFTER SURGERY : PSS5
CONJUNCTIVAL HYPERAEMIA ASSOCIATED WITH THE FIXED COMBINATIONS OF LATANOPROST/TIMOLOL AND BIMATOPROST/ TIMOLOL IN THE TREATMENT OF OCULAR HYPERTENSION OR GLAUCOMA : PSS6
THE APPLICATION OF DISCRETE EVENT SIMULATION TO QUANTITATIVE RISK BENEFIT ANALYSIS : PSS7
COSTS-OF-ILLNESS OF ULCUS CRURIS IN GERMANY: RESULTS OF TWO APPROACHES : PSS8
COSTS OF PATIENTS WITH OCCUPATIONAL SEVERE CHRONIC HAND ECZEMA REFRACTORY TO TOPICAL CORTICOSTEROIDS FOR EMPLOYER'S MUTUAL INSURANCE COMPANIES IN SPAIN : PSS9
COST OF MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN : PSS10
COST OF TREATMENT FAILURE IN ACUTE INFECTIOUS CONJUNCTIVITIS IN SCOTLAND, SPAIN, THE NETHERLANDS AND POTENTIAL ECONOMIC BENEFIT OF TOPICAL MOXIFLOXACIN 0.5% : PSS11
THE ECONOMIC IMPACTS OF ACUTE OTITIS MEDIA IN TAIWAN : PSS12
CATARACT SURGERY COST IN PATIENTS WITH AND WITHOUT ASTIGMATISM: A FRENCH NATIONAL DRG DATABASE ANALYSIS : PSS13
A PATIENT SURVEY/CHART REVIEW STUDY ABOUT TREATMENT PATTERNS, COSTS AND QUALITY OF LIFE IN PATIENTS WITH PSORIASIS IN SWEDEN : PSS14
COSTS OF GLAUCOMA IN DENMARK : PSS15
DECISION MAKING ANALYSIS FOR DIFFERENT NEUROSENSORIAL DEEP HYPOACUSIA TREATMENTS IN COLOMBIA. COST-PRODUCTIVITY ASSESMENT : PSS16
A HEALTH ECONOMIC EVALUATION OF ELIMINATING NONCOMPLIANCE WITH ORAL TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS IN DOGS IN GERMANY : PSS17
A FRENCH ECONOMIC MODEL COMPARING COST-EFFECTIVENESS OF DUOTRAV AND XALACOM IN GLAUCOMA : PSS18
CEFOVECIN AS TREATMENT OF SUPERFICIAL PYODERMA, WOUNDS AND ABSCESSES IN DOGS: ESTIMATION OF THE HEALTH AND ECONOMIC IMPACT OF ELIMINATING ORAL MEDICATION NONCOMPLIANCE IN THE UNITED STATES : PSS19
ECONOMIC EVALUATION OF BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PSORIASIS: ETANERCEPT COMPARED TO ADALIMUMAB AND INFLIXIMAB : PSS20
COST-EFFECTIVENESS OF A NEW TOPICAL PRESERVATIVE-FREE OPHTHALMIC ANTIBIOTIC TREATMENT WITH MOXIFLOXACIN IN THE NETHERLANDS : PSS21
COST-EFFECTIVENESS STUDY OF COMPLICATED SKIN AND SKIN-STRUCTURE INFECTION TREATMENT IN MEXICO : PSS22
COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN ACTINIC KERATOSES : PSS23
COST EFFECTIVENESS ANALYSIS OF TAFLUPROST COMPARED WITH LATANOPROST ON THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN SOUTH KOREA : PSS24
COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS : PSS25
EXPECTED VALUE OF PARTIAL PERFECT INFORMATION IN A MARKOV MODEL OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE TYPE PSORIASIS : PSS26
A COST-UTILITY ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN ITALY : PSS27
COST-EFFECTIVENESS OF USTEKINUMAB VERSUS ETANERCEPT IN SEVERE PLAQUE PSORIASIS PATIENTS: A CANADIAN PERSPECTIVE : PSS28
ADHERENCE TO ANTIGLAUCOMA DRUG TREATMENT IN NEWLY TREATED PATIENTS : PSS29
ETUD GLAUCOME, ETUDE TRANSVERSALE UN JOUR DANS LE GLAUCOME: ONE-DAY CROSS SECTIONAL STUDY IN GLAUCOMA : PSS30
LEVELS OF EMPOWERMENT AMONG PSORIATIC PATIENTS : PSS31
VALIDATION AND ASSESSMENT OF MEASUREMENT INVARIANCE OF THE EYELASH SATISFACTION QUESTIONNAIRE (ESQ) IN US CANCER PATIENTS : PSS32
DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTES WITH PSOARIASIS: ‘PSO-LIFE’ : PSS33
TOOLS TO HELP DIAGNOSIS OF ATOPIC DERMATITIS: A NEED IN PUBLIC HEALTH : PSS34
DEVELOPMENT AND VALIDATION OF A TREATMENT SATISFACTION QUESTIONNAIRE OF HAND SKIN DISEASES: THE DERMSAT QUESTIONNAIRE : PSS35
DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF SCARS MEASURE (PRISM) : PSS36
QUALITY OF LIFE IN CHRONIC HAND ECZEMA AS MEASURED BY THE DERMATOLOGY LIFE QUALITY INDEX : PSS37
INFLUENCE OF DEPRESSION ON HEALTH RELATED QUALITY OF LIFE IN PSORIASIS: RESULTS FROM AN OPEN LABEL STUDY OF ADALIMUMAB IN PATIENTS WITH PSORIASIS : PSS38
PSORIASIS: AN EPIDEMIOLOGIC EVALUATION OF DISEASE BURDEN IN 590 PATIENTS : PSS39
CAN WE RELY ON SCORES FROM THE DERMATOLOGY LIFE QUALITY INDEX? : PSS40
DEVELOPMENT AND ACCEPTABILITY OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE: BEAUTYQOL : PSS41
INTERVENTIONAL PROCEDURES IN GLAUCOMA: RESOURCES AND COSTS IN FIVE EUROPEAN COUNTRIES : PSS42
EVALUATION OF THE IMPLEMENTATION OF UK NATIONAL GUIDANCE ON THE USE OF BIOLOGICS IN SEVERE PSORIASIS : PSS43
ANÁLISE DE AVALIAÇÕES ECONÔMICAS EM SAÚDE NO PROCESSO DE AVALIAÇÃO DA INCORPORAÇÃO DE TECNOLOGIAS DO MINISTÉRIO DA SAÚDE DO BRASIL : CASE1
EXPERIÊNCIA DO VILA VELHA HOSPITAL PARA INCORPORAÇÃO DE NOVAS TECNOLOGIAS EM SAÚDE NA PRESTAÇÃO DE SERVIÇOS DE SAÚDE SUPLEMENTAR : CASE2
INSTRUMENTOS FINANCIEROS Y VIABILIDAD SECTORIAL : CASE3
COST-EFFECTIVENESS ANALYSIS OF A CERVICAL CANCER VACCINE IN FIVE LATIN AMERICAN COUNTRIES : CS1
COST-EFFECTIVENESS OF SMOKING CESSATION INTERVENTIONS IN SEVEN LATIN AMERICAN COUNTRIES : CS2
UN MODELO DE COSTO-UTILIDAD DEL TRASPLANTE RENAL EN COLOMBIA : CS3
THE COST AND HEALTH CONSEQUENCES OF SUBCUTANEOUS IMMUNOTHERAPY PLUS BECLOMETHASONE DIPROPIONATE IN COLOMBIAN CHILDREN WITH MODERATE AND SEVERE ASTHMA : CS4
LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW OF PRO MEASURES FOR BENIGN PROSTATIC HYPERPLASIA : PR1
IMPROVEMENT IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH ADALIMUMAB PLUS METHOTREXATE: WORK OUTCOMES AND THEIR CORRELATIONS WITH CLINICAL AND RADIOGRAPHIC MEASURES FROM A RANDOMIZED CONTROLLED TRIAL COMPANION STUDY : PR2
EFFECT OF PREHOSPITALIZATION PERIOD AND TYPE OF PESTICIDES ON OUTCOMES IN ACUTE ORGANOPHOSPHORUS POISONING : PR3
QUALITY OF LIFE IN PATIENTS WITH EPIDERMOLYSIS BULLOSA : PR4
VALORACIÓN SOCIAL DE LOS ESTADOS DE SALUD EQ-5D EN CHILE: ALCANCES METODOLÓGICOS : MC1
SELF-PERCEPTION OF HEALTH IN LATIN AMERICA : MC2
PREDICCIÓN DEL RIESGO CARDIOVASCULAR EN PACIENTES DIABÉTICOS TIPO 2 UTILIZANDO ÁRBOLES DE DECISIÓN: PRUEBA DE CONCEPTO : MC3
COMPARISON OF DATA AVAILABILITY AND QUALITY FOR PHARMACOECONOMIC ANALYSIS IN BRAZIL VERSUS THE UNITED STATES AND EUROPEAN UNION: THE CASES OF DIABETES & HYPERTENSION : MC4
GASTOS ELEVADOS COM MEDICAMENTOS DO PROGRAMA DE MEDICAMENTOS EXCEPCIONAIS DO MINISTÉRIO DA SAÚDE/BRASIL : CS5
THE INTRODUCTION OF PRE-ENDOSCOPY (EGD) HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITION (HDIVPPI) IN THE MANAGEMENT OF PATIENTS WITH ACUTE UPPER GASTROINTESTINAL BLEEDING (UGIB)—A BUDGET IMPACT ANALYSIS : CS6
COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING ROSUVASTATIN INTO THE BRAZILIAN NATIONAL DRUG FORMULARY : CS7
THE ECONOMIC BURDEN OF GAUCHER AND FABRY'S DISEASE IN COLOMBIA. IMPLICATIONS FOR NATIONAL HEALTH INSURANCE : CS8
ESTIMATION OF THE BURDEN OF CARDIOVASCULAR DISEASE ATTRIBUTABLE TO MODIFIABLE RISK FACTORS AND COST-EFFECTIVENESS ANALYSIS OF PREVENTIVE INTERVENTIONS TO REDUCE THIS BURDEN IN ARGENTINA : CS9
ANÁLISIS DE COSTO EFECTIVIDAD Y COSTO UTILIDAD DEL INTERFERÓN BETA-1B (INFB1B) FRENTE A INTERFERÓN BETA-1A (INFB1A) PARA EL TRATAMIENTO DE ESCLEROSIS MÚLTIPLE REMITENTE RECIDIVANTE EN COLOMBIA : CS10
COST-EFFECTIVENESS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF MAJOR DEPRESSION IN MEXICO : CS11
IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE HEPATITIS A EN COLOMBIA : CS12
CONHECIMENTO DA POPULAÇÃO BRASILEIRA DO CÂNCER DE MAMA E SEU DIAGNÓSTICO : HP1
HEALTH TECHNOLOGY ASSESSMENT IN LATIN-AMERICA AND THE CARIBBEAN, FACILITATORS AND BARRIERS FOR INTERNATIONAL COLLABORATION: A SURVEY : HP2
INFLUÊNCIA DA AVALIAÇÃO DE TECNOLOGIAS EM SAÚDE NOS PROCESSOS DE TOMADA DE DECISÃO NO SISTEMA ÚNICO DE SAÚDE : HP4
TOWARD AN ECONOMIC FRAMEWORK FOR UNDERSTANDING PERFORMANCE-BASED RISK-SHARING AGREEMENTS FOR INNOVATIVE MEDICAL PRODUCTS : MC5
SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION : MC6
COMPARISON OF METHODS: FOR IDENTIFYING DEPRESSION IN PATIENTS WITH DIABETES USING PHYSIOLOGIC, SOCIAL, AND DISEASE SEVERITY MEASURES : MC8
GANHOS ASSOCIADOS A EXAMES CLÍNICOS ASSOCIADOS AO RASTREAMENTO MAMOGRÁFICO PARA MULHERES ACIMA DOS 40 ANOS : CO1
PRESCRIPCIÓN DE MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES HOSPITALIZADOS : CO2
HOW AND WHY AUTOMATED MEDICAL DATABASES SHOULD BE USED TO CREATE BACKGROUND OCCURRENCES FOR DRUG OUTCOMES AND SAFETY STUDIES: GLAUCOMA IN THIN (UK) : CO3
AUTOMATED PHONE CALLS IMPROVED ADHERENCE TO INHALED CORTICOSTEROIDS : CO4
CLINICAL EFFECTIVENESS AND COST UTILITY OF TRUVADA, KIVEXA AND COMBIVIR IN THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS IN MEXICO : CS13
ASSESSMENT OF THE ECONOMICAL IMPACT OF NON-PERSISTENCE WITH ANTIDEPRESSANT TREATMENTS USING THE ADMINISTRATIVE CLAIMS DATABASE OF QUEBEC (CANADA) : CS14
ECONOMIC BURDEN ASSOCIATED WITH DOSE-TITRATION AT INITIATION TO MANAGED CARE IN PATIENTS WITH NON-PSYCHOTIC MAJOR DEPRESSIVE DISORDER : CS15
COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ ITRACONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO : CS16
COSTOS DE LA ESCLEROSIS MÚLTIPLE EN COLOMBIA : CS17
ECONOMIC EVALUATION OF BARIATRIC SURGERY AS TREATMENT FOR OBESITY AND ASSOCIATED COMORBIDITIES—ESTIMATION BY DISCRETE EVENT SIMULATION : CS18
AUDITORIA BASEADA EM EVIDÊNCIAS (ABE): IMPACTO NO CUSTO DO TRATAMENTO QUIMIOTERÁPICO APÓS 3 ANOS DE IMPLANTAÇÃO : CS19
RELATIONSHIP BETWEEN ADHERENCE LEVEL TO STATINS AND CLINICAL ISSUES AND HEALTH CARE COSTS IN REAL LIFE CLINICAL SETTING : CS20
PROFILE OF HTA USERS AND APPLICABILITY OF HTA REPORTS TO INFORM DECISIONS IN LATIN-AMERICA : HP5
EVALUACIÓN ECONÓMICA DE LA TERAPIA CON ESTATINAS EN PREVENCIÓN SECUNDARIA: REVISIÓN SISTEMÁTICA DE LA LITERATURA : HP6
FACTORES PREDICTIVOS DEL ÉXITO EN UN PROGRAMA DE CESACIÓN TABAQUICA EN MÉXICO : HP7
REGULACIÓN Y PATRONES DE PRÁCTICA ACERCA DE TRATAMIENTOS ORALES DE LA DIABETES TIPO 2 EN LATINOAMÉRICA : HP8
EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS : PCN1
ESTUDIO FASE II PARA EVALUAR LA EFICACIA Y SEGURIDAD DE 4′,4′-DIHIDROXIBENZOFENONA-2,4-DINITROFENIL-HIDRAZONA (A-007) GEL TÓPICO EN EL TRATAMIENTO DE LESIONES INTRAEPITELIALES ESCAMOSAS DE ALTO GRADO (LIEAG) DEL CUELLO UTERINO Y SU ASOCIACIÓN AL VIRUS DEL PAPILOMA HUMANO (VPH) DE ALTO RIESGO : PCN2
EXPERIENCIA CLÍNICA Y RESULTADOS CON INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF-R) EN PACIENTES LATINOS CON CÁNCER DE PULMON NO PEQUEÑAS CELULAS (CPNPC) : PCN3
ERYTHROPOIESIS STIMULATING AGENTS (ESA) FOR THE TREATMENT OF CHEMOTHERAPY INDUCED ANEMIA IN PATIENTS WITH HEMOGLOBIN LEVELS (HB) <11G/DL—A SYSTEMATIC REVIEW AND META-ANALYSIS : PCN4
ANÁLISE FARMACOECONÔMICA DE ANTIEMÉTICOS EM QUIMIOTERAPIA ALTAMENTE/MODERADAMENTE EMETOGÊNICA: A PERSPECTIVA DA FONTE PAGADORA : PCN5
COMPARAÇÃO DE CUSTOS E TEMPO PARA PROGRESSÃO ENTRE PEMETREXEDE (P) E DOCETAXEL (D) NO TRATAMENTO DE SEGUNDA LINHA DO CÂNCER DE PULMÃO NÃO PEQUENAS CÉLULAS (NSCLC): DADOS DO MUNDO REAL : PCN6
METASTATIC BREAST CANCER TREATMENT PATTERNS AND COSTS OF OUTPATIENT CARE UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE : PCN7
EVALUACIÓN DE LA CARGA DE ENFERMEDAD POR EL VIRUS DEL PAPILOMA HUMANO EN BOGOTÁ, COLOMBIA : PCN8
ANÁLISIS DE COSTOS DEL TRATAMIENTO EN PACIENTES CON SARCOMA DE TEJIDOS BLANDOS EN ETAPA TEMPRANA EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS) : PCN9
IMPACTO DE LA SUPERVIVENCIA DEL CÁNCER DE MAMA SOBRE LOS COSTOS MÉDICOS DIRECTOS : PCN10
COST ANALYSIS OF THE TREATMENT OF ADVANCED METASTATIC STS IN THE IMSS: ESTIMATING MEDICAL COST WITH CENSORED DATA : PCN11
ECONOMIC EVALUATION OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS OF FEC-D VS FEC, IN PUBLIC HEALTH CARE INSTITUTIONS IN MEXICO : PCN12
COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN COLOMBIA (ONCOLGROUP STUDY) : PCN13
THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MÉXICO : PCN14
ECONOMIC EVALUATION OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN MEXICO : PCN15
THE COST AND HEALTH CONSEQUENCES OF DIFFERENT BREAST CANCER SCREENING STRATEGIES IN COLOMBIA : PCN16
COST EFFECTIVENESS OF IMIQUIMOD IN SUPERFICIAL BASAL CELL CARCINOMA TREATMENT : PCN17
ECONOMIC EVALUATION OF SUNITINIB VS. IMATINIB IN SECOND LINE FOR GASTROINTESTINAL TUMOR (GIST) IN BRAZIL : PCN18
COST-EFFECTIVENESS ANALYSIS OF CLOFARABINE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO : PCN19
COST-EFFECTIVENESS ASSESSMENT FOR COLOMBIA OF LETROZOLE VS. TAMOXIFEN IN ADJUVANT TREATMENT OF HORMONE RECEPTOR-POSITIVE, POST-MENOPAUSAL EARLY BREAST CANCER WOMEN : PCN20
ESTUDIO DE COSTO EFECTIVIDAD DEL USO DE TRASTUZUMAB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER DE MAMA TEMPRANO HER2 POSITIVO EN EL INSTITUTO NACIONAL DE CANCEROLOGÍA DE COLOMBIA, DESDE EL PUNTO DE VISTA DEL PAGADOR : PCN21
COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY : PCN22
ANÁLISE FARMACOECONÔMICA DO TRATAMENTO DO CÂNCER COLORRETAL METASTÁTICO COM BEVACIZUMABE NO BRASIL : PCN23
COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE : PCN24
REVISIÓN SISTEMÁTICA Y EVALUACIÓN ECONÓMICA DE LA ABLACIÓN POR RADIOFRECUENCIA EN TUMORES HEPÁTICOS : PCN25
COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB + INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO : PCN26
COST MINIMIZATION ANALYSIS OF TEGAFUR-URACIL ASSOCIATED TO LEUCOVORIN (UFT/LV) VERSUS CAPECITABINE ALONE FOR METASTATIC COLORECTAL CANCER UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE : PCN27
PHARMACOECONOMIC EVALUATION OF THE USE OF SOMATOSTATIN ANALOGS HANDLING THE ASSOCIATED SYMPTOMS OF CARCINOID SYNDROME : PCN28
REVISÃO DE CONTAS EM ONCOLOGIA E MEDICINA BASEADA EM EVIDÊNCIAS (MBE): IMPACTO FINANCEIRO E BUSCA PELA QUALIDADE : PCN29
IMPACTO EMOCIONAL EN UN GRUPO DE MUJERES MEXICANAS CON DIAGNÓSTICO DE VPH Y NEOPLASIA INTRACERVICAL (NIC-II/III) : PCN30
EL SENTIDO DE VIDA EN UN GRUPO DE MUJERES ACAPULQUEÑAS CON DIAGNÓSTICO DE CÁNCER : PCN31
QUALITY OF LIFE IN DIFFERENT STAGES OF MEXICAN BREAST CANCER PATIENTS : PCN32
QUALITY OF LIFE OF PATIENTS WITH NON-HODGKIN LYMPHOMA AT THE SOCIAL SECURITY MEXICAN INSTITUTE : PCN33
QUALITY OF LIFE IN DIFFERENT STAGES OF COLORECTAL PATIENTS ATTENDED AT THE SOCIAL SECURITY MEXICAN INSTITUTE : PCN34
SYSTEMATIC REVIEW OF THE IMPACT OF CHEMOTHERAPY ON PATIENT REPORTED OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG CANCER : PCN35
A QUALIDADE DE VIDA DOS DOENTES ONCOLÓGICOS : PCN36
ABRANGÊNCIA DO RASTREAMENTO DE CÂNCER DE MAMA POR MAMOGRAFIA EM BENEFICIÁRIAS DE UMA OPERADORA DE PLANO DE SAÚDE : PCN37
TREATMENT PATTERNS OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE TO ANTHRACYCLINE AND TAXANE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE : PCN38
PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND LOW- OR MODERATE-DOSE STATINS IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA : PCV1
PREDICTED OPTIMAL LIPID VALUE ATTAINMENT RATES WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA : PCV2
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND RISK FOR MAJOR CARDIOVASCULAR EVENTS IN MEN AND WOMEN : PCV3
COST AND OUTCOME ANALYSIS COMPARING PTCA & CABG IN LOW AND HIGH RISK PATIENTS : PCV4
PROPHYLAXIS OF HEART TRANSPLANTATION REJECTION: FINANCIAL IMPACT ANALYSIS BY BRAZILIAN PUBLIC HEALTH CARE SYSTEM AND A REVIEW OF ECONOMIC EVALUATIONS STUDIES OF EVEROLIMUS, MMF (MYCOPHENOLATE MOFETIL) AND AZATHIOPRINE : PCV5
IMPACTO ECONÔMICO DA INCORPORAÇÃO DO TESTE RÁPIDO PARA DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA, SOB A PERSPECTIVA DO PAGADOR PRIVADO NO BRASIL : PCV6
IMPACTO ECONÔMICO DA INCORPORAÇÃO DO TESTE RÁPIDO PARA DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA (IC), SOB A PERSPECTIVA DO SISTEMA UNICO DE SAUDE (SUS), NO BRASIL : PCV7
COST OF ILLNESS IN PATIENTS WITH PULMONARY EMBOLISM AFTER ELECTIVE TOTAL HIP REPLACEMENT : PCV8
AVALIAÇÃO DO PERFIL EPIDEMIOLÓGICO E DE PRESCRIÇÃO PARA PACIENTES AMBULATORIAIS MEDICADOS COM ANTI-HIPERTENSIVOS : PCV9
ECONOMIC VALUE OF RESTING HEART RATE AS AN INDEPENDENT CARDIOVASCULAR RISK FACTOR IN STABLE ANGINA PATIENTS : PCV10
COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT OR TOTAL KNEE REPLACEMENT IN COLOMBIA : PCV11
COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE : PCV12
COST-EFFECTIVENESS ANALYSIS OF B-TYPE NATRIURETIC PEPTIDE COMPARED TO CLINICAL JUDGMENT IN PATIENTS PRESENTING TO ACUTE CARE SETTINGS WITH DYSPNEA IN UNIFIED HEALTH SYSTEM : PCV13
COST-EFFECTIVENESS OF PHARMACOLOGIC HYPERTENSION THERAPY: ECONOMIC ANALYSIS OF ARBS IN COLOMBIA : PCV14
COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE : PCV15
COST-EFFECTIVENESS ANALYSIS OF THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (ALTEPLASE) FOR ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE : PCV16
COST EFFECTIVENESS ANALYSIS OF ROSUVASTATIN 10 MG VS. ATORVASTATIN 20 MG FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA : PCV17
COSTO-EFECTIVIDAD DE ETEXILATO DE DABIGATRAN EN LA PROFILAXIS DE LA ENFERMEDAD TROMBOEMBOLICA VENOSA (ETV) ASOCIADA CON CIRUGIA DE CADERA EN EL PACIENTE ADULTO EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS) : PCV18
REVISÃO SISTEMÁTICA DE ESTUDOS DE CUSTO-EFETIVIDADE DA ROSUVASTATINA VS. ATORVASTATINA : PCV19
METABOLIC SYNDROME PATIENT COMPLIANCE WITH DRUG AND NON-DRUG TREATMENT : PCV20
SELF-REPORTED GENERAL HEALTH WAS THE MOST INFLUENTIAL VARIABLE OF EQ-5D SOCIAL PREFERENCES SCORES IN A GENERAL POPULATION SURVEY IN ARGENTINA, AND ITS INFLUENCE DIFFERED ACCORDING TO GENDER, AGE AND INCOME STATUS : PCV21
EFFECTS OF TADALAFIL ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION : PCV22
CALIDAD DE VIDA RELACIONADA CON LA SALUD EN PACIENTES CON RIESGO CARDIOVASCULAR : PCV23
ANÁLISIS DEL CONSUMO DE AGENTES HIPOLIPEMIANTES EN COLOMBIA DEL 2002 AL 2006 : PCV24
EVALUATION OF THREE METHODS: OF SCHEDULING APPOINTMENT USING SIMULATION EXPERIMENTS : PCV25
COSTS OF INSULIN GLARGINE AND INSULIN DETEMIR IN INTENSIVE INSULIN THERAPY FOR TYPE 1 DIABETES MELLITUS IN ARGENTINA: A PROBABILISTIC MODEL : PDB1
COSTS OF DISEASE COMPLICATIONS RELATED TO DM2 IN MEXICO: A SYSTEMATIC REVIEW : PDB2
RESOURCE USE AND DIRECT MEDICAL COSTS ASSOCIATED TO ACROMEGALY TREATMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE : PDB3
COST OF TYPE 2 DIABETES COMPLICATIONS IN MEXICO : PDB4
ESTIMACIÓN DEL COSTO ASOCIADO A LA PÉRDIDA DE PRODUCTIVIDAD POR MORTALIDAD ATRIBUIBLE A LA DIABETES EN ARGENTINA : PDB5
EVALUACIÓN DE LOS COSTOS ASOCIADOS A LA ELECCIÓN DE LA INSULINA: EL DILEMA DE LOS PAGADORES : PDB6
HOSPITALIZACIONES POR INSUFICIENCIA CARDÍACA EN PERSONAS CON DIABETES: LOS COSTOS DE SU PREVENCIÓN VS. LOS DE SU TRATAMIENTO : PDB7
SELF-MONITORING OF BLOOD GLUCOSE FOR TYPE 2 DIABETES PATIENTS ON ORAL ANTI-DIABETIC MEDICATION: COST-EFFECTIVENESS IN MEXICO : PDB8
ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OF ACROMEGALY IN MEXICO: MONOTHERAPY VS SEQUENTIAL THERAPY : PDB9
COST-MINIMIZATION ANALYSIS COMPARING INSULIN GLARGINE TO INSULIN DETEMIR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS IN BRAZIL : PDB10
COMPARATIVE STUDY OF ANNUAL TREATMENT COST OF GLARGINE INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN MEXICO : PDB11
ADHERENCE TO GLIMEPIRIDE FOR TYPE 2 DIABETICS IN COLOMBIA : PDB12
ENCUESTA SOBRE LAS PRACTICAS DE UTILIZACION Y TITULACION DE INSULINA EN LATINOAMERICA : PDB13
UTILIZACIÓN DE RECURSOS Y GASTOS EN SALUD DE PERSONAS CON DIABETES EN ARGENTINA. UN ANÁLISIS DESCRIPTIVO DE LA ENCUESTA NACIONAL DE UTILIZACIÓN Y GASTOS EN SERVICIOS DE SALUD : PDB14
A STRONG NONLINEAR RELATIONSHIP BETWEEN ADHERENCE WITH DRUG THERAPY AND CONTINUOUS RISK FACTORS IN PPI USERS : PGI1
CHRONIC HEPATITIS C VIRUS (HCV) TREATMENT COSTS IN THE TERTIARY REFERENCE HOSPITAL DAS CLíNICAS—UNIVERSITY OF SãO PAULO SCHOOL OF MEDICINE (HC-FMUSP) : PGI2
COST-EFFECTIVENESS OF PEG-IFN ALPHA 2A OR 2B PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C IN MEXICO : PGI3
ESTUDO FARMAECONÔMICO DA INTERVENÇÃO FARMACÊUTICA NA UTILIZAÇÃO DO OMEPRAZOL EM UTI : PGI4
WHAT ARE THE COSTS FOR NON-COMPLIANCE WITH GUIDELINES FOR TREATMENT OF CHRONIC HEPATITIS C? : PGI5
COST-EFFECTIVENESS COMPARISON OF TENSION FREE VERSUS TENSION METHODS: OF INGUINAL HERNIA REPAIR IN BRAZIL : PHC1
COST-EFFECTIVENESS COMPARISON OF TENSION FREE VERSUS TENSION METHODS: OF INGUINAL HERNIA REPAIR IN MEXICO : PHC2
TRANSPARENCY IN LATIN AMERICAN HTA: HOW DO WE MEASURE SUCCESS? : PHP1
DISTORÇÕES CAUSADAS PELAS AÇÕES JUDICIAIS À SAÚDE PÚBLICA NO MUNICÍPIO DE GOIÂNIA : PHP2
MUDANÇAS INSTITUCIONAIS NO PERÍODO RECENTE E SEUS IMPACTOS NA INDUSTRIA FARMACÊUTICA BRASILEIRA: HA UM SISTEMA DE INOVAÇÃO A CAMINHO? : PHP4
JUDICIALIZAÇÃO DO ACESSO AO TRATAMENTO DE DOENÇAS RARAS: DOENÇA DE FABRY NO ESTADO DO RIO GRANDE DO SUL : PHP5
AGRAVOS POR MEDICAMENTOS: FREQUÊNCIA E CUSTO DIRETO PARA O SISTEMA DE SAÚDE : PHP6
GASTOS COM MEDICAMENTOS E CARATERÍSTICAS DOS SERVIÇOS FARMACÊUTICOS NA ATENÇÃO PRIMÁRIA DE SAÚDE DE FORTALEZA EM 2007 : PHP8
ANÁLISE DOS GASTOS E DA DISTRIBUIÇÃO DE MEDICAMENTOS NA ATENÇÃO BÁSICA DE SAÚDE DO MUNICÍPIO DE FORTALEZA, CEARÁ, BRASIL : PHP9
GERENCIAMENTO DE DOENÇAS CRÔNICAS: UM NOVO PARADIGMA PARA OS PLANOS DE SAÚDE? : PHP10
PHARMACOECONOMIC CONTRIBUTION OF LATIN AMERICA TO ISPOR CONFERENCES : PHP12
ATENÇÃO FARMACÊUTICA E FARMACOECONOMIA: UMA REVISÃO DE LITERATURA : PHP13
PROJETO SPIDER: AVALIÇÃO DO IMPACTO DOS CENTROS DE INFORMAÇÕES TOXICOLÓGICAS NO BRASIL : PHP14
EVALUATION OF SEVERITY SCORING INDICES IN ACUTE ORGANOPHOSPHORUS POISONED PATIENTS IN A TERTIARY CARE HOSPITAL : PHP15
DECENTRALIZATION AND ORGANIZATIONAL REFORM IN IRANIAN PUBLIC HOSPITALS AFFILIATED WITH MINISTRY OF HEALTH : PHP17
WHAT DOES BRANDED PHARMA BRING TO LATIN AMERICA AND OTHER EMERGING MARKETS? : PHP19
AVALIAÇÃO DA EFETIVIDADE DA REDE MUNICIPAL PÚBLICA DE APOIO DIAGNÓSTICO EM PATOLOGIA CLÍNICA: O CASO DE BELO HORIZONTE (MG) : PHP27
A SYSTEMATIC REVIEW OF ECONOMIC EVALUATION AND PHARMACOECONOMICS STUDIES IN KOREA : PHP22
PROPUESTA PARA EL ESTABLECIMIENTO DE UN MODELO DE LA EVALUACIÓN DE TECNOLOGÍAS DE LA SALUD EN COLOMBIA: ESTRUCTURA, PROCESO Y METODOLOGÍA : PHP23
EXPERIÊNCIA BRASILEIRA NO TREINAMENTO DE GESTORES E TÉCNICOS NA ELABORAÇÃO DE MINI-ATS: FERRAMENTA CONTRA A JUDICIALIZAÇÃO EM SAÚDE : PHP24
RATIONAL MYTHS AND RISK TRANSFER IN A PUBLIC HEALTH ORGANIZATION. THE CASE OF PUBLIC HOSPITALS IN BUENOS AIRES CITY, ARGENTINA 2000-2004 : PHP26
MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES ATENDIDOS EN ATENCIÓN PRIMARIA DE SALUD : PIH1
USO DE MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN PACIENTES ANCIANOS HOSPITALIZADOS EN MEDICINA INTERNA DE UN HOSPITAL UNIVERSITARIO : PIH2
ANÁLISE DO IMPACTO ORÇAMENTARIO DO CATETER COM BALÃO DE SILICONE PARA ABLAÇÃO TERMICA ENDOMETRIAL (THERMACHOICE®) VERSUS HISTERECTOMIA NO TRATAMENTO DE PACIENTES COM MENORRAGIA DE ETIOLOGIA BENIGNA PÓS-FALHA AO TRATAMENTO FARMACOLÓGICO, NA PERSPECTIVA DO PAGADOR PRIVADO, NO BRASIL : PIH3
AVALIAÇÃO DO USO DE RECURSOS E DOS CUSTOS DAS COMPLICAÇÕES DA ABLAÇÃO ENDOMETRIAL PARA O TRATAMENTO DE PACIENTES COM MENORRAGIA DE ETIOLOGIA BENIGNA PÓS-FALHA AO TRATAMENTO FARMACOLÓGICO, SOB A PERSPECTIVA DO PAGADOR PRIVADO NO BRASIL. UM COMPARATIVO ENTRE DUAS TÉCNICAS: ABLAÇÃO TÉRMICA DE SEGUNDA GERAÇÃO E HISTERECTOMIA : PIH4
AVALIAÇÃO DO USO DE RECURSOS E DOS CUSTOS DAS COMPLICAÇÕES DA ABLAÇÃO ENDOMETRIAL PARA O TRATAMENTO DE PACIENTES COM MENORRAGIA DE ETIOLOGIA BENIGNA PÓS-FALHA AO TRATAMENTO FARMACOLÓGICO, NA PERSPECTIVA DO PAGADOR PÚBLICO. UM COMPARATIVO ENTRE DUAS TECNICAS: ABLAÇÃO TERMICA DE SEGUNDA GERAÇÃO E HISTERECTOMIA : PIH5
RESOURCE USE AND DIRECT MEDICAL COSTS ASSOCIATED TO PNEUMOCOCCAL DISEASE-RELATED HOSPITALIZATIONS ON BRAZILIAN PUBLIC HEALTH CARE SYSTEM : PIH6
COST OF PNEUMONIA HOSPITALIZATION IN ELDERLY PEOPLE FROM TWO LARGE BRAZILIAN HOSPITALS : PIH7
AUTOPERCEPCIÓN DEL ESTADO SALUD DE LA POBLACIÓN ADULTA DE LA REGIÓN METROPOLITANA EN CHILE: UNA APLICACIÓN DE EQ-5D Y DE LA ESCALA VISUAL ANALOGA : PIH8
REDUÇÃO DE GASTOS COM A IMPLANTAÇÃO DE PROTOCOLO DE DILUIÇÃO PARA PREPARO DE MEDICAMENTOS INTRAVENOSOS EM HOSPITAL UNIVERSITÁRIO DE MÉDIA COMPLEXIDADE DE SÃO PAULO : PIH11
ANáLISE DA APRESENTAÇÃO GRÁFICA DA BULA DE MEDICAMENTO NA PERSPECTIVA DAS ESTRATÉGIAS LEITURA DE PACIENTES EM CONTEXTO DE USO : PIH12
THE IMPACT OF FAMILY PHYSICIAN PROGRAM ON HEALTH INDICATORS IN IRAN (2003-2007) : PIH13
GENDER DIFFERENCES IN METABOLIC PROFILE AND CARDIOVASCULAR RISK AMONG BRAZILIAN HIV-INFECTED PATIENTS ON HAART: RAPID II STUDY : PIN1
INTEGRATION OF PHARMACO-ECONOMIC OUTCOME BASED RESEARCH WITH LOCAL CONTEXT: A MODEL FOR RATIONAL HEALTH CARE DECISION-MAKING IN DEVELOPING COUNTRIES : PIN2
HEPATOCELLULAR CARCINOMA (HCC) RISK ESTIMATION BASED ON CHRONIC HEPATITIS B (CHB) VIRAL LOAD LEVELS IN BRAZILIAN PATIENTS : PIN3
IMPACT OF CHRONIC HEPATITIS B IN THE BRAZILIAN HEALTH SYSTEM ACCORDING WITH DATA FROM DATASUS (ADMINISTRATIVE DATABASE) FROM MINISTRY OF HEALTH : PIN4
CARGA FINANCIERA POR HEPATITIS A EN MÉXICO : PIN5
COSTS OF NOSOCOMIAL PNEUMONIA IN A THIRD LEVEL HOSPITAL OF MEXICAN SOCIAL SECURITY INSTITUTE (IMSS) : PIN6
COSTO-BENEFICIO DEL USO DE TIGECICLINA VS. TRIPLE ESQUEMA ANTIMICROBIANO CEFOTAXIMA/AMIKACINA/METRONIDAZOL EN PACIENTES CON INFECCIONES INTRAABDOMINALES Y DE PIEL Y TEJIDOS BLANDOS EN MÉXICO : PIN7
EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE ROTAVIRUS EN EL PAÍS DE COLOMBIA : PIN8
MODELO FARMACOECONÓMICO VORICONAZOL EN ASPERGILOSIS INVASIVA: CASO VENEZUELA : PIN9
COST EFFECTIVENESS OF ENTECAVIR VERSUS LAMIVUDINE IN SUPPRESSING VIRAL REPLICATION TO UNDETECTABLE GOAL IN CHRONIC HEPATITIS B (CHB) PATIENTS IN BRAZIL : PIN10
COST EFFECTIVENESS ANALYSIS OF ELDERLY POLYSACCHARIDE PNEUMOCOCCAL VACCINATION IN SAO PAULO STATE : PIN11
EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE NEUMOCOCO EN COLOMBIA : PIN12
ANÁLISIS COSTO EFECTIVIDAD DE PRUEBAS RÁPIDAS PARA EL DIAGNÓSTICO DEL VIH COMO HERRAMIENTA DE PREVENCIÓN Y CONTROL DE LA EPIDEMIA : PIN13
EVALUACIÓN DE COSTO EFECTIVIDAD COMPARATIVO DE QUATRO ESQUEMAS DE TRATAMIENTO DE INFECCIÓN URINARIA BAJA EN MUJERES JÓVENES, IMPACTO ECONÓMICO EN UN ENTORNO DE SALUD MUNICIPAL DE CARACAS, VENEZUELA : PIN14
EVALUACIÓN ECONÓMICA DEL IMPACTO DE LA INTRODUCCIÓN DE LA VACUNA DE HEPATITIS A EN BOGOTÁ D.C : PIN15
EVALUACIÓN ECONÓMICA DEL IMPACTO DE LA INTRODUCCIÓN DE LA VACUNA DE NEUMOCOCO EN BOGOTÁ, D.C : PIN16
EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE ROTAVIRUS EN EL PAÍS DE BOGOTÁ, D.C : PIN17
IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE INFLUENZA EN COLOMBIA : PIN18
ECONOMIC EVALUATION OF RUBELLA AND CONTROL STRATEGIES DURING AN OUTBREAK IN FORTALEZA (CEARÁ), BRAZIL, 2007 : PIN19
LONG-TERM CONSEQUENCES OF AN INTENSE RUBELLA VACCINATION PROGRAM IN FORTALEZA, BRAZIL: A COST-EFFECTIVENESS ANALYSIS : PIN20
CHANGE IN QUALITY OF LIFE AFTER BEING DIAGNOSED WITH HIV : PIN21
QUÉ FACTORES DETERMINAN LOS PRECIOS INTERNACIONALES DE LOS MEDICAMENTOS ANTIRETROVIRALES? : PIN22
RANKING HOSPITALS ACCORDING TO QUALITY : PMC1
MODELO DE ESTIMACIÓN DE LA VALORACIÓN SOCIAL DE LOS ESTADOS DE SALUD DEL EQ-5D: CASO DE CHILE : PMC2
ESTADO DEL ARTE DE LA EVALUACIÓN DE LA CALIDAD DE VIDA RELACIONADA CON LA SALUD EN VENEZUELA: UNA REVISIÓN SISTEMÁTICA DE LA LITERATURA : PMC3
METHODS: FOR ACHIEVING AND MAINTAINING ADEQUATE STUDY SUBJECT PARTICIPATION FOR A MULTI-SITE TIME-SERIES TRIAL : PMC4
META-ANALYSIS OF CLINICAL OUTCOMES FROM GUIDELINERECOMMENDED PHARMACOTHERAPIES FOR GENERALIZED ANXIETY DISORDER (GAD) : PMH1
SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE : PMH2
FACTORS THAT PREDICT EARLY TREATMENT FAILURE AMONG PATIENTS IN OUTPATIENT TREATMENT FOR OPIOID DEPENDENCE : PMH3
COSTS AND CONSEQUENCES FOR METABOLIC SYNDROME, DIABETES AND CORONARY HEART DISEASE (CHD) RISK AMONG SCHIZOPHRENIA PATIENTS TREATED WITH ARIPIPRAZOLE VERSUS OLANZAPINE IN BRAZIL : PMH4
COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE VERSUS QUETIAPINE IN SCHIZOPHRENIC PATIENTS : PMH5
ANÁLISE DE CUSTO EFETIVIDADE DOS ANTIPSICÓTICOS ATÍPICOS NO TRATAMENTO DA ESQUIZOFRENIA COM BASE NO NNT(NÚMERO NECESSÁRIO TRATAR) : PMH10
COSTO-EFECTIVIDAD DE OCHO MEDICAMENTOS ANTIPSICÓTICOS EN COLOMBIA : PMH6
HEALTH CARE RESOURCE UTILIZATION IN THE TREATMENT OF DEPRESSION IN MEXICO : PMH7
FACTORES ASOCIADOS AL INCUMPLIMIENTO DE TRATAMIENTOS CON ANTIDEPRESIVOS EN SANTIAGO, CHILE : PMH8
VALIDATION OF PEER RELATIONS SCALE FOR ADOLESCENTS TREATED FOR SUBSTANCE USE DISORDER: AN APPLICATION OF RASCH MODELING : PMH9
BUDGET IMPACT ANALYSIS OF ZOLEDRONIC ACID IN POST MENOPAUSAL OSTEOPOROSIS BY BRAZILIAN PUBLIC HEALTH CARE SYSTEM : PMS1
ANÁLISE DE CUSTOS DE RITUXIMABE VERSUS INFLIXIMABE, ADALIMUMABE, ETANERCEPTE E ABATACEPTE PARA TRATAMENTO DA ARTRITE REUMATÓIDE SOB A PERSPECTIVA DE UM PAGADOR PRIVADO NO BRASIL : PMS2
COSTO-EFECTIVIDAD DEL USO DE ETANERCEPT VS LOS ANTICUERPOS MONOCLONALES ANTI-TNF EN PACIENTES CON ARTRITIS REUMATOIDE EN COSTA RICA : PMS4
COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS ANTI-TNF MONOCLONAL ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN MEXICO : PMS5
ESTIMATED CLINICAL & ECONOMIC IMPACT OF POOR PATIENT PERSISTENCE WITH OSTEOPOROSIS MEDICATIONS IN BRASIL : PMS6
COST-EFFECTIVENESS OF COLLAGEN-POLYVINYLPYRROLIDONE IN THE TREATMENT OF STABLE NONUNION TIBIAL FRACTURES : PMS7
ECONOMIC EVALUATION OF THE USE OF HYLAN G-F 20 IN THE HANDLING OF SEVERE KNEE OSTEOARTHROSIS : PMS8
ESTUDIO FARMACOECONÓMICO DE LOS TRATAMIENTOS ACIDO ZOLEDRÓNICO, RISEDRONATO, ALENDRONATO E IBANDRONATO EN EL MANEJO DE LA OSTEOPOROSIS EN MUJERES POSMENOPÁUSICAS EN VENEZUELA. : PMS13
COST-MINIMIZATION ANALYSIS OF VISCOSUPPLEMENTATION TREATMENT OSTEOARTHRITIS OF KNEE IN BRAZIL'S PRIVATE SECTOR : PMS9
ECONOMIC BURDEN OF RHEUMATOID ARTHRITIS IN BRAZILIAN PRIVATE HEALTH SYSTEM : PMS10
PERCEPTIONS OF TREATMENT OUTCOMES AMONG NEW USERS OF TNF ANTAGONISTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS : PMS11
USTEKINUMAB RESULTS: IN RAPID, SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PHYSICAL DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS: FROM A RANDOMIZED AND PLACEBO-CONTROLLED PHASE II TRIAL : PMS12
BUDGET IMPACT ANALYSIS OF FIXED DOSAGE COMBINATION (FDC) OF LEVODOPA/CARBIDOPA/ENTACAPONE IN PARKINSON DISEASE TREATMENT BY DISTRITO FEDERAL PUBLIC HEALTH CARE SYSTEM : PND2
BUDGET IMPACT ANALYSIS OF FIXED DOSAGE COMBINATION (FDC) OF LEVODOPA/CARBIDOPA/ENTACAPONE IN PARKINSON DISEASE TREATMENT BY SÃO PAULO PUBLIC HEALTH CARE SYSTEM : PND3
COST-EFFECTIVENESS ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN AND PLASMA EXCHANGE THERAPIES FOR THE TREATMENT OF GUILLAIN-BARRÉ SYNDROME IN A UNIVERSITY-BASED HOSPITAL IN THE SOUTH OF BRAZIL : PND4
TOBACCO AND INCOME LEVEL: A SYSTEMATIC REVIEW AND META-ANALYSIS : PRS1
BUDGET IMPACT ANALYSIS OF INTRODUCTION FLUTICASONE PROPIONATE/SALMETEROL (500/50 MG) INTO THE BRAZILIAN NATIONAL DRUG FORMULARY : PRS2
A MICROSIMULATION ECONOMIC MODEL TO EVALUATE THE DISEASE BURDEN ASSOCIATED WITH SMOKING IN ARGENTINA : PRS3
COST OF ILLNESS OF ASHTMA IN A HOSPITAL OF A COLOMBIAN REGION 2006-2009 : PRS4
COST-EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR SMOKING CESSATION: CURRENT EVIDENCE AND POLICY IMPLICATIONS : PRS5
COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE/SALMETEROL (500/50 MG) IN THE TREATMENT OF COPD IN BRAZILIAN PUBLIC SECTOR : PRS6
COSTO-EFECTIVIDAD DEL USO DE ETANERCEPT VS LOS ANTICUERPOS MONOCLONALES ANTI-TNF EN PACIENTES CON PSORIASIS EN PLACAS EN MÉXICO : PSS2
A COMPREHENSIVE SYSTEMATIC REVIEW OF THE PSYCHOMETRIC PROPERTIES OF VFQ-25 IN GLAUCOMA : PSS3
FIRST BRAZILIAN REGISTRY OF BIOLOGICAL TREATMENT IN PSORIASIS PATIENTS: PRELIMINARY CONCEPT AND RESULTS: : PSY1
EFFECT OF WRITTEN EMOTIONAL DISCLOSURE INTERVENTIONS IN PERSONS WITH PSORIASIS UNDERGOING NARROW BAND ULTRAVIOLET B PHOTOTHERAPY : PSY2
MODELO DE COSTO BENEFICIO ENTRE BUPRENORFINA TRANSDERMICA, MORFINA PARENTERAL Y OXICODONA ORAL, EN EL TRATAMIENTO DE PACIENTES CON DOLOR CRONICO MODERADO A SEVERO EN UN SERVICIO DE SALUD DE ATENCION DOMICILIARIA : PSY3
ECONOMIC EVALUATION OF METFORMIN, METFORMIN + SIBUTRAMIN OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE DIABETES PATIENTS : PSY4
IMPACT OF DEPRESSION AND ANXIETY ON EMPLOYABILITY AND PRODUCTIVITY IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS : PSY5
USTEKINUMAB IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN OVERALL HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS : PSY6
CONHECIMENTO DO RISCO DA DOENÇA RENAL CRÔNICA NO GRUPO DE RISCO : PUK1
AMPLIAÇÃO DO SERVIÇO DE HEPATOLOGIA CLÍNICA DO HOSPITAL DAS CLÍNICAS—FMUSP: DESAFIOS E OPORTUNIDADES : PCASE1
REMUNERAÇÃO BASEADA EM PERFORMANCE: O QUE EXISTE DE DIFERENTE DA CONSULTA BONIFICADA UTILIZADA EM ALGUMAS UNIMEDS : PCASE2
GESTÃO DE DOENÇAS: O HOSPITAL COMO FONTE DE INFORMAÇÃO DAS CARACTERÍSTICAS DAS DOENÇAS DOS CLIENTES DAS OPERADORAS DE SA&Uaccute;DE : PCASE3
AVALIAÇÃO DO USO RACIONAL DO BENEFÍCIO EM MEDICAMENTOS VISANDO A GARANTIA DE ACESSO EM UMA POPULAÇÃO CONTROLADA POR REGRAS DE ELEGIBILIDADE : PCASE4